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ABSTRACT OF THE DISSERTATION
EXPOSURE TO ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE
TOXICITY IN WOMEN
by
Marisa Morgan
Florida International University, 2014
Miami, Florida
Professor Deodutta Roy, Major Professor
The overall objective of the research presented in this dissertation was to assess
exposure to endocrine disrupting chemicals (EDCs), polychlorinated biphenyls (PCBs),
phthalates, and bisphenol A (BPA) in the general population and evaluate their
associations with adverse reproductive health effects, including cancers, in women.
Given the proven contribution of unopposed estrogens to the risk for endometrial
neoplasia or breast cancer, renewed health concerns have aroused about estrogen
mimicking EDCs found in food, personal care products or as environmental
contaminants. Our meta-analysis showed that exposure to estrogen mimicking PCBs
increased summary risk of breast cancer and endometriosis. We further evaluated the
relationship between endometriosis and breast cancer, and EDCs using a bioinformatics
method. Our bioinformatics approach was able to identify genes with the potential to be
involved in interaction with PCB, phthalates and BPA that may be important to the
development of breast cancer and endometriosis. Therefore, we hypothesized that
exposure to EDCs such as PCBs, phthalates, and BPA, results in adverse reproductive
health effects in women. Using subject data and biomarkers available from the Center for
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Disease Controls National Health and Nutrition Examination Survey database we
conducted a cross-sectional study of EDCs in relation to self-reported history of
endometriosis, uterine leiomyomas, breast cancer, cervical cancer, ovarian cancer, and
uterine cancer. Significantly higher body burdens of PCBs were found in women
diagnosed with breast cancer, ovarian cancer, and uterine cancer compared to women
without cancer. PCB 138 was significantly associated with breast cancer, cervical
cancer, and uterine cancer, while PCBs 74 and 118 were significantly associated with
ovarian cancer. The sum of dioxin-like PCBs were significantly associated with ovarian
cancer (OR of 2.02, 95% CI: 1.06-3.85) and the sum of non-dioxin-like PCBs were
significantly associated with uterine cancer (OR of 1.12, 95%CI: 1.03-1.23).
Significantly higher body burdens of PCBs were also found in women diagnosed with
endometriosis and uterine leiomyomas.

Documenting the exposure to EDCs among the

general U.S. population, and identifying agents associated with reproductive toxicity
have the potential to fill research gaps and facilitate our understanding of the complex
role environmental chemicals play in producing toxicity in reproductive organs.
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INTRODUCTION
There are thousands of chemicals that are manufactured in or imported into the
United States every year. These chemicals are released into the environment and pose a
severe threat to the endocrine systems of wildlife and humans by interfering with normal
growth and development functions (ATSDR 2000). These chemicals commonly known
as endocrine disrupting compounds (EDCs) or endocrine disruptors (EDs) are both
synthetic and natural compounds in the environment that have the ability to disrupt
metabolic pathways by either mimicking or blocking endogenous hormones, or by
altering hormone function. Many EDCs are highly carcinogenic and include a variety of
chemicals such as pesticides, fungicides, industrial compounds, by-products of industrial
processes, and chemicals used in the manufacturing of plastics. Of particular concern are
the hormonally active agents that are persistent in the environment, highly lipophilic, and
readily bio-accumulate and magnify within the food chain (Summarized in Meeker et al.
2009 & Lyche et al. 2009).
Many of these chemicals are used in a variety of consumer products; therefore
exposure to EDCs among the general population is widespread. Human exposure to
EDCs may result from inhalation through the air, absorption through the skin, and most
commonly through the ingestion of contaminated food and water (Balabanic et al. 2001).
In addition, transgenerational exposure can result from exposure of the mother to a
chemical at any time before producing offspring due to the persistence of EDCs in body
fat. In the last decade, exposure to multiple EDCs such as polychlorinated biphenyls
(PCBs), phthalates, and bisphenol A (BPA) have been detected in  90% of blood and
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urine samples collected from the U.S. general population (Woodruff et al. 2011,Calafat et
al. 2008, Silva et al. 2004).
The discovery that chemicals could cause reproductive and endocrine toxicity
dates back to the 1940’s when the usage of the insecticide dichlorodiphenyl
trichloroethane (DDT) was at its peak. DDT was found to induce adverse reproductive
effects in non-target species including feminized male embryos, weakened eggshells,
reduced nesting behavior, and diminished birth rates in numerous bird species (Patisaul et
al. 2009). DDT was ultimately banned in the United States in 1972, however, the
widespread use of EDCs continued worldwide. The first discovery that exposure to
estrogen could adversely affect reproductive health emerged from the widespread use of
the synthetic estrogen diethylstilbestrol (DES). In the 1930’s DES was prescribed to
pregnant women to prevent miscarriage. DES was banned in 1971 when researchers
identified a highly significant association between DES and the development of a very
rare type of clear-cell-adenocarcinoma (CCA) of the vagina and cervix in female
offspring born to mothers who took DES (Herbst et al. 1971). Subsequent studies of
DES exposure in female offspring have since been associated with breast cancer in older
women (Troisi et al. 2007), elevated risk of CCA with age (Smith et al. 2012), early
uterine leiomyomata diagnosis (D’Aloisio et al. 2010), younger age at natural menopause
(Hatch et al. 2006), and irregular menstrual periods (Titus-Ernstoff et al. 2006).
Many EDC’s that persist in the environment today have demonstrated endocrine
disrupting properties. PCBs have shown to have both estrogenic and anti-estrogenic
properties depending on the congener, phthalates have shown the potential to interfere
with male reproductive development through antiandrogenic mechanisms (Swan 2008),
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and BPA has shown to have estrogen mimicking properties. PCBs, BPA, and phthalates
are the most extensively studied EDCs, and therefore, this research focused on analyzing
the risk of reproductive toxicity in association with exposure to these three selected
classes of EDCs – PCBs, BPA, and phthalates.
Polychlorinated biphenyls. PCBs are a group of synthetic organic chemicals that readily
accumulate in the environment and have shown to cause a number of adverse health
effects, including cancer, in humans and animals (ATSDR 2000). PCBs were introduced
into industry in the 1930’s and used primarily for heat exchange in transformers and
capacitors, hydraulic and lubricating fluids, plasticizers, inks, paints, adhesives, flame
retardants, and extenders for pesticides (Letz 1983). The manufacture of PCBs was
banned in the United States in 1977, however, they are still being released into the
environment from inadequately maintained hazardous waste sites; illegal dumping of
PCB wastes; leaks from old transformers; disposal of PCB-containing consumer products
into municipal landfills, and burning of PCB contaminated waste (ATSDR 2000).
PCBs are ubiquitous in the environment and have been found to contaminate air,
land, and aquatic environments thousands of miles away from the disposal site (Letz
1983). Once in the environment, PCBs adsorb strongly to soil and sediment and
continuously cycle between air, water, and soil (ATSDR 2000). Due to their persistence
in the environment, PCBs bioaccumulate in the food chain primarily in fish and marine
animals, eventually reaching levels that are thousands of times higher than in water
(ASTDR 2000). The primary route of human exposure to PCBs is from eating
contaminated food and breathing contaminated air. Once PCBs have entered a person’s
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or animal’s body, they are absorbed into adipose tissue and remain there for very long
periods of time (Summarized in Johnson et al. 1999).
Phthalates. Phthalates are a group of synthetic chemicals that are widely used as
plasticizers and additives in industrial products (Frederiksen et al. 2007). Highmolecular weight phthalates such as di(2-ethylhexyl) phthalate (DEHP), di-isononyl
phthalate (DiNP), and di-isodecyl phthalate (DiDP) are primarily used to impart
flexibility and durability in plastics and polyvinyl chloride (PVC) products, such as floor
and wall coverings, clothing, food packaging, children’s toys, paint, and medical devices
(Summarized in Meeker et al. 2009 & Lyche et al. 2009). Low-molecular weight
phthalates such as diethyl phthalate (DEP), dibutyl phthalate (DBP), and dimethyl
phthalates (DMP) are primarily used in insecticides, varnishes and coatings,
pharmaceuticals, and as detergents in personal care products such as perfume, hair gels,
hair sprays, shampoos, body lotion, deodorant, and nail polish, (Swan 2008, Meeker et al.
2009, Hauser et al. 2003, ATSDR 2002). Although phthalates are rapidly metabolized
and excreted, the widespread use of both low and high molecular weight phthalates has
led to a constant and unavoidable exposure to humans. Ingestion of contaminated food is
the most common route of exposure for the general population, however, dermal and
inhalation exposures are also important routes due to their presence in numerous
personal-care products and cosmetics (Swan 2008, CDC 2005). According to the CDC’s
Third National Report on Human Exposure to Environmental Chemicals the majority of
people in the United States have detectable levels of several phthalate monoesters or their
metabolites in their urine with detectable levels of DEHP concentrations highest in
children (CDC 2005).
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Bisphenol A. Bisphenol A (BPA) is a synthetic chemical that has shown to mimic
estrogen and potentially impact reproductive and developmental function. BPA is one of
the highest production volume chemicals in commerce and has been used extensively for
the past 40 years to manufacture polycarbonate plastics, epoxy resins to line food and
beverage cans and polyester-styrene (Summarized in Talsness et al. 2009 , Cantonwine et
al. 2010, Meeker et al. 2009). BPA can also be found in dental sealants and fillings,
carbonless paper, flame retardants, water storage tanks, and supply pipes (Summarized in
Talsness et al. 2009, Meeker et al. 2009). The majority of human exposure to BPA is via
ingestion of contaminated food products (Summarized in Meeker et al. 2009). This is of
significant concern because many BPA containers are re-used or marketed as
microwavable which accelerates the degradation of BPA into its monomeric form and
leads to an increase in leaching into adjacent materials. Detectable levels of urinary BPA
have been found in 93% of samples from the 2003-2004 NHANES survey cycle (CDC
2005) and in > 92% of Americans tested with higher levels in children and adolescents
(Calafat et al. 2008).
NHANES. Information regarding blood and urine concentrations and adverse health
effects associated with EDCs is important in understanding how the exposure to EDCs
affects the overall health of the U.S. general population. The National Health and
Nutrition Survey (NHANES), conducted annually since 1999 by the Centers for Disease
Control (CDC), is designed to measure the health of the U.S. general population in
subjects  2 months of age (CDC 2012). The surveys consist of a household interview,
medical questionnaires, standardized physical examinations, and the collection of
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biological specimens (blood and urine from participants  1 and  6 years of age,
respectively) (CDC 2012).
The overarching goal of this research was to determine if risk of reproductive
toxicity in the general U.S. population is increased due to exposure to endocrine
disrupting compounds (polychlorinated biphenyls, phthalates, and BPA) commonly
found in the environment today. Using the CDC’s continuous NHANES database, 19992010, statistical analysis was performed to analyze the associations between urinary and
serum biomarkers of EDCs, reproductive health variables, and medical questionnaires
(cancer).
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CHAPTER II
LITERATURE REVIEW
Endocrine Disrupting Compounds
A new recent report by the United Nations Environment Programme (UNEP) and
World Health Organization (WHO) entitled “State of the Science: Endocrine Disrupting
Chemicals - 2012” highlighted that approximately 800 chemicals are suspected to act as
endocrine disruptors (EDs) or mimic natural hormones or disrupt hormone regulation
(UNEP/WHO 2013, EU 2013). Some of these EDs mimic natural or synthetic estrogen.
This recent UNO report has renewed concern by highlighting that there may be some
associations between exposure to estrogen-mimicking EDs and an increased risk of
hormonal cancer in women (UNEP/WHO 2013, EU 2013). EDCs may produce a wide
range of adverse effects because of the complexity of the endocrine system with its
multiple signaling pathways, feedback mechanisms and cross-talks. Although a number
of experimental animal studies have shown many chemicals have potential endocrine
disrupting activities, the data on their endocrine disrupting effects in humans is limited.
The role of EDC’s in the etiology of some of the human cancers and reproductive health
hazards has been implicated, although the linkage between these two processes is highly
controversial (Burantrevedh and Roy, 2001). In addition to their endocrine disrupting
effects, some environmental estrogen-like chemicals produce multiple and multi-types of
genetic and/or nongenetic hits which may contribute to the induction of genomic
instability in stem cells (Roy et al. 1998).
Estrogens and environmental chemicals play a significant role in the development
of adverse reproductive health effects in women and endogenous sex hormones are
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known to contribute to the development of reproductive cancers. Supporting evidence
includes the known factors of early menarche, late menopause, and nulliparity associated
with an increased risk of developing breast cancer. Both endometriosis and breast cancer
have in common one of the etiological factors, i.e., estrogen (Evans 2008). The estrogen
is a contributing factor in the development of endometriosis as well as in breast cancer.
Tamoxifen, a hormonal therapy for breast cancer, stimulates the growth of endometrial
cells and can cause endometriosis (Lin et al. 2009). The increased risk of endometriosis
and breast cancer among postmenopausal women may be due to an altered endogenous
estrogen (Bertelsen et al. 2007, Roy et al. 1997, Roy et al. 1998).

There is a general

agreement that human populations are continually exposed to a wide variety of
environmental estrogen-like chemicals. We are beginning to acknowledge endocrine
disrupting effects of these chemicals in humans through experimental animal data and
epidemiological studies (Bertelsen et al. 2007 and Roy et al. 1997). Only a limited
number of EDCs, such as diethylstilbestrol (DES), bisphenol A, polychlorinated
biphenyls, phthalates and dichlorodiphenyltrichloroethane (DDT), have been studied
extensively to assess the endocrine disrupting effects in experimental models and in
humans. Both human exposure data and epidemiological studies focused on assessing
potential risk of diseases in association with these chemicals have been reported.
Polychlorinated Biphenyls
PCBs are recognized as endocrine disruptors due to their ability to interfere with
reproductive function and development in animals and humans by either increasing or
blocking estrogen activity (Fielden et al. 2001; Ma and Sassoon 2006; McLachlan et al.
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2006). Adverse reproductive health effects have been established in numerous animal
studies and have linked PCB exposure to prolonged estrus and decreased sexual
receptivity in rats, decreased sperm fertilizing ability in mice (Fielden et al. 2001),
decreased conception in mice, changes in the uterine myometrium and gland formation in
mice (Ma and Sassoon 2006), prolonged menstruation, decreased birth weights, and
decreased conception rates in rhesus monkeys (ASTDR 2000), and a significant dosedependent relationship in the prevalence and severity of endometriosis in rhesus monkeys
(Rier et al. 2001). Human studies on reproductive end-points are less conclusive;
however, some studies have linked PCB exposure to menstrual disturbances, early age at
menarche (Schell and Gallo 2009), late miscarriages, a reduction in lactation time,
preterm delivery, low birth weight, and endometriosis (Tsukimori et al. 2008, Yang et al.
2008, Yu et al. 2000, Buck Louis et al. 2005, Mendola et al. 1997, Baibergenova et al.
2003).
In retrospective studies from the Taiwan Yucheng cohort, Yucheng women
exposed to PCBs reported having abnormal menstrual flow twice as often as controls,
prolonged time to pregnancy, and reduced fertility (Yu et al. 2000; Yang et al. 2008).
Japanese women from the Yusho cohort had a 2-fold increase in the proportion of
spontaneous abortion and pregnancy loss and a 5-fold increase in preterm delivery
(Tsukimori et al. 2008). In a New York State Angler cohort PCB exposure level was
significantly associated with a decrease in menstrual cycle lengths as well as a decrease
in the number of months of lifetime lactation, however, time to pregnancy was not
associated unless the duration of fish consumption was three to six years (Mendola et al.
1997; Buck et al. 2000; Kostyniak et al. 1999).
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Studies pertaining to PCBs and breast cancer are controversial. While some
studies reported no significant associations (Xu et al. 2010; Silver et al. 2009; Gammon et
al. 2002, Wolff et al. 2000, Hunter et al. 1997), others report slight increased risks among
parous women who never breastfed (Moysich et al. 1998), or increased risks if genetic
polymorphisms in the cytochrome P-450 1A1 (CYP 1A1) and menopausal status were
considered (Zhang et al. 2004, Li et al. 2005; Moysich et al. 1999). Zhang et al. (2004)
found that breast cancer risk was significantly increased among women with the CYP1A1
m2 variant genotype and among postmenopausal women with elevated serum PCB
levels. In addition, an increased risk of breast cancer recurrence was found only in
women who had PCB concentrations in the highest tertiles (Muscat et al. 2003).
Phthalates
Among various phthalates, di (2-ethylhexyl) phthalate (DEHP), di-butyl phthalate
(DBP) and butylbenzylphthalate (BBP) have been studied for their endocrine disrupting
effects. In numerous animal studies, phthalates have been shown to produce a variety of
adverse effects including hepatic and renal damage, hepatocellular carcinoma,
anovulation, decreased fetal growth, and most significantly anti-androgenic effects by
suppressing testosterone and estrogen production (CDC 2005, Swan 2008). Reproductive
abnormalities reported in rodent females include uterine and ovarian abnormalities
(increased weights and malformations), advanced onset of puberty (delayed vaginal
opening), reduced fecundity, decreased serum estradiol levels, prolonged estrus cycles,
absence of ovulation, and modified morphology of the mammary gland (CDC 2005,
Moral et al. 2011).
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While human studies associating phthalate exposure with adverse reproductive
effects are less conclusive, many of the findings in male infants are consistent with the
anti-androgenic action that has been demonstrated for phthalates in animal studies. In a
follow-up analysis to the 2000 Study of Phthalates in Pregnant Women and Children ,
significant associations were found between AGD and 3 DEHP metabolites (MEHP,
MEHHP and MEOHP) with mean metabolite concentrations found to be several times
greater among males with shorter AGD compared to males with longer AGD (Swan
2008). Additional human studies with adverse reproductive endpoints including a
significantly lower gestational age in newborns considered MEHP-positive (Latini et al.
2003), a dose-response relationship of MBP and low sperm concentration (Summarized
in Swan 2008), a relationship between urinary MEP levels and sperm DNA damage,
decreased sperm motility, and a reduction in serum free testosterone in men with
occupational exposure to DBP and DEHP (Summarized in Frederiksen et al. 2007,
summarized in Meeker et al. 2009). Human studies demonstrating the association
between phthalate exposure and adverse reproductive effects in females are limited to
only a few. Cobellis et al. (2003) reported higher plasma concentrations of DEHP and
MEHP in women with endometriosis. More recently, Huang et al. (2010) reported that
patients with leiomyomas had significantly higher levels of total urinary MEHP, patients
with endometriosis had increased levels of urinary MnBP, and subjects who had the
GSTMI null genotype had a significantly increased risk of adenomyosis.
Bisphenol A
Numerous studies have shown adverse effects of low doses of BPA on the
development of male and female reproductive organs in experimental animals. In rodent
14

females, BPA exposure has shown to cause alterations in the mammary gland
development, changes in gene expression of the mammary gland, cystic ovaries,
endometrial hyperplasia, adenomyosis, leiomyomas, atypical hyperplasia, stromal
polyps, ductal hyperplasias and carcinoma, a decline in fertility and fecundity, decreased
wet weight of the vagina, decreased volume of the endometrial lamina propria, and an
increased expression of estrogen receptor- (ER) and progesterone receptors (Talsness
et al. 2009, Moral et al. 2008, Munoz-de-toro et al. 2005, Cabaton et al. 2011, Markey et
al. 2004). Despite their widespread exposure human epidemiologic studies of BPA
exposure and adverse reproductive endpoints are severely limited. In the few available
studies, BPA levels were reported to be associated with miscarriages, fetuses with
abnormal karyotype, and polycystic ovarian syndrome (Summarized in Meeker et al
2009). In a pilot nested case control study of BPA exposure and prematurity, pregnant
women who delivered less than or equal to 37 weeks of gestation had higher urinary
concentrations of BPA in a single spot urine sample collected during the third trimester
compared to women who delivered after 37 weeks (Cantonwine et al. 2010).
Bioinformatics: EDCs, Breast Cancer and Endometriosis
While there are several studies which link EDCs – PCBs, BPA, and phthalate
exposure to increased risk of a reproductive toxicity, there are other studies which have
been inconsistent or showed no association between these EDCs and risk of breast cancer
or endometriosis. In this study, we used a combined environmental epidemiologic,
genomic, and bioinformatics approach to understand the relationship between EDCs and
risk of developing estrogen-dependent complex chronic diseases – breast cancer and
endometriosis by examining interactions between genes, diseases and these three selected
15

EDCs. We have also evaluated the possibility that ‘‘estrogen mimicking endocrine
disruptor responsive genes’’ are potentially associated with systemic changes in breast
cancer and endometriosis. To accomplish the objectives identified here, we introduce a
comprehensive bioinformatics method using genomics, environmental and epidemiologic
data integration that links with diseases - breast cancer and endometriosis to identify: 1)
genes that interact with EDCs and link to the development of these diseases, and 2)
important pathways that may be influenced by EDC exposures. The first and second
steps in our method included modeling to assess estrogenicity of environmental
chemicals to show the potential of endocrine disruption and assessing association
between EDC exposure and diseases, respectively. The third step in our method included
identifying genes responsive to EDC exposures using the Comparative Toxicology,
Environmental Genome Project and KEGG. These EDC responsive genes were then
compared to a curated list of genes in breast cancer and endometriosis. This comparison
produced a list of genes responsive to the environment and important to breast cancer and
endometriosis that was then further analyzed using gene networking tools such as
RSpider, Cytoscape, and DAVID. Using this bioinformatics method we were able to
identify environmentally responsive genes with the potential to be involved in interaction
with EDCs that may be important to the development of breast cancer and endometriosis.
We meta-analyzed environmental epidemiologic evidence for the risk of breast cancer
and endometriosis with exposure to EDCs - PCB, phthalates, and BPA from 23 selected
publications which we categorized by outcome: breast cancer and endometriosis. Metaanalysis was performed using the general variance-based method and homogeneity was
tested by means of the Q statistic. Analysis was completed using Comprehensive Meta
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Analysis Version 2.2.046 from Biostat, Inc. which can be downloaded at www.MetaAnalysis.com (Borenstein et al. 2005). The resources, workflow, meta-analysis and
bioinformatics tools and integration of environmental epidemiologic, genomic and
disease databases are shown in Figure 1.
.

Figure 1. Flow chart showing the steps involved in identifying genes that illustrate link
between endometriosis and breast cancer based on environmental response on
epidemiologic , genomics, and bioinformatics databases.
EDCs and Breast Cancer
We identified twelve epidemiologic studies related to PCB, phthalate, or BPA
exposure and breast cancer. Ten of the twelve studies assessed the relationship between
PCB exposure and breast cancer (Charlier et al. 2004, Cohn et al 2012, Demers et al.
2002, Gammon et al. 2002, Gatto et al. 2007, Itoh et. al 2009, Millikan et al. 2013, Pavuk
et. al 2003, Recio-Vega et al. 2001, Wolff et al. 2009), one study assessed the
relationship between phthalate exposure and breast cancer (Lopez-Carillo et al. 2010),
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and one study assessed the relationship between BPA exposure and breast cancer (Yang
et al. 2009). All twelve of the identified studies were case-control studies. In all of the
studies, cases had histologically confirmed breast cancer and controls had no history of
breast cancer diagnosis. In the majority of the studies, controls were matched on age and
residence.
PCBs and Breast Cancer. Three of the ten PCB case-control studies failed to find any
associations between exposure to total PCBs and breast cancer risk (Gammon et al. 2002,
Gatto et al. 2007, Wolff et al. 2009) while two of the ten PCB studies found an inverse
association between total PCB levels and breast cancer (Itoh et al. 2009, Pavuk et al.
2003). The largest case-control study conducted by Gammon et al. (2002) consisted of
646 newly diagnosed breast cancer cases and 429 matched controls failed to find any
association between PCB exposure and breast cancer risk when comparing the highest
quintile of serum Peak-4 (nos. 118, 153, 138, and 180) PCB levels to the lowest quintile
(OR=0.83, 95% CI 0.54-1.29). Gatto et al. (2007) did not find any associations with
breast cancer when comparing the highest vs. lowest quintiles of mean total PCB levels
in 355 cases and 327 controls (OR=1.01, 95% CI 0.63-1.63) and Wolff et al. (2009) did
not find any associations with breast cancer when comparing the highest vs. lowest
quartiles of serum total PCB levels in 110 cases and 213 controls. Itoh et al. (2009)
found a decreased risk of breast cancer when comparing the highest quartile of median
total PCB levels to the lowest quartile (OR=0.33, 95% CI 0.14-0.78) and Pavuk et al.
(2003) found higher serum PCB levels to be inversely associated with breast cancer in
total PCBs (OR=0.42, 95% CI 0.10-1.82) and in 3 sub-groups of PCBS: estrogenic, antiestrogenic/dioxin-like, and phenobarbital-type.
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Five of the PCB case-control studies found significant associations between breast
cancer and exposure to individual PCB congeners, total PCBs, or specific sub-groups of
PCBs (Charlier et al. 2004, Cohn et al. 2012, Demers et al. 2002, Millikan et al. 2013,
Recio-Vega et al. 2001). Charlier et al. (2004) measured mean levels of 7 PCB
congeners in 60 breast cancer cases and 60 healthy controls. They found total PCBs to be
significantly different (p = 0.012) between cases and controls (7.08 vs. 5.10 ppb) which
can be attributed to significantly higher serum levels of PCB 153 in breast cancer cases
when compared to controls (1.63 vs. 0.63 ppb, p < 0.0001). The OR of breast cancer for
PCB 153 was 1.8 (95% CI 1.4-2.5). In a nested, matched case-control study of 112 cases
and controls, Cohn et al. (2012) did not find any associations for total PCBs or PCB
groupings, however, a significant association was found for PCB 203 when comparing
the highest vs. lowest quartiles of exposure (OR=6.3, 95% CI 1.9-21.7). In a matched
case-control study of 314 cases and 523 controls, Demers et al. (2002) found breast
cancer risk significantly associated with the sum of mono-ortho congeners (nos. 105, 118,
156) (OR=2.02, 95% CI 1.24-3.28), PCB 118 (OR=1.60, 95% CI 1.01-2.53) and PCB
156 (OR=1.80, 95% CI 1.11-2.94) when comparing the fourth vs. first quartiles. In a
population based case-control study with sub-groups of African-American women and
white women, Millikan et al. (2013) did not find any associations with total PCBs and
breast cancer among all participants (OR=1.09, 95% CI 0.79-1.52) or white women
(OR=1.03, 95% CI 0.68-1.56), but did find a slightly elevated risk for African-American
women (OR=1.74, 95% CI 1.00-3.01). Recio-Vega et al. (2001) found the GM of total
PCBs to be significantly higher in cases than controls (5.26 vs. 3.33 ppb) (OR=1.09, 95%
CI 1.01-1.14) as well as an increased risk of breast cancer among PCBs grouped by
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structure-activity relationships and 8 individual PCB congeners (nos. 118, 128, 138, 170,
180, 195, 206, and 209).
Since the relationship between PCB exposure and breast cancer in ten
epidemiologic studies was inconsistent or conflicting, risk estimates of PCBs on breast
cancer from six case control studies were extracted and summarized using meta-analytic
methods. Combining six studies of exposure to PCBs produced a summary risk estimate
of 1.33 (95% CI: 0.72 – 2.65) (Table 1; Fig. 2). PCB exposures were found to be
associated with development of breast cancer as a meta-analysis of six studies produced
an increased risk of 1.33; however, this was not statistically significant.
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Table 1. Epidemiological studies of the association between exposure to PCBs and risk of breast cancer.
Reference,
location
Charlier et al.
(2004),
Belgium

Study design

Study
Population
60 cases, 60 age
matched healthy
controls

Measurement of
Exposure
7 PCBs from
serum, Total PCBs.

Outcomes

Results

Mean Total PCB levels
(ppb =ng/g)
Cases: 7.08
Controls: 5.10
Logistic Regression (OR95% CI).

Adjustments made for age,
menopausal status, number
of full-term pregnancies,
lactation, use of HRT, and
family history of BC.

Case-control
study

314 cases, 523
controls; matched
by age and
residence.

14 PCB congeners
measured in
plasma (ug/kg of
plasma lipids).
TEQ/kg of lipids
for sum of monoortho congeners
(nos. 105, 118, 156).

Mean TEQ ng/g of lipids:
Cases: 6.4
Controls: 5.8
Logistic Regression (OR95% CI); Quartiles.

Pavuk et al.
(2003), USA

Case-control
study

24 cases, 88
controls

GMs Total PCBs (ng/g of
lipid):
Cases: 3228.2
Controls: 2885.8
Logistic Regression (OR95% CI); Tertiles

Recio-Vega et
al. (2011),
Mexico

Case-control
Study

70 cases, 70
controls

Total PCBs from
serum (n=15);
Groups of PCBs:
(1) estrogenic,
(2) anti-estrogenic,
dioxin-like,
(3) phenobarbitaltype
Individual and
total PCBs from
serum (n=20);
5 PCB groups by
structure-activity
relationships.

Total PCBs significantly
Cases diagnosed with
different in cases than
breast cancer and
controls (p=0.012). High
undergoing a surgical
concentrations of PCB153
intervention.
significantly associated
Controls free of BC at age
with an increased risk of agnosis.
BC (OR=1.8, 95% CI-1.42.5).
Mean total of monoCases: histologically
ortho congeners
confirmed infiltrating
significantly higher in
primary BC. Controls: no
cases than controls
history of BC diagnosis.
(p=0.005).
Significant associations
between breast cancer
risk and PCB 156, 118, &
mono ortho congeners
In 4th vs. 1st
quartiles.(OR=2.02, 95%
CI: 1.24-3.28).
Higher serum levels of
Cases: histologically
total PCBs (OR=0.42,
confirmed invasive BC.
95% CI 0.10-1.82)
Controls: identified
inversely associated with
through random
BC. Groups 1, 2, & 3 also
sampling of primary care
inversely associated.
physicians.

Demers et al.
(2001), Canada

Cases: first diagnosis of
BC by biopsy.
Controls: negative
biopsies from same
hospitals and geographic
area.

Adjusted for age, age at
menarche, lactation,
menopause status, BMI.

Wolff et al.
(2000), US

Prospective
case-control
Study

148 cases, 295
individually
matched controls

Total PCBs from
serum.

GM Total PCBs (ng/g of
lipids):
Cases: 683
Controls: 663
Logistic Regression (OR95% CI); Quartiles

Total PCBs significantly
higher among cases than
controls (OR=1.09, 95%
CI 1.01-1.14). Risk of BC
positively associated with
8 PCB congeners: 118,
128, 138, 170, 180, 195,
206, and 209.
GM Total PCB levels not
significantly different.
No association between
PCB exposure and BC
(OR=2.02 95% CI 0.765.37).

Adjusted for age at
menarche, # of full-term
pregnancies, age at first
birth, family history of BC,
lifetime history of lactation,
BMI, menopausal status at
time of blood donation.

Itoh et al.
(2008), Japan

Matched casecontrol study

403 pairs; matched
by age (3 years)
and residence.

Total PCBs from
serum (Sum of 41
PCB peaks).

Median Total lipidadjusted PCBs (ng/g):
Cases: 170
Controls: 180
Logistic Regression (OR,
95% CI), Quartiles.

BC cases identified
through active follow-up
of the NYU Women’s
Health Study Cohort.
Controls selected at
random from cohort who
were alive and free of
disease at the time of
case diagnosis.
Cases: histologically
confirmed invasive BC.
Controls: selected from
medical checkup
examinees, no BC
diagnosis.

Case-control
study

GM Total PCB levels
(ppb):
Cases: 5.26
Controls: 3.33
Logistic Regression (OR95% CI).

Total PCBs associated
with a decreased risk of
BC.
(OR=0.33, 95% CI: 0.140.78, p-value 0.008);
highest vs. lowest
quartile.

Comments

Confounders

Adjusted for age, residence,
BMI, history of benign breas
disease, breastfeeding
duration.

Adjusted for age, age at
menarche, education, alcoho
consumption, smoking.

Adjusted for lipids, BMI,
menopausal status & age,
smoking, fish & veg
consumption, family history
parity, age at first childbirth
age at menarche, history of
BC screening

Figure 2. Forest plot of epidemiological studies of the association between exposure to
PCBs and risk of breast cancer.

Bisphenol A or phthalate and breast cancer: No meta-analysis was performed on
exposure to BPA or phthalates, because only one study for each chemical fit the criteria.
Lopez-Carillo et al. (2010) found urinary concentrations of monoethyl phthalate (MEP)
to be significantly higher in cases than controls when comparing the highest vs. lowest
tertile of exposure (169.58 vs 106.78 ug/g creatinine). The OR of breast cancer risk in
the highest tertile of urinary MEP, compared with the lowest tertile, was 2.20 (95% CI
1.33-3.63) and became higher when estimated for premenopausal women (OR=4.13, 95%
CI 1.60-10.7). On the contrary, significant negative associations were found for urinary
concentrations of monobenzyl phthalate (MBzP) (OR=0.46, 95% CI 0.27-0.79) and
mono (3-carboxypropyl) phthalate (MCPP) (OR=0.44, 95% CI 0.24-0.80). In a matched

case-control study Yang et al. (2009) measured median blood BPA levels in 70 cases and
80 controls. Median BPA levels were higher in cases than controls (0.61 vs. 0.03 ug/L),
however, the differences were not found to be statistically significant (p = 0.42).
PCBs-Breast Cancer-Gene Association: The CTD search revealed that besides
polychlorinated biphenyls, the five most common PCB congeners studied for gene
interaction were 3,4,3',4'-tetrachlorobiphenyl (77), 2',3,3',4',5-pentachloro-4hydroxybiphenyl (4'-OH-PCB-86), 3,4,5,3',4'-pentachlorobiphenyl (126), 2,3,3',4,4',5hexachlorobiphenyl (153), and 2,2',3,4,4',5,5'-Heptachlorobiphenyl (180) (Table 2).
There were 5289 genes related to PCBs as a family of chemicals and 386 genes related to
breast cancer (Fig. 3). The common genes between PCBs and breast cancer were 200.
The top interacting genes with polychlorinated biphenyls as a chemical class were
CYP1A1, AHR, CYP1A2, AR, CYP1A, CYP1B1, VCAM1, MAPK1, MAPK3, and
PTGS2. The top interacting genes with polychlorinated biphenyls in breast neoplasms
were AR, CYP1A1, CYP1B1, ESR1, ESR2, PTGS2, and RAF1. Out of a total 200 gene
interactions observed with individual PCBs, the interaction of genes AR, BAX, CYP1A1,
CYP1B1, KDR, PARP1, PTGS2, and RAF1 was common with tetrachloride-,
pentachloride-, and hexachloride biphenyls in breast neoplasms (Table 2). CYP1A1,
AHR, AR, CYP1A, CYP1B1, and PTGS2 genes are common in both PCB-gene and
PCB-gene-breast cancer groups. Interactions among these genes are shown in Figure 4.
Enrichment pathway analysis revealed that these genes are part of: 1) pathways in cancer
(KEGG:05200); 2) signal transduction (REACT:111102), 3) mTOR signaling pathway
(KEGG:04150); 4) focal adhesion (KEGG:04510); 5) VEGF signaling pathway
(KEGG:04370); and 6) ErbB signaling pathway (Table 3).
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BPA, Phthalate and Breast Cancer-Gene Association: There were 6365 genes related
to BPA as chemicals. There were 385 genes known to be related to breast cancer. There
were 209 common genes between BPA and breast cancer (Fig. 2). There were 5754 genes
related to phthalate as a family of chemicals and 385 genes related to breast cancer (Fig.
2). The common genes between dibutyl phthalate and breast cancer and diethylhexyl
phthalate and breast cancer were 162, and 89, respectively. Identification of the common
genes with breast cancer and both dibutyl phthalate and diethylhexyl phthalate further
revealed that there were 54 common genes between dibutyl phthalate and diethylhexyl
phthalate and breast cancer: ABCG2, AHR, AKT1, ALDOA, AR, BCL2, BMP2, BMP4,
CADM1, CASP7, CCND1, CD40, CTNNB1, CYP17A1, CYP19A1, CYP1A1, CYP1B1,
CYP3A4, DNMT1, DNMT3A, DNMT3B, EDNRB, EEF2, EGFR, ESR1, ESR2,
ESRRA, F3, FASN, FOS, GPX1, HADHB, HSP90AA1, IGF1, IGFBP7, JUN, LOXL2,
MMP2, MMP9, NDRG1, NFKBIA, NOTCH2, OCLN, PER3, PIK3CA, PTPRD, RPL31,
RPS4X, SOD2, THBS1, TNF, TUBB3, WNT10B, and YBX1 (Table 2). Interactions
among these genes are shown in Figure 3. Enrichment pathway analysis revealed that
some of these genes are part of: 1) pathways in cancer (KEGG:05200); 2) signal
transduction (REACT:111102), and 3) MAPK signaling pathway ( KEGG:04150) (Table
3).
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Table 2. Genes interacting with polychlorinated biphenyls in breast neoplasms.
IUPAC Name (congener number)

Interacting genes

Polychlorinated Biphenyls

65 genes: ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1 | ANGPTL4 | APOBEC3B |
AR | ARAF | AREG | AURKA | BCHE | BIRC5 | CDKN1B | CENPF | CLDN4 |
COMT | CXCL12 | CXCL2 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 |
CYP3A4 | DNMT1 | DNMT3A | DNMT3B | ESR1 | ESR2 | FOS | GPI | GPNMB |
H2AFX | HEY1 | HMOX1 | HP | IFNG | IL6 | JUN | KRAS | MKI67 | MMP3 | NCOA3
| NQO1 | PPARGC1B | PTGS2 | RAD51 | RAD51C | RAD54L | RAF1 | RPS8 | SOD2 |
SPP1 | STC2 | STMN1 | TGM2 | THBS1 | THEMIS2 | TNF | TOP2A | TYMS | UBE2C
11 genes: AR | CYP1A1 | CYP1B1 | CYP2B1 | ESR1 | ESR2 | HIF1A | KDR | PTGS2 |
RAF1 | TP53
3 genes: AR | ESR1 | ESR2
13 genes: ACHE | AHR | AKT2 | APC2 | AR | CYP1A1 | CYP2B1 | EPB41L3 | IGF1R
| MMP2 | PARP1 | PLA2G4A | ZEB2
27 genes: AHR | AR | BAX | CAV1 | CCNE1 | CYP1A1 | CYP1B1 | ESR1 | ESR2 |
GPI | GPX1 | HADHB | HIF1A | HNRNPK | IL1B | IL6 | KDR | MRPL19 | NDRG1 |
NOS3 | NQO1 | PARP1 | PER3 | PTGS2 | RAF1 | RELA | TNF
75 genes: ACVR1 | AFP | APC2 | ARAF | ATM | BIRC5 | BMPR2 | CASP8 | CAV1 |
CD40 | CHEK2 | CSF1 | CSF3 | CST6 | CXCL12 | CXCL2 | CYP17A1 | CYP1A1 |
DAP3 | DDIT3 | DNMT3A | DNMT3B | DPYD | EEF2 | EFNA1 | EGF | ERBB2 | F3 |
FABP7 | FGFR2 | FHL2 | FKBPL | GDF10 | HIF1A | HRG | IL24 | JAG1 | JAG2 | JUN
| LDHB | LEPR | LPAR1 | MFGE8 | MME | MMP2 | MMP3 | MMP9 | MRPL13 |
MTDH | MTHFR | MTR | NDRG1 | NOTCH3 | NOTCH4 | NRCAM | NUDT2 | OCLN
| PARP1 | PDE2A | PDGFA | PHB | PPARGC1B | PTPRD | RGS2 | SLC28A1 | STAT3
| SYNE1 | SYNJ2 | TFRC | THBS1 | THEMIS2 | TOP2A | VEGFC | VPS39 | ZEB1
9 genes: AKT1 | AR | CXCL8 | EGFR | FOS | JUN | MMP3 | OCLN | SRC
4 genes: AHR | AR | CYP1A1 | CYP2B1
10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN |
PTGS2
2 genes: AHR | CYP1A1
10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN |
PTGS2
77 genes: ACVR1 | ADAMTS1 | AFP | AHR | AKAP12 | AKT1 | APRT | AR | AREG |
BARD1 | BAX | BCL2 | BMP4 | BRCA1 | CADM1 | CAV1 | CCL20 | CCND1 | CD74 |
CXCL12 | CXCL8 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | EGF |
ESR1 | F3 | FASN | FGFR2 | FHL2 | FST | GPNMB | HES1 | HIF1A | HMOX1 |
ICAM5 | IGF1 | IGF1R | IGFBP5 | IGFBP7 | IL1B | IL6 | JUN | KDR | LDHAL6B |
LPAR1 | MME | MMP9 | NOS2 | NOS3 | NOTCH1 | NQO1 | NRG1 | OCLN | PAK1 |
PARP1 | PDGFA | PER3 | PHGDH | PLA2G4A | PTGS2 | PTPRD | RAF1 | SERPINB2
| SLC2A5 | SLC5A5 | SNAI1 | SPP1 | STC2 | SYNJ2 | TBX3 | TGM2 | TNF | TP53 |
VEGFC
2 genes: AHR | AR

2,4,4'-trichlorobiphenyl (28)
2,4',5-trichlorobiphenyl (31)
2,5,2',5'-tetrachlorobiphenyl (55)
3,4,3',4'-tetrachlorobiphenyl (77)
2',3,3',4',5-pentachloro-4hydroxybiphenyl (4'-OH-PCB-86;4hydroxy-2 , 2' , 3' , 4' , 5'pentachlorobiphenyl )

2,2',4,6,6'-pentachlorobiphenyl (104)
2,3,3',4,4'-pentachlorobiphenyl (105)
2,3',4,4',5-pentachlorobiphenyl (107)
2,3,4,4',5-pentachlorobiphenyl (114)
2,3',4,4',5-pentachlorobiphenyl (118)
3,4,5,3',4'-pentachlorobiphenyl (126)

2,3,4,2',3',4'-hexachlorobiphenyl
(128)
2,3,3',4,4',5-hexachlorobiphenyl (129)
2,2',3',4,4',5-hexachlorobiphenyl

2,3,6,2',3',6'-hexachlorobiphenyl (136)
2,4,5,2',4',5'-hexachlorobiphenyl (153)

3,4,5,3',4',5'-hexachlorobiphenyl
2,2',3,4,4',5,5'-Heptachlorobiphenyl (180)
17 beta Estradiol

5 genes: AHR | AR | CYP1A1 | CYP1B1 | ESR1
27 genes: ACHE | AHR | AKT2 | APC2 | AR | BRCA1 | CCT5 | CENPF | CFL1 |

2 genes: AR | CYP2B1
51 genes: AHR | AKAP12 | AR | BAX | BCL2 | BRCA1 | CASP8 | CCND1 | CDH1
| CTNNB1 | CXCL12 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 |
EGFR | ESR1 | ESR2 | FASN | FOS | GPX1 | GPX2 | HIF1A | HSPA1B | IFNG |
IGF1 | IL1B | JUN | KDR | MAP3K1 | MEIS1 | NDRG1 | NOTCH1 | NQO1 | NRG1
| OCLN | PARP1 | PTGS2 | PTPRD | RAF1 | SPP1 | SRC | STAT5A | STMN1 |
TFPI2 | TNF | TNFSF10 | TP53 | TUBB3 | XRCC3
7 genes: AHR | BAX | CYP1A1 | CYP1B1 | HIF1A | KDR | PTGS2
19 genes: ABL1 | AHR | AR | BAX | BCL2 | BRCA1 | CYP1A1 | CYP1B1 |
CYP2B1 | FOS | HIF1A | IGF1 | KDR | MMP2 | MMP9 | NOTCH1 | PTGS2 | TP53
| ZEB2
255 genes: ABCG2 | ACHE | ADAMTS1 | AFP | AGR2 | AHR | AKAP12 | AKT1 |
AKT2 | ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | ARTN | ATM |
ATP7B | AURKA | BARD1 | BAX | BCAR3 | BCHE | BCL2 | BIRC5 | BMP2 |
BMP4 | BMPR2 | BRCA1 | BRCA2 | C10ORF10 | CADM1 | CASP7 | CASP8 |
CAV1 | CCL20 | CCND1 | CCNE1 | CD109 | CD40 | CDA | CDH1 | CDH5 |
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Diethyl phthalate
Dibutyl Phthalate and Diethylhexyl
Phthalate

Bisphenol A

CDKN1B | CENPF | CFL1 | CHEK2 | CLDN1 | CLDN4 | COL7A1 | COMT | CSF1
| CSF1R | CSF3 | CST6 | CTNNB1 | CXCL12 | CXCL2 | CXCL3 | CXCL8 |
CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 | DDIT3 | DKK1 |
DNMT1 | DNMT3A | E2F1 | EDNRB | EFEMP1 | EFNA1 | EGF | EGFR | ELK3 |
ENO1 | EPHB4 | EPOR | ERBB2 | ESR1 | ESR2 | ESRRA | ETS2 | ETV4 | EVL |
F3 | FASN | FBL | FGF10 | FGFR1 | FGFR2 | FHL2 | FKBPL | FOS | FOXA1 |
FOXM1 | FOXP3 | FST | GDF10 | GPNMB | GPX1 | GPX2 | GPX4 | GRB7 |
H2AFX | HADHB | HES1 | HEY1 | HEY2 | HIF1A | HIST1H1C | HIST1H2BC |
HIST1H2BK | HMMR | HMOX1 | HP | HPSE | HRAS | HRG | HSP90AA1 |
HSPA1B | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 | IL1B | IL24 | IL6 | JAG1 | JUN
| KCNH1 | KDR | KIT | KRAS | KRT18 | KRT8 | LDHB | LEP | LEPR | LOXL2 |
LPAR1 | LSP1 | MAL | MAP3K1 | MDM4 | MIF | MIR10B | MIR146A | MIR200B
| MIR222 | MKI67 | MME | MMP1 | MMP2 | MMP3 | MMP9 | MTR | NAT2 |
NCOA1 | NCOA2 | NCOA3 | NCOR1 | NDRG1 | NFKBIA | NOS2 | NOS3 |
NOTCH1 | NOTCH2 | NQO1 | NQO2 | NR2F1 | NRG1 | NRIP1 | NUDT2 | PAEP |
PAK1 | PARP1 | PDGFA | PGR | PHB | PHGDH | PIK3CA | PIM1 | PLA2G4A |
PPARGC1B | PPM1D | PTEN | PTGS1 | PTGS2 | PTHLH | RAD51 | RAD51C |
RAF1 | RARB | RB1 | RBM3 | RELA | RGS2 | RPL31 | RPS4X | RPS6 | RPS7 |
RRAD | SERPINB2 | SERPINB5 | SFRP1 | SFRP2 | SLC2A1 | SLC2A2 | SLC2A5 |
SLC39A6 | SLC5A5 | SNAI1 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A |
STC2 | STMN1 | SYNE1 | SYNJ2 | TANK | TBX3 | TCL1B | TERT | TFAP2A |
TFPI2 | TFRC | TGM2 | THBS1 | THEMIS2 | TLE3 | TNF | TNFSF10 | TNIP1 |
TOP2A | TOX3 | TP53 | TRERF1 | TRP53 | TUBB3 | TYMS | UBE2C | VPS39 |
WNT10B | WT1 | ZEB1 | ZEB2 | ZNF365 | ZNF366
AFP, AHR, AR, CXCL8, CYP17A1, CYP1B1, ESR1, ESR2, IFNB1
54 Common genes: ABCG2, AHR, AKT1, ALDOA, AR, BCL2, BMP2, BMP4,
CADM1, CASP7, CCND1, CD40, CTNNB1, CYP17A1, CYP19A1, CYP1A1,
CYP1B1, CYP3A4, DNMT1, DNMT3A, DNMT3B, EDNRB, EEF2, EGFR, ESR1,
ESR2, ESRRA, F3, FASN, FOS, GPX1, HADHB, HSP90AA1, IGF1, IGFBP7,
JUN, LOXL2, MMP2, MMP9, NDRG1, NFKBIA, NOTCH2, OCLN, PER3,
PIK3CA, PTPRD, RPL31, RPS4X, SOD2, THBS1, TNF, TUBB3, WNT10B,
YBX1.
209 genes: ABCG2 | ABL1 | ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1|
ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | AURKA | BAG1
|BARD1 | BAX | BCAR3 | BCL2 | BCL2A1 | BIRC5 | BMP4 | BRCA1 | BRCA2
|CASP7 | CASP8 | CAV1 | CCND1 | CCNE1 | CCT5 | CDH1 | CDH5 | CDKN1B
|CENPF | CFL1 | CHEK2 | CLDN4 | CMC2 | COTL1 | CSF2 | CTNNB1 | CUL5
|CXCL12 | CXCL3 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2D6
|CYP3A4 | DAP3 | DDIT3 | DNMT1 | DNMT3A | DNMT3B | DSC3 | E2F1 | EEF2
|EGF | EGFR | ENO1 | ERBB2 | ESR1 | ESR2 | ESRRA | ETS2 | EVL | EZH2 |
FASN| FBL | FGFR1 | FGFR2 | FHL2 | FOS | FOXM1 | FST | GDF10 | H2AFX |
HADHB |HES1 | HEY2 | HIC1 | HMMR | HMOX1 | HNRNPL | HNRNPR | HP |
HRAS |HSP90AA1 | HSPA1B | IFNB1 | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 |
IL1B |IL6 | JAG1 | JAG2 | JUN | KDR | KIT | KRAS | KRT8 | LEP | LEPR | LLGL1
|LPAR1 | MAL | MAP3K1 | MDM4 | MEIS1 | MFGE8 | MIF | MIR146A |
MIR200B |MIR222 | MIR29A | MIR342 | MKI67 | MME | MMP1 | MMP2 | MMP9
| MRPL13 |MRPL19 | MRPS22 | MTR | NAT2 | NCOA1 | NCOA2 | NCOA3 |
NCOR1 | NDRG1| NOS2 | NOS3 | NOTCH1 | NOTCH2 | NOTCH3 | NQO1 |
NRCAM | NRIP1 |NUDT2 | OCLN | PAK1 | PARP1 | PDGFA | PER3 | PGR | PHB
| PHGDH | PIM1 |PIN1 | PLA2G4A | PTEN | PTGS1 | PTGS2 | RAD51 | RAD51B |
RAD51C |RAD54L | RB1 | RELA | RGS2 | RIBC2 | RPS6 | RPS6KB2 | RPS7 |
RXRB |SERPINB5 | SFRP1 | SFRP2 | SHMT1 | SIRT1 | SLC22A18 | SLC2A1 |
SLC2A2 |SLC5A5 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A | STC2 |
STMN1 |SYNE1 | TANK | TBX3 | TERT | TFAP2A | TFPI2 | TGM2 | THBS1 |
TNF | TNFSF10| TNIP1 | TOP2A | TP53 | TYMS | UBE2C | UMPS | WNT10B |
WT1 | WWOX |XRCC3 | YBX1
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Figure 3. Venn diagram of list of genes common between breast neoplasms and PCBs,
phthalates or bisphenol A.

Figure 4. Gene Set/Pathway enrichment analysis of genes associated with PCBs,
phthalates, or bisphenol A in breast neoplasms.

BPA-Breast Cancer

PCB-Breast Cancer
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Phthalate-Breast Cancer

Table 3. KEGG enrichment pathways for common AREG, CYP19A1, EGFR, FOS, IGF1, KRAS,
and PGR genes in EDCs, breast cancer and endometriosis.

Pathways
Steroid hormone biosynthesis
Metabolic pathways
MAPK signaling pathway
ErbB signaling pathway
Chemokine signaling pathway
p53 signaling pathway
mTOR signaling pathway
Dorso-ventral axis formation
VEGF signaling pathway
Focal adhesion
Adherens junction
Tight junction
Gap junction
Toll-like receptor signaling
pathway
Natural killer cell mediated
cytotoxicity
T cell receptor signaling
pathway
B cell receptor signaling
pathway
Fc epsilon RI signaling pathway
Regulation of actin cytoskeleton
Insulin signaling pathway
GnRH signaling pathway
Pathways in cancer
Pancreatic cancer
Endometrial cancer

Pathway ID
KEGG:00140
KEGG:01100
KEGG:04010
KEGG:04012
KEGG:04062
KEGG:04115
KEGG:04150
KEGG:04320
KEGG:04370
KEGG:04510
KEGG:04520
KEGG:04530
KEGG:04540

Gene association
CYP19A1
CYP19A1
EGFR|FOS|KRAS
AREG|EGFR|KRAS
KRAS
IGF1
IGF1
EGFR|KRAS
KRAS
EGFR||IGF1|
EGFR
KRAS
EGFR|KRAS

Number of
associated genes
1
1
3
3
1
1
1
2
1
2
1
1
2

KEGG:04620

FOS

1

KEGG:04650

KRAS

1

KEGG:04660

FOS|KRAS

2

KEGG:04662
KEGG:04664
KEGG:04810
KEGG:04910
KEGG:04912
KEGG:05200
KEGG:05212
KEGG:05213

FOS|KRAS|
KRAS
EGFR|KRAS
KRAS
EGFR|KRAS
EGFR|FOS|IGF1|KRAS
EGFR|KRAS
EGFR|KRAS

2
1
2
1
2
4
2
2

Association between endometriosis and exposure to PCB, phthalates, or BPA: We
identified 11 epidemiologic studies related to PCB, phthalate, or BPA exposure and
endometriosis. Seven of the studies assessed the relationship between PCB exposure and
endometriosis (Buck et al. 2005, Heiler et al. 2005, Niskar et al. 2009, Pauwels et al.
2001, Porpora et al. 2009, Trabert et al. 2010, Tsukino et al. 2005), two studies assessed
the relationship between phthalate exposure and endometriosis (Kim et al. 2001 and
Upson et al. 2013), one study assessed the relationship between BPA exposure and
endometriosis (Itoh et al. 2007) and one study assessed the relationship between phthalate
and BPA exposure and endometriosis (Buck et al. 2013). Of these studies, eight were
case-control studies, one was a cross-sectional study; and two were cohort studies. In all
of the studies, endometriosis cases were confirmed with a laparoscopic examination
and/or biopsy and in nine of the eleven studies controls were also confirmed to be disease
free through laparoscopic examination. Controls in the remaining two studies were
randomly selected from a list of Group Health Enrollees that were known to not have
endometriosis.
PCBs and endometriosis. All seven of the studies that addressed the relationship between
PCB exposure and endometriosis presented individual congener results as well as a
measure of total PCBs, the sum of individual congeners. Only three of the eight PCB
case-control studies found any associations between exposure to total PCBs and risk of
endometriosis (Buck et al. 2005, Heiler et al. 2005, Porpora et al. 2009). Buck Louis et
al. (2005) measured total PCBs (n=62), the sum of estrogenic PCBs (n=12), and the sum
of anti-estrogenic PCBs (n=4) in a cohort study of 84 women undergoing laparoscopy
(32endometriosis cases, 52 controls). They found a significant increased risk of

endometriosis for the sum of anti-estrogenic PCBs for women in the third tertile
(OR=3.77, 95% CI 1.12-12.68), however, the risk remained elevated but not significant
when adjusted for all listed covariates. In a case-control study of 158 women (80 cases
and 78 controls), Porpora et al. (2009) found the GM of total PCBs to be significantly
higher in cases than controls (301.3 vs. 203.0, p < 0.01). The OR of endometriosis risk in
the highest tertile of total PCBs compared with the lowest tertile, was 5.63 (95% CI 2.2514.10). Significant increased risk of endometriosis was also found for PCB congeners
118, 138, 153, and 170. Heiler et al. (2005) conducted a case-control study of 50 cases
(25 with peritoneal endometriosis (PE) and 25 with deep endometriotic (DE) nodules)
and 21 controls. Multiple dioxin-like PCBs were measured and expressed as toxic
equivalent (TEQ) per gram of serum lipids. Dioxin-like PCB concentrations were higher
in women with DE compared to controls (12.4 vs. 8.5, p = .026) but did not significantly
differ for women with PE compared to controls (11.0 vs. 8.5) and for women with DE
compared to women with PE (12.4 vs. 11.0).
Four of the PCB case-control studies failed to find significant associations
between endometriosis and exposure to individual PCB congeners, total PCBs, or
specific sub-groups (Niskar et al. 2009, Trabert et al. 2010, Pauwels et al. 2001, Tsukino
et al. 2005). Niskar et al. (2009) conducted a case-control study with 60 confirmed
endometriosis cases staged as I (minimal), II (mild), III (moderate), and IV (severe) and
30 controls. Mean lipid-adjusted PCB concentrations were not significantly different
(179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases, stage III cases, stage
IV cases, and controls, respectively. In the largest case-control study, conducted by
Trabert et al. (2010), total PCBs (n=20), estrogenic PCBs (n=6), and individual PCB
30

congeners were measured in the serum from 251 cases and 538 controls, matched for age
and reference year. Adjusted total and estrogenic PCBs in the highest quartiles were not
associated with an increased risk of endometriosis (Total: OR=1.2, 95% CI: 0.6-2.3,
Estrogenic: OR=0.9, 95% CI: 0.5-1.4). In two case-control studies measuring median
TEQ values (pg TEQ/g lipid) Pauwels et al. (2001) found no association between
endometriosis and the median TEQ values (pg TEQ/g lipid) in cases and controls (29 vs.
27) and Tsukino et al. (2005) found no difference in median TEQ values for
endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs. 3.59, PCBs:
4.61 vs. 5.14), respectively. The OR of endometriosis risk in the highest quartile of total
PCBs compared with the lowest quartile was 0.41 (95% CI: 0.14-1.27).
Like breast cancer, results of the association between PCB exposure and
endometriosis in eight epidemiologic studies were inconsistent or conflicting, therefore,
we extracted and summarized risk estimates of PCBs on endometriosis from four case
control studies using meta-analytic methods. Combining four studies of exposure to
PCBs produced a summary risk estimate of 1.91 (95% CI: 1.05 – 5.54) (Table 4; Fig. 5).
PCB exposures were found to be significantly associated with development of
endometriosis as a meta-analysis of four studies produced an increased risk of 1.91.
However, there is not much confidence in the combined risk estimate of endometriosis
with exposure to PCBs because of the lower estimate of CI being barely higher than 1
(1.05).
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Table 4. Epidemiological studies of the association between exposure to PCBs and risk of endometriosis.
Reference,
location
Heiler et al.
(2005),
Belgium

Study design

Study Population

Measurement of
Exposure
Multiple PCBs from
serum - 12 dioxinlike PCBs (pg
TEQ/g lipids).

Outcomes

Results

Comments

Confounders

Case-control
Study

50 cases: (25 with
PE, 25 with DE), 21
controls.

Mean serum PCB
Range (pg TEQ/g
lipids):
Controls: 6.9-10.5
PE Cases: 9.1-13.3
DE Cases: 0.3-14.9;
Logistic Regression
(OR-95% CI).

Significant risk with
DE nodules (OR=6.7;
95% CI, 1.4-31.2).

Controls did not
present for infertility;
normal pelvic exam.
Cases confirmed with
histological exam of
lesions.

60 cases,
30 controls/
64 controls.

Serum total PCBs
(ng/g) (n=36).

No significant
differences in GMs
(p=.97).
No significant
associations (OR=
1.00, 95% CI 0.991.01).

Prospective
case-control
study

42 cases, 27 controls

Multiple PCBs from
serum; Total PCBs,
TEQ (pg TEQ/g
lipid).

Porpora et al.
(2009), Italy

Case-control
study

80 cases, 78
controls

Multiple PCBs from
serum, Total PCBs.

GM Total PCBs (ng/g
lipid):
Cases stage I-II
(179.98),
stage III (217.33),
stage IV (194.76),
Controls (193.37).
Logistic Regression
(OR-95% CI).
Median TEQ (pg
TEQ/g lipid):
Cases (29), Controls
(27).
Logistic Regression
(OR, 95% CI).
GM of Total PCBs
(ng/g of fat):
Cases: 301.3
Controls: 203.0;
Logistic Regression
(OR-95% CI).

Cases confirmed with
laparoscopic
examination and/or
biopsy.
30 controls confirmed
with laparoscopy, 27
with infertile partner
and 7 with ovulation
problems.
Cases and controls
infertile.
Endometriosis
confirmed with
laparoscopic
examination.
Cases and controls
confirmed with
laparoscopic
examination.

Adjusted for age, BMI,
tobacco consumption,
age at menarche,
duration of OC use,
family history,
menstrual cycle
regularity, # of
children, breastfeeding duration.
Adjusted for age,
gravidity, education,
income.

Niskar et al.
(2009), USA

Case-control
study

Pauwels et al.
(2001), Belgium

Trabert et al.
(2010), USA

Case-control
study

251 cases, 538
controls; matched
for age (5 year) and
reference year.

Multiple PCB
congeners in serum
(n=20); Total PCBs,
Estrogenic PCBs.

Logistic Regression
(OR-95% CI);
Quartiles.

Tsukino et al.
(2005), Japan

Case-control
study

139 women:
Controls: Stage 0 &
I,
Cases: Stage II-IV;
Stage 0=59
Stage I=22
Stage II=10
Stage III=23
Stage IV=25

Multiple PCBs in
serum; Total TEQ
values of cPCBs and
PCBs.

Median TEQ values
(pg TEQ/g lipid);
Logistic Regression
(OR-95% CI);
Quartiles.

No significant
associations found
(OR=4.33, 95% CI
0.49-38.19).
Total PCB
concentrations
significantly higher in
cases (OR=5.63, 95%
CI 2.25-14.10);
Significant increased
risk for PCBs 118, 138,
153, and 170 for 2nd
and 3rd tertiles when
compared to the
lowest tertile.
No significant
associations found.

No significant
associations found
(OR=1.2, 95% CI 0.62.3).

Cases: Group Health
(GH) enrollees with
endometriosis
diagnosis,
Controls: randomly
selected from list of
GH enrollees.
Cases and controls
confirmed with
laparoscopic
examination.

Age, BMI, alcohol
consumption.

Adjusted for age, BMI,
smoking habits,
weight modification.

Adjusted for matching
factors, serum lipids,
income, alcohol
consumption, DDE
exposure.
Adjusted for
menstrual regularity
and average cycle
days.

Figure 5. Forest plot of epidemiological studies of the association between exposure to
PCBs and risk of endometriosis.

Bisphenol A or phthalate and breast cancer. Table 5 lists epidemiological studies of the
association between EDCs - phthalate or BPA and endometriosis. No meta-analysis was
performed on exposure to BPA or phthalates and endometriosis, because only two studies
that met our criteria of selection examined the association between endometriosis and
phthalates (Kim et al. 2011 and Upson et al. 2013), one study addressed the association
between endometriosis and BPA (Itoh et al. 2007) and one study addressed the
association between both BPA and phthalates and endometriosis (Buck et al. 2013).
Besides these two studies, there are several other epidemiological studies that have
examined the association between phthalate or BPA exposure and endometriosis (Table

5). Kim et al. (2011) measured plasma levels of mono (2-ethylhexyl) phthalate (MEHP)
and di-(2-ethylhexyl) phthalate (DEHP) in 97 women with advanced-stage endometriosis
and 169 control women. Mean plasma levels of MEHP and DEHP were found to be
significantly higher in cases than controls (MEHP: 17.4 vs. 12.4, p < .001, DEHP: 179.7
vs. 92.5, p = .010). In a population-based case-control study conducted by Upson et al.
(2013) 8 urinary phthalate metabolites were measured in 92 surgically-confirmed
endometriosis cases and 195 controls. A significant inverse association was found
between urinary MEHP and risk of endometriosis (OR=0.3, 95% CI 0.1-0.7). The
ENDO study was designed to assess the relationship between exposure to environmental
chemicals and endometriosis. Buck Louis et al. (2013) analyzed 14 phthalate metabolites
and total BPA in urine from 495 women who underwent laparoscopy (operative cohort)
and 131 women (population cohort) who underwent pelvic magnetic resonance imaging
(MRI) for the assessment of endometriosis. In the operative cohort, GMs of phthalate
metabolites were not found to be significantly higher in women with endometriosis,
whereas, in the population cohort, GMs of six phthalate metabolites were found to be
significantly higher for women with endometriosis and a twofold or higher increase in
ORs was observed for mono-n-butyl phthalate (mBP), mono- (2-ethyl-5-carboxyphentyl)
phthalate (mECPP), mono-[(2-carboxymethyl) hexyl] phthalate (mCMHP), mono (2ethyl-5-hydroxyhexyl) phthalate (mEHHP), mono (2-ethyl-5-oxohexyl) phthalate
(mEOHP), and mono (2-ethylhexyl) phthalate (mEHP). No significant associations were
found for urinary BPA concentrations in either the operative cohort or the population
cohort. In a hospital based cross-sectional study, conducted by Itoh et al. (2007), urinary
BPA concentrations were analyzed in 140 women who underwent laparoscopy. The
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severity of endometriosis was classified into 5 stages: 0 (n=60), I (n=21), II (n=10), III
(n=24), and IV (n=25). Median creatinine adjusted urinary BPA concentrations did not
significantly differ by endometriosis stage (0.74 vs. 0.93, p = 0.24) for stage 0-I and stage
II-IV, respectively.
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Table 5: Epidemiological studies of the association between EDCs - Phthalate or BPA and endometriosis.

EDCs

Biological samples

Bisphenol A

Serum

Bisphenol B

Serum

Phthalate esters

Plasma
Serum

Diethylphthalate
Monoethylphthalate
Monobutylphthalate

Blood/peritoneal fluid
Blood/peritoneal fluid
Urine
Urine

Monobutylphthalate

Urine
Urine
Urine

Study Population

Outcomes

References

69 fertile women
undergoing laparoscopy,
Naples, Italy
69 fertile women
undergoing laparoscopy,
Naples, Italy
220 South Indian women
undergoing laparoscopy
108 South Indian women
undergoing laparoscopy
59 fertile women
undergoing laparoscopy
59 fertile women
Undergoing laparoscopy
1,227 women from the
NHANES study, United
States
109 women undergoing
laparotomy, Taiwan

Detected in cases

Cobellis et al. 2009

Detected in cases

Cobellis et al. 2009

Increased risk

Reddy et al. 2006b

Increased risk

Reddy et al. 2006a

Higher in cases

Cobellis et al. 2003

No association

Cobellis et al. 2003

No association

Weuve et al. 2010

Increased in cases

Huang et al. 2010

1,227 women from
the NHANES study, USA
109 women undergoing
laparotomy, Taiwan
137 infertile
Japanese women
undergoing
laparoscopy

No association

Weuve et al. 2010

Increased in cases
No association

Huang et al. 2010
Itoh et al. 2009

Several hundred genes are altered by exposure to PCBs, phthalate or bisphenol A
(Fig. 6). The genes related to polychlorinated biphenyls and PCB congeners - 3,4,3',4'tetrachlorobiphenyl (77), 3,4,5,3',4'-pentachlorobiphenyl (126), and 2,4,5,2',4',5'hexachlorobiphenyl (153) in endometriosis were 19, 11, 36 and 18, respectively (Table
6). All these PCBs or their congener-related endometriosis genes were also associated
with 17 beta estradiol. The top interacting genes with polychlorinated biphenyls and
endometriosis were ESR2, NR3C1, CYP19A1, EGFR, FKBP5, ITGB8, MAOB, PGR,
PRLR, SLC16A6, SST, and TXNIP. There were 80 common genes between BPA and
endometriosis (Fig. 6). The two phthalates with most gene interactions were: dibutyl
phthalate and diethylhexyl phthalate. The genes related to dibutyl phthalate and
diethylhexyl phthalate were 4692 and 1646, respectively. There were 71 common genes
between dibutyl phthalate and endometriosis and 29 common genes between diethylhexyl
phthalate and endometriosis (Fig. 6). The common genes between both phthalates dibutyl phthalate and diethylhexyl phthalate, and endometriosis were 22: CNR1,
CYP19A1, CYP26A1, DUSP1, EGFR, ESR2, FKBP5, FOS, GPX3, IGF1, ITGB1,
MAOA, MED1, NR3C1, NR4A1, NR5A1, PRLR, PTGER2, PTGER4, SRD5A1,
TGFB2, and TXNIP (Table 6). Interactions among these genes are shown in Figure 7.
Enrichment pathway analysis revealed that some of these genes are part of: 1) pathways
in cancer (KEGG:05200); 2) signal transduction (REACT:111102), and 3) MAPK
signaling pathway ( KEGG:04150) (Table 3).

Figure 6. Venn diagram of list of genes common between endometriosis and PCBs,
phthalates, and bisphenol A.

Figure 7. Gene Set/Pathway enrichment analysis of genes associated with PCBs,
phthalates, and bisphenol A in endometriosis.
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Table 6. Genes interacting with PCBs and endometriosis.
IUPAC Name (congener number)

Interacting genes

Polychlorinated Biphenyls

19 genes: AKR1C3 | ANKRD1 | AREG | ARNT | CYP19A1 | DUSP1 | ESR2 | FBN1 | FOS | GREB1 |
IGFBP1 | KRAS | NR2C2 | NR3C1 | PAPPA | PTGER4 | STC2 | TGFB2 | THRA
2 genes: ESR2 | NR3C1
11 genes: ARNT | DDX5 | ESR2 | FKBP5 | ITGB8 | KLF13 | MAOB | NR1D2 | PRLR | SULF2 | TXNIP
25 genes: ABCC9 | BRD8 | CD55 | CNR1 | ELAVL1 | ERRFI1 | FKBP5 | IFNGR1 | IGFBP1 | MED1 |
MED4 | MTA1 | NCOA6 | NR2C1 | NR3C1 | NR3C2 | NR4A1 | NRP1 | PRLR | SLC16A6 | SPARCL1 |
SST | TAGLN | THRA | TNC
2 genes: EGFR | FOS
36 genes: AREG | CD55 | CXCL14 | CYP19A1 | DUSP1 | ENPP1 | FBN1 | GPX3 | HBEGF | HSD17B1 |
HSD17B2 | IGF1 | IGFBP1 | IGFBP6 | IL1R1 | IMPA2 | MAOA | MAOB | MED1 | NEDD4L | NR3C1 |
OSR2 | PRLR | RASL11A | SEPP1 | SLC20A1 | SLC40A1 | SLC7A8 | SPARCL1 | SRD5A1 | SRD5A2 |
SST | STC2 | TAGLN | TGFB2 | TXNIP
10 genes: FBLN1 | FOS | HBEGF | IGF1 | NEFM | PRL | SLC16A6 | SRD5A1 | SRD5A2 | SST
2 genes: AR | CYP2B1
18 genes: CYP19A1 | DCSTAMP | EGFR | ESR2 | FOS | HSD17B1 | HSD17B2 | IFIT1 | IGF1 | ITGB8 |
MAOB | NR3C1 | SEPP1 | SLC16A6 | SRD5A1 | SRD5A2 | SST | TXNIP
114 genes: ABCC9 | ABI3BP | ACTA2 | AKR1C1 | AKR1C2 | AKR1C3 | ANKH | ANKRD1 | AREG |
ARHGAP28 | ARNT | BMP7 | C10ORF10 | C1R | CCNE2 | CD55 | CFD | CLDN1 | CNIH3 | CNR1 | CPM |
CXCL14 | CYB5A | CYP19A1 | CYP26A1 | DDX5 | DICER1 | DIO2 | DKK1 | DUSP1 | EGFR | ELAVL1 |
ERRFI1 | ESR2 | FBLN1 | FBN1 | FKBP5 | FOS | GPX3 | GREB1 | HDAC1 | HDAC2 | HERC5 |
HS3ST3B1 | HSD17B1 | HSD17B2 | IDO1 | IFIT1 | IGF1 | IGFBP1 | IGFBP6 | IHH | IL15 | IL1R1 | IL7R |
ITGA2 | ITGB1 | ITGB8 | KLF13 | KLF9 | KRAS | LMOD1 | LTF | MAOA | MAOB | MED1 | MED14 |
METTL7A | MIR21 | MYLIP | NCOA1 | NCOA6 | NCOR1 | NEDD4L | NR2F2 | NR3C1 | NR3C2 | NR4A1
| NR5A1 | NRP1 | NTRK3 | OLFM4 | OSR2 | PAPPA | PGR | PRL | PRLR | PTGER2 | PTGER4 | RARB |
RASGRP1 | RGS4 | RORB | RXFP1 | SEPP1 | SLC16A6 | SLC1A1 | SLC20A1 | SLC40A1 | SLC7A8 |
SMPDL3A | SPARCL1 | SRD5A2 | STC2 | SULF2 | TACSTD2 | TAGLN | TGFB2 | THRA | TNC | TOB1 |
TRH | TXNIP | VCAN ZEB2
71 genes: ABI3BP | ACTA2 | AKR1C1 | ANKRD1 | AREG | ARNT | BMP7 | BRD8 | C1R | CCNE2 | CD55
| CLDN1| CNR1 | COPS2 | CYB5A | CYP19A1 | CYP26A1 | DDX5 | DICER1 | DUSP1 | EGFR | ELAVL1 |
ENPP1 | ERRFI1 | ESR2 |FKBP5 | FOS | GPX3 | HDAC1 | HSD17B1 | IGF1 | IL1R1 | ITGB1 | ITGB8 |
KLF9 | LMOD1 | MAOA | MAOB | MED1 |MED14 | MED17 | NR1D2 | NR2F2 | NR2F6 | NR3C1 |
NR4A1 | NR5A1 | NRP1 | OSR2 | PAPPA | PGR | PRLR | PTGER2 |PTGER4 | RASL11A | SEPP1 |
SLC16A6 | SLC20A1 | SLC40A1 | SLC7A8 | SMPDL3A | SRD5A1 | STC2 | SUCLG2 |SULF2 | TAGLN |
TGFB2 | THRA | TOB1 | TXNIP | VCAN.
29 genes: CNR1 | CYP19A1 | CYP26A1 | EGFR | ESR2 | FKBP5 | FOS | HERC5 | IGF1 | IGFBP1 | ITGB1 |
MAOA | NCOA1 | NR3C1 | NR4A1 | NR5A1 | PAX2 | PRL | PRLR | PTGER2 | PTGER4 | SRD5A1 |
TGFB2 | DUSP1 | FMO2 | GPX3 | MED1 | NCOR1 | TXNIP
22 genes: CNR1, CYP19A1, CYP26A1, DUSP1, EGFR, ESR2, FKBP5, FOS, GPX3, IGF1, ITGB1,
MAOA, MED1, NR3C1, NR4A1, NR5A1, PRLR, PTGER2, PTGER4, SRD5A1, TGFB2, TXNIP
80 genes: ABCC9 | ACTA2 | AREG | ARHGAP28 | ARNT | BMP7 | BRD8 | CCNE2 | COPS2 | CYB5A |
CYP19A1 | CYP26A1 | DDX5 | DICER1 | DIO2 | DUSP1 | EGFR | ELAVL1 | ENPP1 | ERRFI1 | ESR2 |

2,4,4'-trichlorobiphenyl (28)
3,4,3',4'-tetrachlorobiphenyl (77)
2',3,3',4',5-pentachloro-4-hydroxybiphenyl
(4'-OH-PCB-86;4-hydroxy-2 , 2' , 3' , 4' ,
5'-pentachlorobiphenyl )
2,2',4,6,6'-pentachlorobiphenyl (104)
3,4,5,3',4'-pentachlorobiphenyl (126)

2,2',3',4,4',5-hexachlorobiphenyl (137)
2,3,6,2',3',6'-hexachlorobiphenyl (136)
2,4,5,2',4',5'-hexachlorobiphenyl (153)
17 β Estradiol

Dibutyl Phthalate

Diethylhexyl Phthalate
Dibutyl Phthalate and Diethyl-hexyl
Phthalate
Bisphenol A

Integration of genes overlapped among EDCs, Breast Cancer and Endometriosis:
Integration of genes associated with exposure to PCBs, and breast cancer and
endometriosis based enriched disease analysis showed that there were 16 endometriosis
genes overlapped with breast neoplasms – AREG, C10ORF10, CLDN1, CYP19A1,
DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, RARB, and
STC2 (Tables 2 and 6). All of these genes were also associated with estrogen in breast
neoplasms. Out of these 16 genes, there were 14 genes - AREG, CLDN, CYP19A1,
DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, RARB, and
STC2 common among 17 beta estradiol, breast cancer, and endometriosis (Tables 2, 6
and 7). PCBs associated AREG, CYP19A1, ESR2, FOS, KRAS and STC2 genes; PCB
126 associated AREG, CYP19A1, and STC2 genes and PCB 15 associated
CYP19A1,EGFR,ESR2,FOS and IGF1 genes overlapped with 17 beta estradiol, breast
cancer, and endometriosis (Tables 2, 6 and 7). Similarly, we identified dibutyl phthalate
and diethyl-hexyl phthalate associated overlapping genes with 17 beta estradiol, breast
cancer, and endometriosis: AREG, CLDN1, CYP19A1, EGFR, ESR2, FOS, IGF1,
NR2F6, PGR and STC2; and CYP19A1,EGFR,ESR2,FOS,IGF1 and NCOA1.

There

were 5 common overlapped genes between these two phthalates, 17 beta estradiol, breast
cancer and endometriosis: CYP19A1, EGFR, ESR2, FOS, and IGF1. We also identified
another 11 EDC -BPA associated genes that were common among 17 beta estradiol,
breast cancer and endometriosis: AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS,
NCOA1, NCOR1, PGR, and STC2. Five genes - CYP19A1, EGFR, ESR2, FOS, and
IGF1 were common among all three EDCs -PCBs, phthalates and BPA, 17 beta estradiol,

breast cancer, and endometriosis. For the gene ontology terms associated with each gene,
please see Table 8.
Since both of these diseases are dependent on unopposed estrogen for their
growth, we examined whether estrogen receptor signaling pathway genes are common
among estrogen, EDCs, breast cancer and endometriosis. PCBs and congeners
3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'-hexachlorobiphenyl (153) were
associated with some of the same estrogen receptor signaling pathway genes – AR,
ESR1, ESR2, NCOA3, and PPARGC1B; AR, BRCA1, ESR1, IGF1, and PAK1; and
AR, BRCA1, CTNNB1, ESR1, ESR2, IGF1, and SRC, respectively (Table 7). The
following were also observed with 17 beta estradiol - AR, BRCA1, CCNE1, CTNNB1,
ESR1, ESR2, FHL2, FOXA1, IGF1, NCOA1, NCOA2, NCOA3, NRIP1, PAK1, PGR,
PHB, PPARGC1B, RB1, SFRP1, SRC, and ZNF366. Similarly, common genes of
estrogen receptor signaling pathways were also observed with another three EDCs.
Dibutyl phthalate associated AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2,
FHL2,,HEYL, IGF1,PGR, RB1 and SRC genes; diethylhexyl phthalate associated - AR,
CTNNB1, ESR1, ESR2, IGF1, NCOA1, and PPARGC1B, and BPA associated AR,
BRCA1, CCNE1, CTNNB1, ESR1, ESR2, FHL2, IGF1, NCOA1, NCOA2, NCOA3,
NRIP1, PAK1, PGR, PHB, RB1, SFRP1, SIRT1, and SRC genes which are also
associated with 17 beta-estradiol in breast neoplasms (Table 7). Another factor that
appears to be common in both diseases is inflammation. Therefore, we also examined
whether inflammation associated genes are common among estrogen, EDCs and breast
cancer. PCBs and congeners 3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'hexachlorobiphenyl (153) were associated with the following inflammation related genes
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– AHR, CXCL2, HMOX1, IFNG, IL6, PTGS2, SOD2, and TNF; AHR, CXCL8,
HMOX1, IL1B, IL6, MMP9, NOS2, NOS3, PARP1, PTGS2, and TNF; and AHR, IFNG,
IL1B, PARP1, PTGS2, and TNF, respectively (Table 7). Dibutyl phthalate, diethyl-hexyl
phthalate and BPA-associated set of inflammation-related genes were AHR, CXCL8,
HMOX1, IL1B, IL6, MIF, MMP9, PARP1, SOD2, TFRC and TNF; AHR, CSF2,
CXCL8, IFNG, LEP, MMP9, SOD2 and TNF; and AHR, CSF2, HMOX1, IFNG, IL1B,
IL6, LEP, MIF, MMP9,NOS2, NOS3, PARP1, PTGS2,SOD2, and TNF, respectively.
All of these genes were also associated with 17 beta estradiol in breast neoplasms. In
summary, EDC associated inflammation set of genes in breast neoplasms are estrogen
responsive.
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Table 7. EDC-interacting endometriosis, environmental response and inflammation
associated estrogen responsive genes in breast neoplasms.
EDC interacting
with genes in
breast
neoplasms
17 beta
Estradiol

Steroid hormone receptor
signaling pathway

Endometriosis

Inflammation

21 genes AR, BRCA1, CCNE1,
CTNNB1, ESR1, ESR2, FHL2,
FOXA1, IGF1, NCOA1, NCOA2,
NCOA3, NRIP1, PAK1, PGR,
PHB, PPARGC1B, RB1, SFRP1,
SRC, ZNF366

AREG, CLDN1,
CYP19A1, DKK1,
EGFR, ESR2, FOS,
IGF1, KRAS,
NCOA1, NCOR1,
PGR, RARB, STC2

PCBs

AR,ESR1,ESR2,NCOA3,
PPARGC1B

3,4,5,3',4'pentachlorobiph
enyl (126)

AR, BRCA1, ESR1, IGF1, PAK1

AREG,CYP19A1,
ESR2,FOS,KRAS
STC2
AREG, CYP19A1,
STC2

2,4,5,2',4',5'hexachlorobiph
enyl (153)
Dibutyl
Phthalate

AR,BRCA1,CTNNB1,ESR1,ESR
2,IGF1,SRC

CYP19A1,EGFR,
ESR2,FOS,IGF1

AHR,CSF3,CXCL2,
CXCL8,HMOX1,
IFNG,IL1B,IL6
LEP,MIF,MMP9
NOS2,NOS3,PARP1
PTGS2,SOD2,TFRC
TNF
AHR,CXCL2,HMO
X1, IFNG,IL6
PTGS2,SOD2,TNF
AHR,CXCL8,HMO
X1,IL1B,IL6,MMP9,
NOS2,NOS3,
PARP1,PTGS2,TNF
AHR,IFNG,IL1B,
PARP1,PTGS2,TNF

AR,BRCA1,CCNE1,CTNNB1,E
SR1,ESR2,FHL2,HEYL,IGF1,PG
R,RB1,SRC

Diethylhexyl
Phthalate

AR,CTNNB1,ESR1
ESR2,IGF1,NCOA1
PPARGC1B
AR,BRCA1,CCNE1,CTNNB1,E
SR1,ESR2,FHL2,IGF1
NCOA1,NCOA2,NCOA3
NRIP1,PAK1,PGR,PHB
RB1,SFRP1,SIRT1,SRC

AREG,CLDN1,
CYP19A1,EGFR
ESR2,FOS,IGF1
NR2F6,PGR,STC2
CYP19A1,EGFR
ESR2,FOS,IGF1
NCOA1
AREG,CYP19A1,
EGFR, ESR2, FOS,
IGF1, KRAS,
NCOA1, NCOR1,
PGR, STC2

Bisphenol A
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AHR,CXCL8,HMO
X1, IL1B, IL6, MIF
MMP9, PARP1,
SOD2, TFRC,TNF
AHR,CSF2,CXCL8
IFNG,LEP,MMP9
SOD2,TNF
AHR, CSF2,
HMOX1, IFNG,
IL1B, IL6, LEP,
MIF, MMP9, NOS2,
NOS3, PARP1,
PTGS2,SOD2, TNF

Table 8. Integration of changes in the expression of genes showing common genes modified in EDCs, breast cancer and
endometriosis.
Gene name

Gene ID

Location

Database*

Gene function

AREG

374

4q13–q21

E

Amphiregulin

CYP19A1

1588

15q21.1

E

cytochrome P450, family 19, subfamily A, polypeptide 1

EGFR

1956

7p12

E

epidermal growth factor receptor

ESR2

3468

14q23.2

H

estrogen receptor 2 (ER beta)

FOS

2353

14q24.3

E

v-fos FBJ murine osteosarcoma viral oncogene homolog

IGF1

3479

12q22-q23

E

insulin-like growth factor 1 (somatomedin C)

KRAS

6407

12p12.1

H

Kirsten rat sarcoma viral oncogene homolog

NCOA1

7668

2p23

H

nuclear receptor coactivator 1

NCOR1

7672

17p11.2

H

nuclear receptor corepressor 1

PGR

5241

11q22-q23

E

progesterone receptor

STC2

11374

5q35.1

H

stanniocalcin 2

Underline shows 5 genes that were common among all three EDCs -PCBs, phthalate and bisphenol A, breast cancer and
endometriosis. Environmentally responsive genes are indicated in database column.
*(E): Environmental responsive gene based on Environmental Genome Project; (H): HGNC database.

Literature based validation of genes showing links between endometriosis and
breast cancer: The set of estrogen responsive genes from EDCs, environmental,
inflammation, and toxicogenomics showing a link between endometriosis and breast
cancer is shown in Table 7. Research supporting the potential involvement and
importance of all EDC responsive common genes in breast cancer and endometriotic
lesions was found in the literature and human genome databases. The search of the
environmental genome project databases showed that six genes out of 12 PCBs
associated genes - AREG, CYP19A1, EGFR, FOS, IGF1, and PGR were environmentally
responsive genes (Table 8). These common genes were then compared to a curated list of
genes in PCB exposed human cell lines. PCB congeners 77 and 153 increased the
expression of the following estrogen responsive genes AREG, CYP19A1, EGFR, ESR2,
FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR,STC2 (De et al. 2010). The
expression of estrogen responsive genes common to breast cancer: AREG, CYP19A1,
EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR,STC2 genes was
upregulated in human endometriotic lesions (Burney et al. 2007, Hever et al. 2007, Sha et
al. 2007).
We also analyzed the interaction among AREG, CYP19A1, EGFR, ESR2, FOS,
IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, and STC2 genes using enrichment
pathway analysis (Fig. 8). In order to investigate connections between PCBs responsive
gene lists in breast cancer and endometriosis, we performed Bayesian network analysis.
The Bayesian network analysis on the Cancer Genome Atlas (TCGA) Research Network
data available through cbioportal.org identified the maximum likelihood structure of
PCBs associated genes in breast neoplasm (Fig. 9). Figure 9 shows plausible interactions

among genes. Parents of a variable in Bayesian networks are defined as variables that
arcs are originated to that variable. For example, in Figure 9, parents of BCHE are
PTGS2 and HMOX1. Ancestors of a variable are all the parents of the variable, all
parents of parents, and so on. Arcs in Figure 9 indicate correlations and they indicate
Markov conditions. In Figure 9, from the arcs, the relationships between PTGS2 and
BCHE was the strongest among all pairwise relationships, but also they formed a special
Y structure (Spirtes et al. 2000) that indicates plausible causality, i.e., PTGS2 regulating
BCHE. Similarly we have analyzed mRNA expression endometriosis data (Fig.10).
These genes were more sparsely connected.
Some of the common estrogen responsive interacting genes are part of steroid
hormone biosynthesis; metabolic pathways; MAPK signaling pathway; ErbB signaling
pathway; chemokine signaling pathway; p53 signaling pathway; mTOR signaling
pathway; VEGF signaling pathway; focal adhesion; adherens junction; tight junction; gap
junction; toll-like receptor signaling pathway; natural killer cell mediated cytotoxicity; T
cell receptor signaling pathway; B cell receptor signaling pathway; Fc epsilon RI
signaling pathway; regulation of actin cytoskeleton; insulin signaling pathway; GnRH
signaling pathway; and pathways in cancer (Table 3). We also compared these common
genes to a curated list of genes in breast cancer, endometriosis as well as EDC exposed
populations. The search of the environmental databases showed that some of these
common genes were environmentally responsive. All these EDC associated set of genes
are estrogen responsive (Table 8). All these PCB, Phthalate and BPA associated common
genes are altered in human breast tumor, uterine tumor tissues and endometriosis lesions
(Table 8).
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Figure 8. Interaction of common genes between estrogen, PCBs and breast neoplasms:
AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR,
and STC2.

Figure 9. Identification of the maximum likelihood structure of PCBs associated genes
in breast neoplasm.
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Discussion
In the present study, we determined whether estrogen mimicking EDCsassociated gene expression contributed to the risk of breast cancer among women with
endometriosis with the aim of elucidating the role of environmental endocrine disrupting
chemicals- PCBs, phthalates and BPA while focused on identifying environmental
epidemiologic evidence and molecular signatures. Women with endometriosis have been
implicated to develop certain types of cancer, including breast and ovarian cancers
(Melin et al 2007). Although several molecular and environmental risk factors are
common to endometriosis and breast cancer, the results of epidemiologic studies have
been inconsistent on whether endometriosis is linked to particularly breast cancer. Both
of these diseases are dependent on unopposed estrogen for their growth. Endometrial
tissue shows elevated activity of aromatase, and this enzyme is a key for the biosynthesis
of estrogens (Irahara et al. 2006). Our meta-analysis showed that exposure to estrogen
mimicking EDC - PCBs increased summary risk of both breast cancer and endometriosis.
We further evaluated the relationship between endometriosis and breast cancer, and
EDCs using a bioinformatics method. Our bioinformatics approach was able to identify
genes with the potential to be involved in interaction with PCBs and other EDCs –
phthalates and BPA that may be important to the development of breast cancer and
endometriosis. We identified six PCBs associated genes - AREG, CYP19A1, EGFR,
FOS, IGF1, and PGR that are environmentally responsive. Similarly, we also observed
dibutyl phthalate and diethyl-hexyl phthalate associated 5 common genes - CYP19A1,
EGFR, ESR2, FOS, and IGF1 in breast cancer and endometriosis; and BPA associated
11 genes - AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1,
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PGR, and STC2 that were common in both breast cancer and endometriosis. Five genes CYP19A1, EGFR, ESR2, FOS, and IGF1 were common among all three EDCs –PCB
153, phthalates and BPA, breast cancer, and endometriosis. All five common genes are
modified in human breast tumor, uterine tumor tissues and endometriosis lesions. All of
these genes are estrogen responsive. These findings suggest that the increased risk
associated with endometriosis may be due to common environmental and molecular risk
factors between endometriosis and breast cancer.
Human and wild life populations are continually exposed to a wide variety of
EDCs. Experimental animal and human studies have indicated that EDCs have the
ability to cause endocrine toxicity. For example, exposure to PCBs has been reported to
show a significant delay in puberty in boys. De-feminization, early secondary breast
development, or thelarche have been reported in girls exposed to phthalates (Roy et al.
2009). Despite existing debates over the form and amount of BPA to which developing
and adult humans are exposed, there is considerable data indicating that exposure of
humans to BPA is associated with increased risk for breast cancer and reproductive
dysfunctions (Bertelsen et al. 2007 and Roy et al. 1997). Postmenopausal women with
high serum levels of BPA and mono-ethyl phthalate have been reported to have elevated
breast density, one of the risk factors for breast cancer (Buck Louis et al. 2005). These
findings are consistent with parallel research in experimental models (Colerangle et al.
1997, Munoz-de-Toro et al. 2005, Newbold et al. 2007, Murray et al. 2007). For
example, fetal bisphenol A exposure induces the development of preneoplastic and
neoplastic lesions in the mammary gland in rats (Newbold et al. 2007). Fetal exposure of
BPA significantly increases susceptibility to DMBA to produce mammary tumors in
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mice (Murray et al. 2007). BPA has also been reported to promote tumor growth of
human breast cancer cells -MCF-7 in ovariectomized NCR nu/nu female mice. Excess
exposures to polychlorinated dioxins and certain PCBs in women who lack detoxifying
enzymes are risk factors in breast cancer. A landmark UN report assessing effects of
human exposure to hormone-disrupting chemicals acknowledges that approximately 800
chemicals are suspected to act as endocrine disruptors or mimic natural hormones or
disrupt hormone regulation (UNEP, 2013). This report highlights that there is some
associations between exposure to many of the endocrine disruptors, particularly,
estrogen-mimicking chemicals and an increased risk of breast cancer in women.
Exposure to EDCs, such as, PCBs and BPA during early development of the breast,
endometrium, and prostate can alter their development, and possibly contribute to the
susceptibility to diseases through effects on stem cells.
Breast cancer and endometriosis are complex chronic diseases and they are not
caused by one agent or one environmental factor. The majority of the epidemiologic
studies have largely focused on a single EDC and have ignored the possibility that
multiple environmental agents may act in concert. It is important to consider that during
the development of an individual from the single cell to prenatal stages to adolescent to
adulthood and through the complete life span, humans are exposed to countless
environmental EDCs. Like genes, environmental factors also interact among themselves.
A single exposure to an EDC alone cannot explain the development of a complex chronic
disease – like breast cancer, rather it appears that exposure to multiple EDCs across the
lifespan and their interactions influence the development of breast cancer in an
individual. A recent study from Spain lends support to the above concept. They have
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shown that the body burden of lipophilic estrogenic organ halogen chemicals through
cumulative exposure is associated with breast cancer risks (Ibarluzea et al. 2000). The
temporal and spatial environmental modulations of the normal genetic and phenotypic
changes in a cell lead to the development of a particular type of disease phenotype.
However, the majority of epidemiologic studies measured EDC exposures later in a
woman’s life, when the breast or endometrium tissue is less vulnerable. In-utero exposure
to the estrogenic anti-miscarriage compound- diethylstilbestrol (DES) underlines the
importance of early life EDC exposure in breast cancer development and is apparent from
the recent report showing elevated breast cancer risks in the daughters of exposed women
(Palmer et al. 2006). Given the proven contribution of unopposed estrogens in the
development of breast cancer and endometriosis, it is biologically plausible that less
potent EDCs may also contribute to risks of chronic diseases, such as breast cancer and
endometriosis (Bertelsen et al. 2007 and Roy et al. 1997).
To date, most research on the endometriosis connection to breast cancer biology has
focused on a few mechanisms and pathways in their development. Genes involved in
estrogen biosynthesis, metabolism, estrogen signaling pathway and signal transduction
have been suggested to affect susceptibility of breast cancer and endometriosis. ESR is an
important molecular risk factor in the pathogenesis of breast cancer (Treek et al. 2009).
We examined the association of estrogen receptor ESR2 and estrogen biosynthesis
enzyme, aromatase, CYP19A1 with endometriosis and breast cancer. Both mRNA and
protein levels of estrogen receptor 2 (ESR2) were found higher in endometriotic tissue
(Xue et al 2007). Increased expression of aromatase has been found in breast tumors
(Irahara et al. 2006). In women with endometriosis, elevated tissue levels of estradiol due
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to increased aromatase activity are found (Bulun et al. 2009). In this we found that five
common estrogen responsive genes, including CYP19A1 and ESR2 were associated with
all three EDCs -PCBs, phthalates and BPA, breast cancer, and endometriosis. We also
observed association of EGFR, FOS and IGF1 genes with EDCs, endometriosis and
breast cancer. Increased circulating IGF1 level is associated with and increased risk of
breast cancer (Al Zahrani et al. 2006). Another common gene identified in both
endometriosis and breast cancer in this study was stanniocalcin 2 (STC2). This is a
downstream target of estrogen signaling pathways (Raulic et al. 2008). The expression of
STC2 is induced in MCF-7 cells and the endometrial gland of women by 17 beta
estradiol and in breast tumors (Wood et al. 2010 and Gruvberger et al. 2001). Modified
expression of these genes is known to be involved in pathway of cancer, including breast
cancer, mTOR signaling pathway, focal adhesion, VEGF signaling pathway and ErbB
signaling pathway. However, the link of these common genes between the 2 diseases and
EDCs does not prove that one causes the other. Furthermore, our study also revealed that
PCBs and congeners 3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'hexachlorobiphenyl (153) are associated with some of the same estrogen receptor
signaling pathway genes in breast neoplasm that are also observed with 17 beta estradiol.
Similarly, common genes of estrogen receptor signaling pathways were also observed
with EDCs -dibutyl phthalate; diethylhexyl phthalate; and BPA and breast neoplasms that
are also observed with 17 beta-estradiol. These finding support genes involved in
estrogen biosynthesis and estrogen signaling pathway may contribute to the susceptibility
of breast cancer and endometriosis.
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Another factor that appears to be common in both diseases is inflammation. The
role of estrogen in inflammation is complex. On one hand, studies have observed
suppression of inflammation with increased estrogen in several animal models of chronic
inflammatory diseases. On the other hand, there is evidence of proinflammatory effects in
some chronic autoimmune diseases in humans. Estrogen induces proinflammatory
cytokines, such as interleukin-1 beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha), and a number of other inflammation associated genes. Inflammation-mediated
oxidative stress is involved in the development of both of these diseases (Roy et al.
2007). Prostaglandin E2 is up regulated in endometriosis as a result of inflammation,
which increases estrogen synthesis by up regulating aromatase. A proinflammatory
milieu can also directly increase estrogen production. Hence, inflammation may work in
conjunction with or in addition to estrogen exposure in the development of breast cancer
in women with endometriosis (Modungo et al. 2005).
There are several strengths of the meta-analysis of EDCs associated with breast
cancer or endometriosis. The use of the general variance based method gave more
weight to larger studies, considered confounding, and limited the number of studies
excluded because of missing data. Most studies used interview data to assess exposure,
providing a more direct accounting of exposure. Finally, the combining of similar
exposure time periods and splitting of occupational and household agricultural/nonagricultural exposures allowed for assessment of the range of possible external etiological
factors involved in breast cancer or endometriosis development. Limitations of the study
include those typical of the epidemiological studies combined in meta-analyses such as
publication bias, recall bias and exposure misclassification. Also, EDCs and breast
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cancer type, along with individual practices of participants, were not distinguished in
most studies. There are also obvious limitations to this type of bioinformatics analyses.
While this analysis provides numerous hypotheses for potential gene-EDC interactions, it
can only suggest possibilities, and therefore further research in a lab setting is necessary
to validate their involvement in breast cancer and endometriosis.

While we did choose

studies and databases we felt would provide a comprehensive set of modified genes, we
did not assess the entire set of literature on breast cancer and endometriosis-related genes,
and therefore may have missed some potential modified genes in our analysis.
Furthermore, we have not included epigenetic genes in our analysis and therefore may
have missed other potential gene-EDC interaction pathways to breast cancer and
endometriosis through these mechanisms. While these are shortcomings of this type of
research, the clear benefit of this study in particular, is the identification of genes with
potential to contribute to breast cancer and endometriosis. Furthermore, generation of
gene-EDCs interaction data relevant to breast cancer and endometriosis through this
bioinformatics method provides highly useful information for a more comprehensive
understanding of gene-EDCs interaction in the development breast cancer and
endometriosis. Further research with an integrated bioinformatic, biostatistic and
molecular epidemiologic approach is needed to study
CONCLUSION
In summary, the major novel findings emerged from the meta-analyses that PCBs
exposure may increase risk of breast cancer and endometriosis. A single exposure to an
internal or external environmental factor alone cannot explain the development of a
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complex chronic disease, such as breast cancer and endometriosis, rather it appears that
exposure to multiple environmental and molecular factors across the lifespan and their
interactions influence the development of these chronic diseases in an individual. There
may be common molecular risk factors between endometriosis and breast cancer and it is
biologically plausible that an altered endogenous estrogen levels presumably from
exposure to estrogen mimicking EDCs may contribute to the risk of these diseases. Our
bioinformatics approach helps to identify genes associated with EDCs, and to generate a
new hypothesis to evaluate the relationship between endometriosis and breast cancer.
Endocrine disruptor responsiveness and systems impacts consistent with system-wide
findings in breast cancer and endometriosis are thus supported as important
considerations in identifying the numerous and complex modes of gene-EDCs interaction
in these diseases. Given the proven contribution of unopposed estrogens to the risk for
endometriosis or endometrial neoplasia or breast cancer, renewed health concerns have
aroused about estrogen mimicking EDCs found in food, personal care products or as
environmental contaminants. Although limited and inconsistent evidence exists for an
association between some EDC’s and adverse human reproductive outcomes, the
widespread human exposure to EDC’s and the increasing concern for their potential to
induce reproductive toxicity, especially in susceptible populations with sensitive gene
polymorphisms, demonstrates a clear need for more research.
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HYPOTHESIS
Exposure to EDCs through altering hormone levels results in an increased risk of
reproductive toxicity in females.
SPECIFIC AIMS
This research was designed in response to the recent resurgence of findings
related to the potential reproductive and endocrine toxicity of endocrine disrupting
compounds (EDCs). Using the CDC’s NHANES database, statistical analysis was
performed to analyze the associations between urinary and blood biomarkers of EDCs,
reproductive health variables, and medical questionnaires (cancer). The objective of this
research was to assess exposure to endocrine disrupting compounds in the general U.S.
population through the CDC’s National Health and Nutrition Examination Survey and
determine if risk of reproductive dysfunction is increased due to exposure to endocrine
disrupting compounds (polychlorinated biphenyls, phthalates, and bisphenol A)
commonly found in the environment today.
Specific Aim 1: To assess exposure to PCBs in the general U.S. population using blood
serum PCB biomarkers available in the CDC’s 1999-2004 NHANES database and
conduct secondary statistical analysis to determine if there is an association between
higher body burdens of PCBs and breast cancer in women.
Sub Aim 1a: Female participants in the 1999-2004 NHANES cycles, 20 years of
age and older who have higher body burdens of PCBs will have an increased risk
of breast cancer.
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Specific Aim 2: To assess exposure to PCBs in the general U.S. population using blood
serum PCB biomarkers available in the CDC’s 1999-2004 NHANES database and
conduct secondary statistical analysis to determine if there is an association between
higher body burdens of PCBs and adverse reproductive health effects in women.
Sub Aim 2a: Female participants in the 1999-2004 NHANES cycles, 20-54 years
of age who have higher body burdens of PCBs will have an increased risk of
endometriosis.
Sum Aim 2b: Female participants in the 1999-2004 NHANES cycles, 20-54
years of age who have higher body burdens of PCBs will have an increased risk
of uterine leiomyomas.
Specific Aim 3: To assess exposure to EDCs in the general U.S. population using blood
serum and urinary biomarkers available in the CDC’s 1999-2010 NHANES database and
conduct secondary statistical analysis to determine if there is an association between
higher body burdens of EDCs and reproductive cancers (breast cancer, cervical cancer,
ovarian cancer, and uterine cancer) in women.
Sub Aim 3a: Female participants in the 1999-2004 NHANES cycles, 20 years of
age and older who have higher body burdens of PCBs will have an increased risk
of cervical cancer, ovarian cancer, or uterine cancer.
Sum Aim 3b: Female participants in the 2003-2010 NHANES cycles, 20 years
of age and older who have higher body burdens of phthalates will have an
increased risk of breast cancer, cervical cancer, ovarian cancer, or uterine cancer.
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Sum Aim 3c: Female participants in the 2005-2010 NHANES cycles, 20 years of
age and older who have higher body burdens of bisphenol A will have an
increased risk of breast cancer, cervical cancer, ovarian cancer, or uterine cancer.
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CHAPTER III
METHODS
Study Design
The primary objective of this study was to assess exposure to EDCs (PCBs, BPA,
and phthalates) and determine whether exposure to these agents is a contributing factor in
reproductive dysfunction in the U.S. general population. To support or refute the
proposed role of EDCs, secondary statistical analysis was conducted using data from the
CDCs 1999-2010 National Health and Nutrition Examination Study. The National
Center for Health Statistics (NCHS), a branch of the U.S. Public Health Service in the
U.S. Department of Health and Human Services, developed the National Health and
Nutrition Examination Survey (NHANES). NHANES, conducted annually since 1999 by
the Centers for Disease Control and Prevention (CDC), is an ongoing cross-sectional
survey designed to be nationally representative of the non-institutionalized, U.S. civilian
population. The survey design is a complex multistage probability sample, with
oversampling of adolescents 12-19 years of age, adults greater than or equal to 60 years
of age, low-income persons, Mexican Americans, and non-Hispanic blacks.
Oversampling of subgroups is done to allow for more precise and valid estimates to be
derived than a simple random sampling would allow. To obtain a representative sample
of the U.S. population, the country is divided into geographic areas known as primary
sampling units which are then combined to form strata, each strata is then divided into a
series of neighborhoods. From these neighborhoods, households are chosen at random
and inhabitants are interviewed to determine if they are eligible for participation in the
study. Once eligibility is determined participants complete a confidential and voluntary
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home interview followed by a standardized physical examination in a specially equipped
mobile evaluation clinic (MEC). The MEC examination consists of a physical
examination, dental examination, detailed face-to-face personal interview, and collection
of biological specimens. Blood is obtained by venipuncture from a subsample of
participants aged 1 year and older and urine specimens were collected from a subsample
of participants aged 6 years and older. Each survey includes a nationally representative
sample of approximately 5,000 participants. The study protocol was reviewed and
approved by the CDC institutional review board and informed consent was obtained from
all subjects prior to participating in the NHANES. All data collected is held in the
strictest confidence and cannot be given out without consent. Code numbers are assigned
in place of names or other identifying factors to maintain confidentiality. All
participants received a cash payment for time and effort, as well as, reimbursement for
transportation and baby/elder care (CDC, 2012)
Laboratory Methods
In each 2-year survey period, environmental chemicals or their metabolites were
measured in blood serum or urine specimens from random subsamples of approximately
2,500 participants. The measurement of environmental chemicals in blood, serum, and
urine reflect the amount of the chemical that enters the body through ingestion,
inhalation, or dermal exposure routes. Environmental exposure measurements were made
by the CDC’s Environmental Health Laboratory (Division of Laboratory Sciences,
National Center for Environmental Health) by isotope dilution mass spectrometry,
inductively coupled plasma mass spectrometry, or graphite furnace atomic absorption
spectrometry. For chemicals measured in urine, levels are expressed per volume of urine
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or per gram of creatinine. For lipophilic compounds such as dioxins, furans, PCBs, and
organochlorine pesticides, serum levels are expressed per gram of total lipid and per
whole weight of serum reflecting the amount of compounds that are stored in body fat.
Blood serum and urinary samples collected during the MEC exam were stored at 4
degrees Celsius or frozen at -20 degrees Celsius and then shipped to the CDC’s National
Center for Environmental Health, Division of Environmental Health Laboratory Sciences
for analysis. (CDC, 2013b).
Serum PCB, urinary BPA, and urinary phthalate metabolites. PCB levels were
measured in serum from a random one-third subsample of people aged 12 years and older
in the 1999-2000 and 2003-2004 survey cycles and people aged 20 years and older in the
2001-2002 survey cycle. Analytical results for PCBs are reported on a whole weight
(ng/g or ppb) and a lipid-adjusted basis (ng/g or ppb). Urinary Bisphenol A (BPA) was
measured in a random one-third subsample of participants aged 6 years and older in the
2003-2004, 2005-2006, 2007-2008, and 2009-2010 survey cycles. Urinary phthalate
monoesters were measured in a random one-third subsample of participants aged 6 years
and older in the 1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008 survey
cycles (CDC, 2012).
Questionnaire Methods
Demographic data was collected during the household interview in persons 16
years of age and older and emancipated minors. Reproductive health data was obtained
during the Mobile Examination Center (MEC) private face-to-face interview in female
participants aged 12 years and older. Medical health data was also obtained during the
MEC interview from male and female participants, however, questions vary by age and

70

gender. All interviewers completed a comprehensive two-week training program which
included role-playing exercises and practice interviews, monitored by NCHS and
contractor staff. In addition, MEC interviewers received extensive training on personal
and audio-computer-assisted interview administration. Prior to implementing
questionnaires a full pilot test was conducted as well as several types of quality control
monitoring methods (CDC, 2012).
Selection of Participants
Inclusion criteria for the study included women, 20 years of age and older who
completed a private face to face interview and provided a blood and/or urine sample in
the mobile examination center. All subjects had to have available PCB, BPA, or phthalate
measurements to be included in the study populations. In addition to available biological
data, subjects in the 1999-2010 survey cycles had to complete the reproductive health and
medical conditions questionnaires. To be included in the data for manuscript 1 and/or 3,
female participants had to provide a response to the medical question “Have you ever
been told by a doctor or other health professional that you had cancer or a malignancy of
any kind?” Participants with missing values for this question were deleted from the
dataset. For manuscript 2, female participants had to provide a response to the
reproductive health question “Has a doctor or other health professional ever told you that
had endometriosis?” and/or “Has a doctor or other health professional ever told you that
you had uterine fibroids?” Survey participants with missing values for these questions
were deleted from the dataset (CDC, 2012).
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Sample Weights and Limits of Detection
Due to the complex survey design of NHANES, sample weights must be used to
adjust for unequal probability of selection and possible bias resulting from non-response.
Environmental chemicals are measured in subsamples of the study population and
therefore must be weighted accordingly. PCBs, phthalates, and BPA were measured in a
randomly selected 1/3 subsample for each survey cycle. When merging data from
multiple survey cycles, appropriate sampling weights must be created according to
NHANES analytic guidelines (CDC, 2013b )
A detection limit variable is provided for all PCBs, phthalates, and BPA in the
data sets. The variable LBD_LC has two values: the value “0” indicates that the result
was below the limit of detection and the value “1” indicates that the result was at or
above the limit of detection. Any participant with a serum PCB concentration below the
limit of detection was assigned a serum level of the LOD divided by the square root of
two. Limits of detection vary by individual PCB congener and survey cycle and can be
found in the CDC’s Fourth National Report on Human Exposure to Environmental
Chemicals (CDC, 2013). LOD values may vary by survey year due to improvements in
analytical methods. While most LODs are constant for each individual specimen
analyzed, individual PCB samples have their own LODs because the sample volume used
for analysis differed for each sample. For chemicals measured in urine, LOD
calculations were performed using the chemical concentration expressed per volume of
urine and for chemicals measured in serum, LOD calculations were performed using the
chemical concentration expressed per amount of lipid because these concentrations
determine the analytical sensitivity (CDC, 2013b).
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EDC Exposure Assessment
PCB Variables. NHANES sampled for 22 PCB congeners in the 1999-2000 survey
cycle, 34 PCB congeners in the 2001-2002 survey cycle, and 38 PCB congeners in the
2003-2004 survey cycle. To avoid bias among those below the LOD, we selected 6
individual PCB congeners that were available in the 1999-2000, 2001-2002, and 20032004 survey cycles and had concentrations above the LOD in at least 60% of the study
subjects. The data analysis explored the relationship between reproductive health
variables in women using the following six individual PCB congeners: 2,4,4’,5tetrachlorobiphenly (74), 2,2’4,4’,5-pentachlorobiphenyl (99), 2,3’,4,4’,5pentachlorobiphenyl (118), 2,2’,3,4,4’,5-hexachlorobiphenyl (138), 2,2’,4,4’,5,5’hexachlorobiphenyl (153), and 2,2’,3,4,4,5,5’-heptachlorobiphenyl (180). Analysis was
also conducted on the sum of non-dioxin-like PCBs (99, 138, 153, 180) and the sum of
dioxin-like PCBs (74 and 118). We conducted analysis of PCBs and breast cancer and
PCBs and other reproductive cancers (cervical, ovarian, and uterine) using 1999-2004
survey cycles with female participants 20 to 85 years of age. We conducted analysis of
PCBs and endometriosis and uterine leiomyomata using the 1999-2004 survey cycles and
women 20-54 years of age (CDC, 2012).
Phthalate Variables. NHANES sampled for 13 urinary phthalate metabolites in the
2003-2004 survey cycle, and 15 urinary phthalate metabolites in the 2005-2006, 20072008, and 2009-2010 survey cycles. We selected the following seven urinary phthalate
metabolites for our analysis: mono-n-butyl phthalate (MnBP), mono-isobutyl phthalate
(MiBP), mono-ethyl phthalate (MEP), mono-(3-caroxypropyl) phthalate (MCPP), monobenzyl phthalate (MZP), and three metabolites of di (2-ehtylhexyl) phthalate (DEHP):
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[mono-2-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP),and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP). These metabolites were
chosen because they were consistently measured in the 2003-2010 survey cycles and their
concentrations were above the LOD in 98% of the study subjects, with the exception of
MEHP which was present in concentrations above the LOD for 68% of the study
subjects. Data analysis was conducted using the 2003-2004, 2005-2006, 2007-2008 and
2009-2010 survey cycles and female participants, 20 years of age and older (CDC, 2012).
BPA Variables. Urinary BPA measurements are available from the 2003-2004, 20052006, 2007-2008, and 2009-2010 survey cycles in survey participants aged 6 years and
older. We conducted analysis of BPA and reproductive cancers using the 2005-2006,
2007-2008, and 2009-2010 survey cycles and female participants, 20 years of age and
older. We did not include the 2003-2004 survey participants because BPA samples were
taken from a different subsample of participants (subsample A vs. subsample B) and the
CDC does not recommend combining different subsamples across survey cycles (CDC,
2012).
Reproductive and Medical Health Variables
Data analysis explored the relationship between serum PCB, urinary BPA and
urinary phthalate levels and self-reported health outcomes obtained from the reproductive
and medical health questionnaires of female participants 20 years of age and older.
Medical Health Questionnaire. Self-reported cancer status was obtained through the
medical questionnaires in participants’ 20 years of age and older who provided a
response for “Have you ever been told by a doctor or other health professional that you
had cancer or a malignancy of any kind?” Women who answered “yes” were
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subsequently asked “What kind of cancer was it?” and “What was your age at
diagnosis?” Only women who reported no cancer diagnosis or a breast cancer diagnosis
were included in our study population for manuscript 1. Participants who reported no
cancer diagnosis and breast cancer, ovarian cancer, uterine cancer, or cervical cancer
diagnosis were included in the analyses for manuscript 3. Cancer diagnosis (yes/no) was
modeled as a categorical dependent variable for all analyses (CDC, 2012).
Reproductive Health Questionnaire. NHANES data was used to examine the
relationship between serum PCB levels and endometriosis and uterine leiomyomata in
manuscript 2. Self-reported endometriosis diagnosis was obtained through the
reproductive health questionnaire in participants 20 to 54 years of age, who provided a
response for “Have you ever been told by a doctor or other health professional that you
have endometriosis?” Women who answered “yes” were subsequently asked “What was
your age at diagnosis?” Self-reported uterine fibroid diagnosis was obtained through the
reproductive health questionnaire in participants 20 to 54 years of age, who provided a
response for “Have you ever been told by a doctor or other health professional that you
have uterine fibroids?” Women who answered “yes” were subsequently asked “What was
your age at diagnosis?” Endometriosis (yes/no) and uterine leiomyomas (yes/no) were
modeled as categorical dependent variables in our analysis. Additionally, the following
outcomes from the reproductive health questionnaire were evaluated using categorical
data: having undergone a medical procedure (hysterectomy, oophorectomy, or both:
yes/no), age at menarche (< 12 years, 12-14 years, ≥15 years), number of pregnancies
resulting in live births (0, 1, ≥2), oral contraceptive use (yes/no) and history of lactation
(yes/no) (CDC, 2012).
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Statistical Analysis
Females, 20 years and older with PCB, BPA, and/or phthalate levels and available
reproductive or medical health data were used in our analyses. Reproductive health
outcomes are normally distributed and were modeled untransformed, while all PCBs,
BPA, and phthalate metabolites are not normally distributed and were log transformed
prior to statistical analyses. In addition, all urinary BPA and phthalate metabolites were
creatinine corrected prior to analyses. All estimates were weighted according to the
National Center for Health Statistics guidelines to produce accurate national estimates,
adjusting for the oversampling of minority subgroups (CDC, 2013b). Variance
estimation was conducted using the required stratum and PSU variables from the
demographics data files. Geometric means (GM), geometric standard errors (GSE), and
proportions of EDCs were calculated for demographic and reproductive health variables.
GMs of EDCs were compared among reproductive health variables by means of
Student’s t-test or chi-square tests, depending on the type of variable. We used logistic
regression models to calculate ORs and their 95% CIs to investigate the risk between
blood and urinary levels of EDCs and breast cancer, ovarian cancer, uterine cancer, and
cervical cancer as well as PCBs and endometriosis and uterine leiomyomas. All
statistical analyses were performed using SAS for windows (release 9.2; SAS Institute
Inc. Cary, N.C.). These analyses used a 5% significance level (p≤0.05).
Potential Confounding Variables
Potential confounding variables from the demographics file include age,
race/ethnicity, education and income. All potential confounding variables from the
demographics file were inputted as categorical variables. For analysis of EDCs and
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reproductive cancers (manuscripts 1 and 3), age was categorized into three groups (20-59
years, 60-74 years and ≥ 75 years) due to a small number of reproductive cancer cases in
the lower age range and race was categorized into two groups (non-Hispanic White and
Other) due to a small number of reproductive cancer cases from races other than nonHispanic white. Women classified as ‘Other’ included non-Hispanic Blacks, Mexican
Americans, Other Hispanic, and Other Races including Multi-Racial. For analysis of
PCBs and endometriosis and uterine leiomyomas (manuscript 2), age was categorized
into four groups (20-29 years, 30-39 years, 40-49 years, and 50-54 years) and race was
categorized into three groups (non-Hispanic White, non-Hispanic Black, and Other).
Women classified as ‘Other’ included Mexican Americans, Other Hispanic, and Other
Races including Multi-Racial. Data on BMI was obtained through the examination
component of the MEC exam and smoking status, alcohol consumption, education
completed, and annual family income were obtained in the household interview. For all
of our analyses, body mass index (BMI, kg/m2) (> 25, 25-30 and ≥ 30), smoking status
[“Have you smoked at least 100 cigarettes in your entire life?” (yes/no)], alcohol
consumption [In any one year, have you had at least 12 drinks of any type of alcoholic
beverage?” (yes/no)], education completed (< 12th grade, 12th grade and > 12th grade) and
annual family income (0-$24,999, $25,000-$54,999, $55,000-$74,999 and ≥ $75,000)
were evaluated as potential confounding variables, however smoking status, alcohol
consumption, education completed, and annual family income were not retained in the
final logistic regression models for manuscripts 1 and 3 because they were not found to
be significant predictors of risk; manuscript 2 did not retain education and income in the
final models.

From the reproductive health questionnaire, additional covariates of age at
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menarche (< 12, 12-14, ≥ 15) , parity, history of breastfeeding (yes/no), oral
contraceptive use (yes/no) were evaluated for use in logistic regression models. Parity
and oral contraceptive use were not retained in the final logistic regression models for
manuscript 1, breast feeding was not retained in the final logistic regression models for
manuscript 2, and parity, breastfeeding, and oral contraceptive use were not retained in
the final logistic regression models for manuscript 3 because of they contained a large
number of missing values that significantly decreased the number of cancer cases in the
model.
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CHAPTER IV
MANUSCRIPT 1
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND BREAST CANCER
AMONG U.S. WOMEN: ANALYSES OF NHANES DATA 1999-2004
ABSTRACT
Background: Breast cancer is the most commonly diagnosed cancer among women
worldwide. A number of chemicals are suspected to act as endocrine disruptors (EDs) by
mimicking natural or synthetic estrogen resulting in an increased risk of breast cancer in
women. Polychlorinated biphenyls (PCBs) have been recognized as endocrine disrupters
due to their ability to interfere with reproductive function and development in animals
and humans by either increasing estrogen activity or blocking estrogens from acting.
Objectives: The purpose of this study was to examine the cross-sectional relationship
between exposure to PCBs and breast cancer among U.S. women.
Methods: We analyzed data from female participants (20 years of age and older) who
provided blood samples for the Centers for Disease Control and Prevention’s National
Health and Nutrition Examination Survey (NHANES) between 1999 and 2004. Exposure
was based on lipid adjusted serum levels of 6 individual PCB congeners (PCB 074, 099,
118, 138, 153, and 180), the sum of dioxin-like PCBs (074 + 118), and the sum of nondioxin-like PCBs (099 + 138 + 153+187) in conjunction with data obtained from the
medical and reproductive health questionnaires. We calculated geometric means to
compare PCB concentrations in women who self-reported a breast cancer diagnosis vs.
women who self-reported never being diagnosed with cancer. We used logistic regression
models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the
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association between PCB measurements and breast cancer. We evaluated age,
race/ethnicity, age at menarche, body mass index (BMI; kg/m2), and lactation as potential
confounders in our final models.
Results: Separate analyses showed weighted geometric mean levels of all 6 PCB
congeners to be significantly higher among women with breast cancer when compared to
the rest of the study population. After adjusting for age, race, and BMI we found breast
cancer risk to be significantly associated with PCB 138 in the 50-75th and ≥75th percentile
groups, [odds ratios of 2.93, 95% confidence interval (CI): 1.04-8.26 and 3.43, 95% CI:
1.12-10.4], respectively. After adjusting for age, race, BMI, lactation, and age at
menarche we found that PCB 138 and 180 were significantly associated with breast
cancer [ORs of 2.88; 95% CI: 1.14-7.30 and 4.54, 95% CI: 1.11-18.6, respectively] in
women with higher body burdens of individual PCB congeners (> 50th percentile). After
adjusting for age and race, we also found the sum of non-dioxin-like PCBs to be weakly
associated with breast cancer [OR of 1.14; 95% CI: 1.00-1.29].
Conclusions: Our results suggest a link between environmental exposures to PCBs and
increased risk of breast cancer among U.S. women. Despite the ban on PCB production,
environmental exposures appear to continue posing significant threats on the health of the
general population.
Keywords: PCBs, NHANES, breast cancer
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MANUSCRIPT 1
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND BREAST CANCER
AMONG U.S. WOMEN: ANALYSES OF NHANES DATA 1999-2004
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer among women in both
developing and developed nations, representing 11.9% of all cancers diagnosed
worldwide (SEER 2013, IARC 2012). Incidence rates of breast cancer vary greatly, with
age standardized rates reaching 43.3 per 100,000 worldwide and 92.9 per 100,000 in
North America (IARC 2012). The latest estimates released by the World Health
Organization’s (WHO) International Agency for Research on Cancer (IARC)
GLOBOCAN 2012 database indicate that breast cancer incidence has increased 20%
while mortality has increased 14% since 2008 (IARC 2012). While estimates vary,
breast cancer cases cannot be solely attributed to risk factors such as family history,
parity, prolonged exposure to endogenous estrogens (Bodicoat et al. 2014), physical
inactivity, alcohol use, and obesity (Madigan et al 1995). A new recent report by the
United Nations Environment Programme (UNEP) and WHO entitled “State of the
Science: Endocrine Disrupting Chemicals - 2012” highlighted that approximately 800
chemicals are suspected to act as endocrine disruptors (EDs) or mimic natural hormones
or disrupt hormone regulation (UNEP/WHO 2013, EU 2013). Some of these EDs mimic
natural or synthetic estrogen. This recent UNEP/WHO report has renewed the concern by
highlighting that there may be some associations between exposure to estrogen-
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mimicking EDs and an increased risk of breast cancer in women (UNEP/WHO 2013, EU
2013).
Polychlorinated biphenyls (PCBs) are a group of synthetic organic chemicals that
were introduced into industry in the late 1920’s and used primarily for heat exchange in
transformers and capacitors, hydraulic and lubricating fluids, plasticizers, inks, paints,
adhesives, flame retardants, and extenders for pesticides (ATSDR 2000). Despite the ban
of PCBs in the late 1970’s due to serious health concerns, environmental exposures are
still possible due to a release from hazardous waste sites; illegal dumping; leaks from old
transformers; and burning of PCB contaminated waste (Carpenter 2006, Johnson et al.
1999). Furthermore, PCBs bioaccumulate in the fatty tissues of fish and mammals,
increasing the likelihood of dietary exposures. Elimination half-lives of PCBs vary
substantially in humans for each PCB congener and range from a few months to a few
decades depending on PCB chlorination, age, body fat, and breast feeding (Anderson et
al. 1998, Phillips et al. 1989, Paris-Pombo et al. 2003, Tee et al. 2003, Milbrath et al.
2008).
PCBs have been recognized as endocrine disrupters due to their ability to interfere
with reproductive function and development in animals and humans by either increasing
estrogen activity or blocking estrogens from acting (Fielden et al. 2001, Aoki et al. 2001,
Ma and Sassoon 2006, McLachlan et al. 2006). Estrogen is a contributing factor in the
development of breast cancer (Lin et al. 2009). The increased risk of breast cancer among
postmenopausal women may be due to an altered endogenous estrogen (Bertelsen et al.
2007, Roy et al. 1997, Roy et al. 1998). Furthermore, animal and limited human data
suggest that exposure to PCBs may lead to a number of adverse reproductive effects such
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as decreased conception rates, prolonged time to pregnancy, irregular menstrual cycles,
spontaneous abortion, preterm delivery, abnormal sperm morphology, decreased sperm
motility, preterm delivery, low birth weight, reduced lactation time, and late miscarriages
(Arisawa et al. 2005, Baibergenova et al. 2003, Buck et al. 2000, Kostyniak et al. 1999,
Mendola et al. 1997, Rylander et al. 1998, Tsukimori et al. 2000, Yu et al. 2000, Yang et
al. 2008).
Studies pertaining to PCBs and breast cancer are controversial. While some
studies reported no significant associations (Gammon et al. 2002, Gatto et al. 2007, Wolff
et al. 2000), or inverse associations (Pavuk et al. 2003, Itoh et al. 2009) other studies have
found an increased breast cancer risk when analyzing total PCB exposure or specific
individual PCB congeners (Charlier et al. 2004, Cohn et al. 2012, Demers et al. 2002,
Millikan et al. 2013, Recio-Vega et al. 2001, Muscat et al. 2003). Charlier et al. (2004)
found concentrations of PCB 138 (1.25 vs. 0.94 ppb; p = 0.0068), PCB 153 (1.63 vs.
0.63; p < 0.0001), and total PCBs (7.08 vs. 5.10 ppb; p = 0.012) to be significantly higher
in cases when compared to controls. After adjusting for confounding risk factors, PCB
153 was found to be significantly associated with an increased risk of breast cancer
(OR=1.8; 95% CI, 1.4-2.5) (Charlier et al. 2004). Cohn et al. (2012) did not find any
associations between breast cancer risk and the sum of total PCBs or PCB groupings,
however, a significant association was found for PCB 203 when comparing the highest
vs. lowest quartiles of exposure (OR=6.3; 95% CI, 1.9-21.7). Demers et al. (2002) found
mean plasma lipid concentrations of individual PCB congeners 99, 118, and 156 and
mean total concentrations of mono-ortho PCB congeners (nos. 105, 118, and 156) to be
significantly higher in breast cancer cases than controls. Breast cancer risk was found to
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be significantly associated with the sum of mono-ortho congeners (nos. 105, 118, 156)
(OR=2.02; 95% CI, 1.24-3.28), PCB 118 (OR=1.60; 95% CI, 1.01-2.53) and PCB 156
(OR=1.80, 95% CI 1.11-2.94) when comparing the fourth vs. first quartiles (Demers et al.
2002). Millikan et al. (2013) did not find any associations with total PCBs and breast
cancer among all participants (OR=1.09; 95% CI, 0.79-1.52) or white women (OR=1.03;
95% CI, 0.68-1.56), but did find a slightly elevated risk for African-American women
(OR=1.74; 95% CI, 1.00-3.01). Recio-Vega et al. (2001) found the GM of total PCBs to
be significantly higher in cases than controls (5.26 vs. 3.33 ppb) (OR=1.09; 95% CI,
1.01-1.14) as well as an increased risk of breast cancer among PCBs grouped by
structure-activity relationships and 8 individual PCB congeners (nos. 118, 128, 138, 170,
180, 195, 206, and 209) and Muscat et al. (2003) found that PCB concentrations in the
highest tertile for PCB congener 118 (RR=4.0; 95%, CI 1.32-4.9) and total PCBs
(RR=2.9; 95% CI, 1.02-8.2) were related to an increased risk of breast cancer recurrence
in women with nonmetastatic breast cancer. Stronger associations were reported between
PCB exposure and breast cancer risk in studies that considered genetic polymorphism of
the CYP 1A1 enzyme and menopausal status (Zhang et al. 2004, Li et al. 2005, Moysich
et al. 1998, Moysich et al. 1999). CYP1A1-M2 genetic variants were found to modify the
association between PCB exposure and breast cancer in postmenopausal Caucasian
women, while CYP1A1-M3 genotypes were found to modify this association in African
American women (Zhang et al. 2004, Li et al. 2005).
In this study, we examined the relationship between 6 individual PCB congeners,
the sum of dioxin-like PCBs and the sum of non-dioxin-like PCBs with self-reported
breast cancer in female subjects participating in the National Health and Nutrition
85

Examination Survey (NHANES) between the years 1999-2004. The objectives of this
study were to: 1) describe the mean PCB levels in women (≥ 20 years of age) diagnosed
with breast cancer compared to women not diagnosed with cancer; and 2) assess the
association between higher body burdens of PCBs and increased risk of breast cancer.
METHODS
Study design and population. NHANES is an ongoing cross-sectional survey designed to
be nationally representative of the non-institutionalized U.S. civilian population.
Conducted annually since 1999 by the National Center for Health Statistics of the Centers
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage
sampling design where approximately 5,000 survey participants a year complete in-home
interviews and physical examinations in mobile examination units (CDC 2012). All
participants provided written informed consent and all procedures were approved by the
National Center for Health Statistics (NCHS) Institutional Review Board (CDC 2012).
We merged data from the 1999-2000, 20012-2002, and 2003-2004 survey cycles. We
limited our analysis to women 20 to 85 years of age who completed the reproductive and
medical health questionnaires in a face-to-face interview at a mobile examination center.
PCB measurements. Blood serum concentrations of individual PCB congeners were
measured in a representative, random one-third subsample of people 12 years of age and
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were
measured in serum by high-resolution gas chromatography/isotope-dilution highresolution mass spectrometry (HRGS/ID-HRMS). NHANES provides both wet-weight
and lipid adjusted values for each sample, corrected for sample weight and analyte
recovery; we used lipid adjusted values in our analyses. Detailed laboratory methods
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were consistent among survey cycles and are available online (CDC 2013b). A detection
limit variable is provided for all PCB congeners in the data set. The variable LBD_LC
has two values: the value “0” indicates that the result was below the limit of detection
and the value “1” indicates that the result was at or above the limit of detection. Any
participant with a serum PCB concentration below the limit of detection was assigned a
serum level of the LOD divided by the square root of two. Limits of detection vary by
individual PCB congener and survey cycle and can be found in the CDC’s Fourth
National Report on Human Exposure to Environmental Chemicals (CDC 2013). Lipidadjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (118 + 138
+153 + 170) were used in this study. PCB congeners 74, 99, 118, 138, 153, and 180 were
selected because they were available in all three survey cycles and concentrations were
above the LOD in > 60% of the survey participants.
Breast cancer diagnosis. We included female 1999-2004 NHANES participants 20 to 85
years of age who completed the self-reported medical health questionnaire and provided a
response for “Have you ever been told by a doctor or other health professional that you
had cancer or a malignancy of any kind?” Women who answered “yes” were
subsequently asked “What kind of cancer was it?” 8,315 women 20 to 85 years of age
provided a response in the 1999-2004 survey cycles. After deleting observations that
were missing PCB data and 25 additional observations that were missing values for
PCB99, our study population consisted of 2,007 participants: 43 who reported a breast
cancer diagnosis and 1,964 who reported no cancer diagnosis. There were 43 breast
cancer cases for all six PCB congeners and 1959 non cancer cases for PCBs 74, 99, 118,
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and 138; 1960 non cases in PCB153; and 1954 noncases in PCB 180. The sum of dioxinlike PCBs and non-dioxin-like PCBs were available in 1,996 and 1,984 subjects,
respectively (CDC 2012).
Statistical analysis. All statistical analyses were performed using SAS system software
(release 9.2; SAS Institute Inc. Cary, N.C.). A six year subsample weight was calculated
according to the National Center for Health Statistics guidelines to adjust for
oversampling of minority groups in the merged 1999-2004 NHANES data cycles (CDC
2013b). Nonmissing values for serum concentrations below the LOD were assigned a
serum level of the LOD divided by the square root of two. In our analysis, all lipidadjusted serum PCB concentrations were log transformed to satisfy normality
assumptions. Due to a small number of breast cancer cases, participants were
categorized the following ways depending on data analysis: < LOD vs. ≥ LOD; < LOD
to 50th percentile vs. ≥ 50th percentile; and < LOD to 50th percentile vs. 50th percentile to
75th percentile vs. ≥ 75th percentile. We also conducted separate analyses on all females
with serum PCB levels > LOD where breast cancer cases were compared with non-cancer
cases. Significance was set at p < 0.05 for all analyses.
We used PROC SURVEYMEANS to account for the complex sampling design of
NHANES and to obtain weighted means, 95% confidence intervals, and standard errors
of individual PCB congeners, the sum of dioxin-like PCBs, and the sum of non-dioxinlike PCBs. We used the Taylor Series (linearization) method to estimate standard errors.
A two-sided student t-test was calculated using PROC SURVEYREG to test whether the
mean PCB levels between women who reported a breast cancer diagnosis and women
who reported no cancer diagnosis were significantly different. Geometric mean (GM)
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PCB levels and geometric standard errors (GSE) were reported for breast cancer status,
age at interview, and race/ethnicity for all participants with individual serum PCB levels
above the LOD. Arithmetic mean serum levels of dioxin-like and non-dioxin-like PCBs
and 95% CIs were reported for breast cancer status and select confounding variables (age,
race, BMI, lactation, age at menarche, lactation, oral contraceptive use, smoking status,
alcohol consumption, education completed and annual family income). Age was divided
into three groups (20-59 years, 60-74 years, and ≥ 75 years) that were selected based on
the age distribution of breast cancer cases and noncases in our data set. Race/ethnicity
was divided into two groups (non-Hispanic White and ‘Other’) due to a very small
number of breast cancer cases from races/ethnicities other than non-Hispanic White. The
category of ‘Other’ includes Mexican American, Non-Hispanic Black, Other Hispanic
and Other Race – Including Multi-Racial. To account for the different age structures
among non-Hispanic whites and ‘Other’ ethnicities in our study population, we presented
age standardized GM PCB levels for individual PCB congeners and age standardized
arithmetic mean dioxin-like and non-dioxin-like PCB levels for race/ethnicity. We also
calculated both crude and age standardized GMs for breast cancer cases and noncases in
women with PCB levels above the LOD. We used the direct method for age
standardization provided by the CDC (CDC 2014).
Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs and
their 95% CIs to evaluate the association between exposure to PCBs and breast cancer.
We conducted separate analyses for the sum of dioxin-like and non-dioxin-like PCBs and
individual PCB congeners and breast cancer. Due to a small number of breast cancer
cases, ORs and 95% CIs were calculated using the following groups: < LOD to 50th
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percentile vs. ≥ 50th percentile; and < LOD to 50th percentile vs. 50th percentile to 75th
percentile vs. ≥ 75th percentile.

The reference group for each PCB congener is defined

as those participants whose serum concentrations were < LOD to 50th percentile. We
conducted further analyses which included participants (breast cancer cases vs. noncases)
with only PCB levels > LOD. ORs and 95% CIs were reported for each group in the
model.
Covariates. We considered a number of potential confounders based on previous
literature and well-established risk factors for breast cancer. The following potential
confounders were either self-reported in the questionnaire interviews or taken as a
laboratory measurement. The demographic variables of age at interview (20-59 years,
60-74 years, and ≥ 75 years), race (white vs. other), education completed (< 12th grade,
12th grade, > 12th grade) and income (0-$24,999, $25,000-$54,999, $55,000-$74,999)
were obtained during the NHANES home interview (CDC 2012). Reproductive variables
including age at menarche (<12 years, 12-14 years, ≥15 years), history of regular periods
(yes/no), parity (0, 1, ≥ 2), oral contraceptive use (yes/no) and breast-feeding (yes/no) as
well as lifestyle variables including smoking (yes/no) and alcohol use (yes/no) were
obtained from health questionnaires completed in the mobile examination center. Body
mass index (< 25 kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2) was obtained through the
body measurement component in the mobile examination center (CDC 2013b). For
individual PCB congeners, ORs and 95% CIs are reported for three models: unadjusted;
age, race/ethnicity and BMI adjusted; and age, race/ethnicity, BMI, lactation, and age at
menarche adjusted. For the sum of dioxin-like and non-dioxin-like PCBs, ORs and 95%
CIs are reported for four models: unadjusted; race/ethnicity adjusted; age and
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race/ethnicity adjusted; and age, race/ethnicity, BMI, lactation, and age at menarche
adjusted. Parity and oral contraceptive use were not included in the models because of
the extent of missing data. Smoking history, alcohol use, education, and income were not
significant predictors of breast cancer risk and therefore were also not presented in the
final logistic regression models.
RESULTS
Descriptive Statistics. The study population included 2,007 female participants 20 years
of age and older with available PCB data and who completed the medical conditions
questionnaire and provided a response for “Have you ever been told by a doctor or other
health professional that you had cancer or a malignancy of any kind?” Women who
answered “yes” were subsequently asked, “What kind of cancer was it?” Among the
2,007 participants, 1,964 (97.9%) reported never being diagnosed with cancer and 43
(2.14%) reported being diagnosed with breast cancer (Table 1.1). Participants were fairly
evenly distributed over the two races: 48.6% were of non-Hispanic white ethnicity and
51.4% were classified as ‘Other’, however the majority of breast cancer cases were in
non-Hispanic white women (81.5%). The majority of participants were 20-59 years of
age at the time of interview (68.6%) (Table 1.1). The mean age at time of interview was
45.5 years for women who reported never being diagnosed with cancer and 65.2 years for
women who reported being diagnosed with cancer with a mean age at breast cancer
diagnosis of 55.3 years (Table 1.1). BMI was normal (< 25 kg/m2) for 39.6%,
overweight (25to < 30 kg/m2) for 30.6%, and obese (≥ 30 kg/m2) for 35.1% of study
participants. Age of menarche was < 12 years of age for 19.4%, 12-14 years for 66.2%,
and ≥ 15 years for 14.3% of study participants. The majority of study participants
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reported ≥ 2 live births (73.9%), responded yes to breastfeeding (59.4%), responded yes
to oral contraceptive use (60.8%) , responded no to a history of smoking (69.3%), yes to
alcohol consumption (56.4%), completed more than 12th grade (45.2%), and reported a
yearly family income of 0-$24,999 (37.1%) (Table 1.1).
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Table 1.1. Descriptive statistics for breast cancer status and selected covariates among women ≥ 20 years
of age, NHANES 1999-2004.
Breast Cancer
No Breast Cancer
Variable
n(%)
n (%)
Total Population (n,%)
43(2.14%)
1964(97.9%)
Age at interview (years; mean ± se)
65.2 ± 2.10
45.5 ± .43
Age at diagnosis (years; mean ±se)
55.3 ± 3.11
Race/Ethnicity
Non-Hispanic white
35 (1.74%)
940 (46.8%)
Other
8 (0.40%)
1024(51.0%)
Age at time of interview (years)
20-59
7 (0.35%)
1368(68.2%)
60-74
26 (1.30%)
384 (19.1%)
≥ 75
10 (0.50%)
212 (10.6%)
Age at menarche (years)
< 12 years
6 (0.33%)
344 (19.1%)
12-14 years
30 (1.67%)
1160 (64.5%)
≥ 15 years
4 (0.22%)
254 (14.1%)
Parity (no. of live births)
0
0 (0.00%)
82 (5.27%)
1
5 (0.32%)
319 (20.5%)
>2
29 (1.86%)
1120 (72.0%)
2
BMI (kg/m )
Normal weight (18.5 to <25)
12(0.62%)
655 (33.7%)
Overweight (25 to <30)
18 (0.93%)
578 (29.7%)
Obese (≥30)
12 (0.62%)
670 (34.5%)
Breastfed
Yes
19(1.33%)
835 (58.1%)
No
15 (1.05%)
558 (39.1%)
Oral Contraceptive Use
Yes
19 (1.03%)
1103(59.8%)
No
21 (1.14%)
701 (38.0%)
Ever Smoked
Yes
23 (1.15%)
773 (38.5%)
No
20 (1.00%)
1190 (59.3%)
Alcohol Use
Yes
24 (1.30%)
1018 (55.1%)
No
16 (0.87%)
790 (42.8%)
Education
< 12th grade
15 (0.75%)
445 (22.2%)
th
15 (0.75%)
626 (31.2%)
12 grade
th
13 (0.65%)
893(44.5%)
> 12 grade
Income (yearly family income)
0-$24,999
17 (0.96%)
642 (36.1%)
$25,000-$54,999
13 (0.73%)
566 (31.8%)
$55,000-$74,999
1 (0.06%)
208 (11.7%)
≥ $75,000
7 (0.39%)
326(18.3%)
Estimated percent distribution after applying NHANES sampling weights.
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Table 1.2 presents GMs and GSEs of lipid adjusted PCBs by breast cancer status in
participants with individual PCB concentrations above the LOD. Crude GM PCB levels
were significantly higher for all 6 PCB congeners in women who reported a breast cancer
diagnosis compared to women who reported no cancer diagnosis (Table 1.2). Overall GM
levels of individual blood PCBs ranged from 7.24 ng/g lipid to 31.8 ng/g lipid in women
who reported never being diagnosed with cancer and from 9.87 ng/g lipid to 55.1 ng/g
lipid in women who reported being diagnosed with breast cancer, with the lowest levels
observed for PCB congener 99 and the highest levels observed for PCB 153 (Table 1. 2;
Figure 1.1). After adjusting for age, GM PCB levels in women with breast cancer
remained significantly higher in breast cancer cases for PCB congeners 99, 138, 153, and
180. Age standardized GM PCB levels ranged from 7.03 ng/g lipid to 31.5 ng/g lipid in
women who reported never being diagnosed with cancer and from 10.4 ng/g lipid to 47.5
ng/g lipid in women who reported being diagnosed with breast cancer. These results are
consistent with crude GM PCB levels with the lowest and highest blood levels being
observed for PCB congeners 99 and 153, respectively.

Table 1.2. Geometric Mean PCB levels (ng/g) by breast cancer status among women ≥ 20 years of age
with PCB concentrations above the LOD, NHANES 1999-2004.
Geometric mean2(ng/g) (GSE)
Noncases/
No
Breast
No
Breast
Analyte1
Cases
Cancer
Cancer
Cancer3
Cancer3
PCB 074
1483/43
9.87 (1.07)
16.0 (1.07) b
9.58 (1.03)
10.8 (1.23)
7.03 (1.04)
10.4 (1.11)b
PCB 099
1334/41
7.24 (1.09)
9.87 (1.03) b
b
PCB 118
1533/43
11.7 (1.06)
17.5 (1.16)
11.4 (1.03)
10.9 (1.23)
PCB 138
1594/43
23.6 (1.06)
39.6 (1.07) a
23.1 (1.03)
33.8 (1.19)b
PCB 153
1651/43
31.8 (1.06)
56.3 (1.08) a
31.5 (1.03)
47.5 (1.16)b
a
PCB 180
1599/43
23.3 (1.63)
44.3 (1.05)
22.9 (1.02)
36.2 (1.12)a
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
3
Age Standardized: 20-59 years, 60-74 years, ≥75 years.
PCB levels significantly higher in women with breast cancer vs. women without cancer;
a
p < 0.0001, bp < 0.05
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Figure 1.1. Geometric mean PCB levels (ng/g) by cancer status for women ≥ 20 years of age with PCB
concentrations above the LOD, NHANES 1999-2004.

GM PCB levels were also examined by age group in women with individual PCB
concentrations above the LOD (Table 1.3). The overall GM levels of PCBs in blood
significantly increased with age for each individual PCB congener measured with the
exception of PCB 99, which decreased slightly for women diagnosed with breast cancer
in the 60-74 year old age group. In the first age group (20-59 years), women diagnosed
with breast cancer had significantly higher GM PCB levels of congeners 99, 138, 153,
and 180 when compared to women never diagnosed with cancer (Table 1.3). Significant
differences in GM PCB levels were not found in the other two age groups between
women who reported being diagnosed with breast cancer and women who reported never
being diagnosed with cancer (Table1. 3).
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Table 1.3 Geometric Mean PCB levels (ng/g) by age group and breast cancer status among women with
PCB concentrations above the LOD, NHANES 1999-2004.
Geometric mean2 (ng/g) (GSE, n)
Age: 20-59 years
Age: 60-74 years
Age: ≥ 75 years
No
Breast
No
Breast
No
Breast
Analyte
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
PCB 074
PCB 099
PCB 118
PCB 138
PCB 153
PCB 180

7.54 (1.04, 902)
5.99 (1.04, 796)
9.03 (1.04, 952)
18.9 (1.03, 1019)
25.0 (1.03, 1072)
18.0 (1.03, 1016)

8.85 (1.30, 7)
10.6 (1.13, 6)b
8.76 (1.30, 7)
31.2 (1.23, 7)b
43.4 (1.21, 7)b
32.8 (1.15, 7)a

18.0 (1.04, 372)
10.5 (1.04, 341)
21.8 (1.04, 371)
40.9 (1.04, 370)
59.1 (1.03, 371)
44.3 (1.03, 375)

18.2 (1.11, 28)
9.49 (1.14, 25)
20.9 (1.17, 27)
42.1 (1.11, 28)
58.6 (1.11, 28)
45.6 (1.09, 28)

28.2 (1.05, 209)
14.6 (1.07, 197)
32.1 (1.06, 210)
58.0 (1.04, 205)
83.1 (1.04, 208)
61.6 (1.03, 208)

25.8 (1.09, 10)
10.5 (1.21, 10)
27.4 (1.15, 10)
48.4 (1.11, 10)
74.4 (1.09, 10)
61.6 (1.12, 10)

1

Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with breast cancer vs. women without cancer;
a
p < 0.0001, bp < 0.05.
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Table 1.4 presents age standardized GMs and GSEs of lipid adjusted PCBs by
race/ethnicity in participants with individual PCB concentrations above the LOD. For
women who reported being diagnosed with breast cancer, women classified as ‘Other’
had significantly higher GM PCB levels for PCB congeners 74, 99, 118, 138, 153, and
180 compared to non-Hispanic white women (Table 1.4). In women who reported never
being diagnosed with cancer, only PCBs 74, 153, and 180 were found to be significantly
higher in non-Hispanic white women compared to classified as ‘Other’ (Table 1.4).
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Table 1.4. Age standardized geometric mean PCB levels (ng/g) by race/ethnicity amongwomen ≥ 20 years
of age with PCB concentrations above the LOD, NHANES 1999-2004.
Geometric mean2(ng/g) (GSE, n)
No Cancer
Breast Cancer
Non-Hispanic
Non-Hispanic
White
Other
White
Other
Analyte1
PCB 074
10.4 (1.08, 772)e
8.67 (1.07, 711)
15.3 (1.07, 35)d
27.4 (1.05, 8)b,c
PCB 099
7.17 (1.11, 679)
7.39 (1.08, 655)
9.12 (1.08, 34)d
23.1 (1.00, 7)a ,c
PCB 118
12.2 (1.06, 779)
11.8 (1.07, 754)
16.4 (1.21, 35)
32.8 (1.01, 8)b,c
d
PCB 138
24.0 (1.06, 800)
22.6 (1.07, 794)
37.7 (1.11, 35)
69.4 (1.12, 8)b ,c
e
c
PCB 153
33.1 (1.06, 826)
29.1 (1.06, 825)
54.1 (1.09, 35)
90.9 (1.12, 8)b,c
e
c
PCB 180
24.8 (1.05, 809)
20.3 (1.04, 790)
43.4 (1.05, 35)
52.5 (1.17, 8)c
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
PCB levels significantly higher in ‘Other’ women with breast cancer vs. non-Hispanic white women with
breast cancer; ap < 0.0001, bp < 0.05
PCB levels significantly higher in women with breast cancer vs. women without breast cancer;
c
p < 0.0001, dp < 0.05
PCB levels significantly higher in non-Hispanic white women without cancer vs. ‘Other’ women without
cancer, ep < 0.0001.

Table 1.5 shows the arithmetic means and 95% CIs of serum levels of dioxin-like
PCBs for breast cancer status and selected variables in the study population. Arithmetic
means of dioxin-like PCBs were significantly higher in women who reported being
diagnosed with breast cancer (5.64 ng/g) compared to women who reported never being
diagnosed with cancer (4.33 ng/g), however mean dioxin-like PCBs did not remain
significant after adjusting for age (Table 1.5). Mean dioxin-like PCBs increased with
age, however there were no significant differences in the three age groups for women
who reported being diagnosed with breast cancer compared to women who reported
never being diagnosed with cancer. Age standardized dioxin-like PCBs were found to be
significantly higher for breast cancer cases in both races (non-Hispanic white and
‘Other’) but were not found to significantly different from each other. With the
exception of age at menarche (< 12 years) and education (<12th grade completed) ,
dioxin-like PCBs were found to be significantly higher in women who reported a breast
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cancer diagnosis compared to women who reported no cancer diagnosis (Table 1.5) for
all covariates in the study population (Table 1.5). Table 1.6 shows the arithmetic means
and 95% CIs of serum levels of non-dioxin-like PCBs for breast cancer status and
selected variables in the study population. Crude arithmetic means of non-dioxin-like
PCBs were significantly higher in women who reported being diagnosed with breast
cancer (13.7 ng/g) compared to women who reported never being diagnosed with cancer
(11.1 ng/g), and remained significant after adjusting for age (13.2 ng/g vs 11.2 ng/g)
(Table 1.6). Mean non-dioxin-like PCBs increased with age, however only the women
diagnosed with breast cancer in the first age group (20-59 years) had significantly
higher non-dioxin-like PCBs compared to women never diagnosed with cancer. Age
standardized non-dioxin-like PCBs were found to be significantly higher for breast
cancer cases in both races (non-Hispanic white and ‘Other’) but were not found to
significantly different from each other. With the exception of age at menarche, nondioxin-like PCBs were found to be significantly higher in women who reported a breast
cancer diagnosis compared to women who reported no cancer diagnosis for all covariates
in the study population (Table 1.6).
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Table 1.5. Serum Levels of dioxin-like PCBs (ng/g) in the study population, women ≥ 20 years of age,
NHANES 1999-2004.
Mean1 (ng/g) (95% CI)
Variable
Noncase s/Cases
No Cancer
Breast Cancer
Dioxin-like PCBs2
1953/43
4.33 (4.21-4.54)
5.64 (5.09-6.18)a
Dioxin-like PCBs3
1752/45
4.38 (4.28-4.48)
4.77 (3.97-5.57)
Dioxin-like PCBs_504
2.96 (2.89-3.03)
3.27 (3.02-3.51)
<LOD to 50%
973/4
≥ 50%
979/39
5.76 (5.67-5.84)
6.11 (5.80-6.44) b
Age
20-59 years
1362/7
3.82 (3.71-3.95)
4.35 (3.29-5.41)
60-74 years
≥ 75 years
Race/Ethnicity3
Non-Hispanic White
Other
Age at Menarche (years)
< 12 years
12-14 years
≥ 15 years
BMI (kg/m2)
Normal weight ( <25)
Overweight (25 to <30)
Obese (≥30)
Breastfed
No
Yes
Oral Contraceptive Use
No
Yes
Ever Smoked
No
Yes
Alcohol Use
No
Yes
Education
< 12th grade
12th grade

379/26
212/1 0

5.92 (5.76-6.08)
6.73 (6.48-6.98)

5.94 (5.45-6.43)
6.56 (6.11-7.00)

933/35
1020/8

4.43 (3.98-4.26)
4.12 (4.28-4.58)

5.53 (4.94-6.12)b
6.80 (6.60-7.00)a

342/6
1154/30
252/4

4.35 (4.06-4.63)
4.34 (4.19-4.50)
4.34 (4.12-4.57)

5.77 (3.45-8.09)
5.65 (5.12-6.19)a
6.11 (5.44-6.78)a

651/12
573/18
668/12

4.14 (3.98-4.31)
4.45 (4.25-4.65)
4.41 (4.27-4.55)

5.34 (4.40-6.28)b
5.76 (4.91-6.60)b
5.70 (4.73-6.67)b

554/15
831/19

4.71 (4.54-4.88)
4.43 (4.27-4.58)

6.03 (5.36-6.70) b
5.34 (4.58-6.10)b

698/21
1095/19

4.87 (4.68-5.05)
4.12 (3.99-4.26)

5.98 (5.38-6.58) b
5.49 (4.65-6.33)b

1184/20
768/23

4.37 (4.24-4.51)
4.28 (4.10-4.46)

5.78 (5.20-6.35)a
5.52 (4.77-6.26)b

784/16
1013/24

4.47 (4.28-4.66)
4.28 (4.15-4.42)

6.16 (5.73-6.60)a
5.49 (4.69-6.29)b

441/15
624/15

4.46 (4.26-4.67)
4.67 (4.42-4.91)

5.31 (4.38-6.25)
5.95 (5.52-6.39)a

> 12th grade
888/13
4.16 (4.02-4.29)
5.72 (4.51-6.92)b
Income (yearly family income)
0-$24,999
639/17
4.60 (4.41-4.80)
6.31 (5.80-6.82)a
$25,000-$74,999
772/14
4.19 (4.05-4.33)
5.14 (4.33-5.94)b
≥ $75,000
323/7
4.23 (3.99-4.46)
5.30 (4.11-6.50)
1
Means calculated after applying NHANES sampling weights.
2
Sum of Dioxin-like PCBs = (074 +118); Lipid adjusted and log transformed PCBs.
3
Age Standardized Dioxin-like- PCBs
4
Serum Dioxin-like Levels: < 50th percentile vs ≥ 50th percentile
PCB levels significantly higher in women with breast cancer vs. women without breast cancer; ap < 0.0001,
b
p < 0.05
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Table 1.6. Serum Levels of non-dioxin-like PCBs (ng/g) in the study population, women ≥ 20 years of age,
NHANES 1999-2004.
Mean1 (ng/g) (95% CI)
Variable
Noncases/Cases
No Cancer
Breast Cancer
Non-Dioxin-like PCBs2
1941/43
11.1 (11.0-11.3)
13.7 (13.0-14.5)a
Non-Dioxin-like PCBs3
1941/43
11.2 (11.0-11.4)
13.2 (12.0-14.3)b
4
Non-Dioxin-like PCBs_50
8.56 (8.41-8.71)
9.62 (8.86-10.4)b
<LOD to 50%
967/2
≥ 50%
974/41
13.8 (13.7-13.9)
14.1 (13.6-14.6)
Age
20-59 years
1354/7
10.3 (10.1-10.5)
12.9 (11.4-14.3)b
60-74 years
380/26
13.8 (13.5-14.1)
13.9 (13.1-14.6)
≥ 75 years
207/1 0
15.1 (14.6-15.5)
14.7 (13.9-15.4)
Race/Ethnicity3
Non-Hispanic White
926/35
11.3 (11.1-11.5)
13.5 (12.8-14.3)a
Other
1015/8
10.8 (10.5-11.1)
15.8 (14.8-16.8)a
Age at Menarche (years)
< 12 years
340/6
11.0 (10.5-11.5)
13.4 (9.50-17.3)
12-14 years
1145/30
11.1 (10.9-11.4)
13.8 (13.1-14.4)a
≥ 15 years
252/4
11.5 (11.1-11.9)
14.0 (12.0-16.0)b
2
BMI (kg/m )
Normal weight ( <25)
649/12
11.1(10.8-11.3)
13.8 (12.7-14.9)a
Overweight (25 to <30)
570/18
11.3 (11.0-11.6)
13.9 (13.0-14.8)a
Obese (≥30)
664/12
10.9 (10.7-11.2)
13.4 (11.8-15.0)b
Breastfed
No
551/15
12.1 (11.8-12.4)
14.1 (13.2-14.9) a
Yes
824/19
11.3 (11.1-11.6)
13.2 (12.1-14.3)b
Oral Contraceptive Use
No
693/21
11.9 (11.6-12.3)
14.1(13.4-14.8)a
Yes
1090/19
10.8 (10.6-11.0)
13.4 12.1-14.7)b
Ever Smoked
No
1176/20
11.0 (10.7-11.2)
13.5 (12.4-14.5)a
Yes
764/23
11.4 (11.1-11.7)
14.0 (13.2-14.8)a
Alcohol Use
No
781/16
11.3 (11.0-11.6)
14.3 (13.4-15.1)a
Yes
1006/24
11.1 (10.8-11.3)
13.5 (12.3-14.6)b
Education
< 12th grade
435/15
11.4 (13.3-14.5)
13.9 (13.3-14.5)a
th
621/15
11.8 (11.3-12.2)
14.2 (13.2-15.2)a
12 grade
th
885/13
10.8 (10.6-11.0)
13.1 (11.0-15.2)b
> 12 grade
Income (yearly family income)
0-$24,999
635/17
11.5 (11.2-11.8)
14.5 (13.5-15.4)a
$25,000-$74,999
765/14
10.9 (10.6-11.1)
12.4 (11.0-13.9)a
≥ $75,000
323/7
11.1 (10.7-11.5)
14.5 (13.8-15.1) b
1
Means calculated after applying NHANES sampling weights.
2
Sum of non-Dioxin-like PCBs = (099 + 138 + 153 + 180); Lipid adjusted and log transformed PCBs.
3
Age Standardized Non-Dioxin-like PCBs.
4
Serum Non-Dioxin-like Levels: < 50th percentile vs ≥ 50th percentile.
PCB levels significantly higher in women with breast cancer vs. women without breast cancer; ap < 0.0001,
b
p < 0.05.
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GM and 95% CI’s of lipid-adjusted PCB levels are reported in table 1.7 for
women with PCB levels < LOD and ≥ LOD. PCB congeners 74, 118, 138, 153, and 180
did not have any breast cancer cases with PCB levels < LOD. Women with PCB
concentrations ≥ LOD who reported being diagnosed with breast cancer had significantly
higher GM levels of PCB74 (16.0 ng/g vs 9.87 ng/g), PCB 99 (9.87 ng/g vs. 7.24 ng/g),
PCB118 (17.5 ng/g vs 11.7 ng/g), PCB138 (39.6 ng/g vs. 23.6 ng/g), PCB153 (56.2 ng/g
vs. 31.8 ng/g), and PCB180 (44.3 ng/g vs. 23.3 ng/g), compared to women who reported
never being diagnosed with cancer (Table1.7).
Table 1.7. Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES
1999-2004
Geometric mean2(ng/g) (95% CI)
No.
No.
Analyte1
Noncases Cases
No Cancer
Breast Cancer
PCB 074
< LOD
476
0
4.01 (3.90-4.13)
≥ LOD
1483
43
9.87 (7.24-13.5)
16.0 (12.1-21.3)b
PCB 099
< LOD
625
2
3.94 (3.82-4.01)
3.13 (3.03-3.25)
≥ LOD
1334
41
7.24 (4.85-10.8)
9.87 (8.50-11.5)b
PCB 118
< LOD
426
0
4.01 (3.90-4.14)
≥ LOD
1533
43
11.7 (9.03-15.3)
17.5 (9.12-33.4)b
PCB 138
< LOD
365
0
11.9 (11.0-12.8)
≥ LOD
1594
43
23.6 (18.5-30.3
39.6 (28.8-55.1)a
PCB 153
< LOD
309
0
16.4 (15.5-17.6)
≥ LOD
1651
43
31.8 (24.8-40.9)
56.2 (40.9-78.3)a
PCB 180
< LOD
355
0
7.69 (7.24-8.17)
≥ LOD
1599
43
23.3 (18.4-29.7)
44.3 (35.9-54.1)a
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001,
b
p < 0.05.

To account for the lack of breast cancer cases in women with low blood PCB
levels and in women with blood PCB levels below the LOD, we divided lipid-adjusted
PCB levels into the following two groups: < LOD to 50th percentile and ≥ 50th percentile
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(Table 1.8). Women with PCB concentrations in first group (< LOD to 50th percentile)
who reported a breast cancer diagnosis had significantly higher GM PCB levels
compared to women who reported never being diagnosed with cancer for PCB congeners
74 (5.58 ng/g vs. 4.26 ng/g), 138 (15.0 ng/g vs. 11.4 ng/g), 153 (23.3 ng/g vs. 15.3 ng/g),
and 180 (21.1 ng/g vs. 10.5 ng/g) (Table 1.8). GM PCB concentrations did not
significantly differ between any breast cancer cases and non-cases in the second group (≥
50th percentile) (Table 1.8).
Table 1.8. Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES
1999-2004.
Geometric mean2(ng/g) (95% CI)
No.
No.
Analyte1
Noncases Cases
No Cancer
Breast Cancer
PCB 074
< LOD to 50%
1047
4
4.26 (4.10-4.44)
5.58 (4.39-7.17)b
≥ 50%
912
39
17.3 (16.6-18.0)
19.9 (17.1-23.1)
PCB 099
< LOD to 50%
1172
12
3.74 (3.60-3.90)
4.48 (3.67-5.42)
≥ 50%
787
31
13.1 (12.4-13.6)
14.0 (11.7-16.6)
PCB 118
< LOD to 50%
999
6
4.71 (4.53-4.85)
5.26 (4.48-6.23)
≥ 50%
960
37
21.5 (20.5-22.4)
24.3 (19.9-29.4)
PCB 138
< LOD to 50%
1068
4
11.4 (10.9-11.9)
15.0 (13.2-19.1)b
≥ 50%
891
39
45.6 (43.8-47.5)
47.5 (41.3-54.1)
PCB 153
< LOD to 50%
1078
4
15.3 (14.7-16.0)
23.3 (18.4-30.0)b
≥ 50%
882
39
64.1 (61.6-66.0 )
64.1(55.1-74.4)
PCB 180
< LOD to 50%
1148
4
10.5 (9.97-10.9)
21.1 (16.9-26.0)a
≥ 50%
806
39
48.9 (47.0-50.4)
48.9 (42.1-56.8)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001,
b
p < 0.05.

We further divided lipid-adjusted GM PCB levels into the following three groups:
< LOD to 50th percentile, 50th percentile to 75th percentile, and ≥ 75th percentile (Table 1.
9). Women in the first group (< LOD to 50th percentile) who reported a breast cancer
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diagnosis had significantly higher GM levels of PCB 74 (5.58 ng/g vs. 4.26 ng/g),
PCB138 (16.0 ng/g vs. 11.5 ng/g), PCB153 (23.3 ng/g vs. 15.5 ng/g), PCB170 (8.08 ng/g
vs. 5.00 ng/g), PCB180 (21.1 ng/g vs. 10.5 ng/g), and PCB187 (6.05 ng/g vs. 3.90 n/g)
compared to women who reported never being diagnosed with cancer (Table 1.9). GM
PCB concentrations did not significantly differ between breast cancer cases and noncases in the second group (50th percentile to 75th percentile) or third group (≥ 75th
percentile).
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Table 1.9. Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES
1999-2004.
Geometric mean2(ng/g) (95% CI)
No.
No.
Noncases Cases
No Cancer
Breast Cancer
Analyte1
PCB 074
< LOD to 50%
1047
4
4.26 (4.10-4.44)
5.58 (4.39-7.17)b
50 – 75%
351
10
11.1 (10.9-11.5)
11.2 (10.1-12.8)
≥ 75%
561
29
24.5 (23.6-25.5)
25.3 (22.4-28.5)
PCB 099
< LOD to 50%
1172
12
3.74(3.60-3.90)
4.48 (3.67-5.42)
50 – 75%
357
10
8.58 (8.33-8.76)
8.50 (7.85-9.12)
≥ 75%
430
21
19.3(18.5-20.3)
18.0 (15.5-20.7)
PCB 118
< LOD to 50%
999
6
4.71 (4.53-4.85)
5.26 (4.48-6.23)
50 – 75%
388
9
12.7 (12.4-13.1)
12.8 (10.7-15.3)
≥ 75%
572
28
33.1 (31.5-34.8)
32.1 (27.4-37.7)
PCB 138
< LOD to 50%
1068
4
11.5 (10.9-11.9)
15.0 (11.7-19.3)b
50 – 75%
394
14
30.0 (29.7-30.6)
31.5 (28.8-34.8)
≥ 75%
497
25
67.4 (64.7-70.8)
62.8 (54.1-73.7)
PCB 153
< LOD to 50%
1078
4
15.3 (14.9-16.0)
22.9 (16.9-30.6)b
50 – 75%
383
14
43.8 (42.5-44.7)
44.3 (42.1-47.0)
≥ 75%
499
25
92.8 (89.1-96.5)
86.5 (75.9-98.5)
PCB 180
< LOD to 50%
1148
4
10.5 (9.97-10.9)
21.1 (16.9-26.0)a
50 – 75%
386
19
35.2 (34.5-35.9)
38.1 (34.8-41.3)
≥ 75%
420
20
72.2 (69.4-75.9)
69.4 (59.7-79.8)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001,
b
p < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having breast cancer
and the six individual PCB congeners are shown in table 1.10. Due to the lack of breast
cancer cases in women with low blood PCB levels and in women with blood PCB levels
below the LOD, the following two groups were used to estimate breast cancer risk: <
LOD to 50th percentile (reference group) and ≥ 50th percentile. Results are presented for
three logistic regression models: unadjusted; age, race/ethnicity, and BMI adjusted; and
age, race/ethnicity, BMI, lactation, and age at menarche adjusted. In unadjusted models,
PCBs were significantly associated with breast cancer risk for subjects in the second
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group (≥ 50th percentile) when compared to the reference group (< LOD to 50th
percentile) for PCB congeners 74, 99, 118, 138, 153, and 180 (Table 1.10). After
adjusting for age, race/ethnicity and BMI, PCB138 was found to be significantly
associated with breast cancer [OR of 3.16 (95% CI: 1.14-8.76) (Table 1.10). After
adjusting for age, race/ethnicity, BMI, lactation, and age at menarche, PCB138 and
PCB180 were found to be significantly associated with breast cancer [OR of 2.88, 95%
CI: 1.14-7.30 and OR of 4.54, 95% CI: 1.11-18.6], respectively (Table 1.10). Adjusting
for lactation and age at menarche decreased the sample size to 34 breast cancer cases and
1324 and 1320 cancer noncases in PCB138 and PCB180, respectively.
Table 1.10. Estimated ORs (95% CIs) of breast cancer by concentration of PCB levels among women ≥ 20
years of age, NHANES 1999-2004.
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
4
1047
1.00
1.00
1.00
≥ 50%
39
912
5.82 (2.56-13.3)a
1.55 (0.46-5.24)
2.64 (0.59-12.0)
PCB 099
< LOD to 50%
12
1172
1.00
1.00
1.00
1.39 (0.66-2.92)
1.67 (0.60-3.43)
≥ 50%
31
787
3.09 (1.60-5.98)b
PCB 118
< LOD to 50%
6
999
1.00
1.00
1.00
≥ 50%
37
960
4.34 (1.95-9.67)b
1.32 (0.38-4.65)
2.01 (0.48-8.44)
PCB 138
< LOD to 50%
4
1068
1.00
1.00
1.00
≥ 50%
39
891
7.35 (3.10-17.4)a
3.16 (1.14-8.76)b
2.88 (1.14-7.30)b
PCB 153
< LOD to 50%
4
1078
1.00
1.00
1.00
≥ 50%
39
882
9.20 (2.30-36.7)b
3.96 (0.59-26.4)
3.6 (0.73-18.6)
PCB 180
< LOD to 50%
4
1148
1.00
1.00
1.00
4.61 (0.86-24.7)
4.54 (1.11-18.6)b
≥ 50%
39
806
10.6 (3.03-37.1)b
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age, race/ethnicity, BMI;
Cases/Noncases: 42/1898 in 74, 138, 180; 42/1900 in 099; 42/1899 in 153; 42/1894 in 180.
3
Adjusted for age, race/ethnicity, BMI, lactation, age at menarche;
Cases/Noncases: 34/1323 in 74; 34/1326 in 99, 118; 34/1324 in 138; 34/1325 in 153; 34/1320 in 180.
Significance ap < 0.0001, bp < 0.05.

105

ORs and 95% confidence intervals for breast cancer were further explored for
subjects with PCB concentrations divided into the following three groups: < LOD to 50th
percentile, 50th to 75th percentile, and ≥ 75th percentile (Table 1.11). Subjects with PCB
concentrations in the first group (< LOD to 50th percentile) were used as the reference
group. In all of the unadjusted models, a significant risk of breast cancer was found for
subjects with PCB concentrations in the second group (50th to 75th percentile) for all six
PCB congeners except PCB 99 and in the third group (≥75th percentile) (Table 1.11). In
unadjusted models, the strongest associations with breast cancer risk among subjects in
the third group (≥75th percentile) were found for PCB congeners 180, 153, 138, and 74
[ORs of 10.0 (95% CI: 3.20-31.4), 9.99 (95% CI: 2.59-38.5), 8.49 (95% CI: 3.41-21.1),
and 7.30 (95% CI: 3.08-17.3), respectively] (Table 1.11). In age, race/ethnicity and BMI
adjusted models, we found PCB138 significantly associated with breast cancer for
subjects in the second (50th to 75th percentile) and third (≥75th percentile) groups: [ORs
of 2.93, 95% CI: 1.04-8.26 and 3.43, 95% CI: 1.13-10.4, respectively] (Table 1.11).
However, this risk did not remain for either group after adjusting for age, race/ethnicity,
BMI, lactation, and age at menarche. Race/ethnicity was significantly associated with
breast cancer in models for all six PCB congeners, however, only BMI category four (≥
30 kg/m2) was significantly associated with breast cancer in models for PCB congener
180. The association between individual PCBs and breast cancer was also examined in
multiple variable adjusted models that included the covariates parity, oral contraceptive
use, smoking status, alcohol use, education, and yearly family income, however these
variables were not included in the final model because they significantly decreased the
sample size and were not found to be significant predictors of breast cancer risk.
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Table 1.11. Estimated ORs (95% CIs) of breast cancer by concentration of PCB levels among women ≥ 20
years of age, NHANES 1999-2004.
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
4
1047
1.00
1.00
1.00
1.51 (0.44-5.17)
1.79 (0.29-10.8)
50% to 75%
10
351
3.96 (1.52-10.3)b
1.61 (0.42-6.17)
1.65 (0.24-11.4)
≥ 75%
29
561
7.30 (3.08-17.3)a
PCB 099
< LOD to 50%
12
1172
1.00
1.00
1.00
50% to 75%
10
357
2.12 (0.77-5.80)
1.12 (0.39-3.25)
1.26 (0.36-4.49)
1.63 (0.77-3.44)
1.64 (0.60-4.49)
≥ 75%
21
430
4.01 (2.16-7.47)a
PCB 118
< LOD to 50%
6
999
1.00
1.00
1.00
1.19 (0.31-4.58)
1.27 (0.21-7.79)
50% to 75%
9
388
2.98 (1.29-6.85) b
≥ 75%
28
572
5.48 (2.32-12.9) a
1.45 (0.40-5.24)
1.45 (0.26-7.92)
PCB 138
< LOD to 50%
4
1068
1.00
1.00
1.00
2.93 (1.04-8.26)b
1.93 (0.76-4.86)
50% to 75%
14
394
6.17 (2.46-15.5)b
3.43 (1.13-10.4)b
2.70 (0.90-8.09)
≥ 75%
25
497
8.49 (3.41-21.1)a
PCB 153
< LOD to 50%
4
1078
1.00
1.00
1.00
50% to 75%
14
383
8.40 (1.75-40.3)b
3.82 (0.47-31.1)
2.57 (0.39-16.8)
≥ 75%
25
499
9.99 (2.59-38.5)b
4.14 (0.73-23.4)
3.28 (0.62-17.4)
PCB 180
< LOD to 50%
4
1148
1.00
1.00
1.00
5.00 (0.84-29.9)
3.60 (0.72-17.9)
50% to 75%
19
386
11.1 (2.63-46.6)b
3.89 (0.87-17.5)
2.77 (0.61-12.6)
≥ 75%
20
420
10.0 (3.20-31.4)a
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age, race/ethnicity, BMI; Breast Cancer Cases/Noncases:
42/1898 in 74, 138, 180; 42/1900 in 99; 42/1899 in 153; 42/1894 in 180.
3
Adjusted for age, race/ethnicity, BMI, lactation, age at menarche; Breast Cancer Cases/Noncases:
34/1323 in 74; 34/1326 in 99, 118; 34/1324 in 138; 34/1325 in 153; 34/1320 in 180.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having breast cancer
and dioxin-like and non-dioxin-like PCBs are shown in table 1.12. In the unadjusted and
race/ethnicity adjusted models, dioxin-like PCBs were significantly associated with
breast cancer [ORs of 1.50, 95% CI: 1.27-1.77 and 1.49, 95% CI: 1.24-1.79] as well as
non-dioxin-like PCBs [ORs of 1.28, 95% CI: 1.18-1.38 and 1.29, 95% CI: 1.18-1.40],
respectively. After adjusting for age, race/ethnicity, and BMI, non-dioxin-like PCBs
remained significantly associated with breast cancer risk [OR of 1.14, 95% CI: 1.00-1.29]
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(Table 1.12). Neither dioxin-like or non-dioxin-like PCBs remained significantly
associated for breast cancer in the models after adjusting for age, race/ethnicity, BMI,
lactation, and age at menarche (Table 1.12).

We further analyzed breast cancer risk of

dioxin-like and non-dioxin-like PCBs using the following two groups: < LOD to 50th
percentile (reference group) and ≥ 50th percentile. In subjects with PCB levels ≥ 50th
percentile, breast cancer was significantly associated with dioxin-like and non-dioxin-like
PCBs in the unadjusted models [ORs of 4.95, 95%CI: 2.36-10.4 and 11.6, 95% CI: 2.3757.2] and in the race/ethnicity adjusted models [ORs of 4.65, 95% CI: 2.00-10.8 and
11.1, 95% CI: 2.24-55.1], respectively. The risk of breast cancer did not remain
significant for these dioxin-like and non-dioxin-like PCBs after further adjustment for
age, lactation, and age at menarche (Table 1.12).
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Table 1.12. Estimated ORs (95% CIs) of breast cancer by concentrations of dioxin-like and non-dioxin-like PCBs among women ≥ 20 years of
age, NHANES 1999-2004.

4

Dioxin-like PCBs

Cases/Noncases
43/1953

Unadjusted OR
(95% CI)
1.50 (1.27-1.77)a

Adjusted OR1
(95% CI)
1.49 (1.24-1.79)a

Adjusted OR2
(95% CI)
1.08 (0.84-1.40)

Adjusted OR3
(95% CI)
1.07 (0.78-1.49)+

Dioxin-like PCBs_504,6
< LOD to 50%
≥ 50%

4/973
39/979

1.00
4.95 (2.36-10.4)a

1.00
4.65 (2.00-10.8)b

1.00
1.47 (0.46-4.71)

1.00
1.58 (0.29-8.53)+

Dioxin-like PCBs_754,7
< LOD to 75%
≥ 75%

12/1404
31/543

1.00
5.08 (2.19-11.8)a

1.00
4.63 (2.17-9.89)a

1.00
1.71 (0.82-3.54)

1.00
1.45 (0.57-3.69)+

Non- Dioxin-like PCBs5

43/1941

1.28 (1.18-1.38)b

1.29 (1.18-1.40)a

1.14 (1.00-1.29)b

1.10 (0.94-1.29)++

Non-Dioxin-like PCBs_505,6
< LOD to 50%
≥ 50%

15/1274
45/1315

1.00
11.6 (2.37-57.2)a

1.00
11.1 (2.24-55.1)b

1.00
4.73 (0.92-4.50)

1.00
3.97 (0.52-22.3)++

Non-Dioxin-like PCBs_755,7
< LOD to 75%
2/967
1.00
1.00
1.00
4.43 (2.25-8.72)a
2.04 (0.92-4.50)
≥ 75%
41/974
4.56 (2.35-8.83)a
1
Adjusted for race/ethnicity.
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche, lactation.
4
Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118).
+
34 breast cancer cases/1420 noncases.
5
Non-Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (099 + 138 + 153 + 180).
++
34 breast cancer cases/1312 noncases.
6
Serum PCB Levels < 50th percentile vs ≥ 50th percentile.
7
Serum PCB Levels < 75th percentile vs ≥ 75th percentile.
Significance ap < 0.0001, bp < 0.05.

1.00
2.63 (0.88-7.87)++

DISCUSSION
This cross-sectional assessment of a representative sample of U.S. women
demonstrated that higher body burdens of PCBs were significantly associated with breast
cancer in the general population. We evaluated 6 individual PCB congeners, the sum of
dioxin-like PCBs, and the sum of non-dioxin-like PCBs. Analysis of GM levels of PCBs
by breast cancer status, age, and race was done to assess PCB concentrations in
subpopulations. All PCB congeners and total PCBs showed an increasing trend with age.
These results are supported by previously reported associations of PCB body burdens and
age in women (Axelrad et al. 2009, Thompson et al. 2013). While this may be a result of
lower levels of PCBs in the environment today, it may also be due to the persistent nature
of PCBs and increased accumulations in the human body over time. In women who
reported being diagnosed with breast cancer, women classified as ‘Other’ had
significantly higher age standardized GMs of PCB than non-Hispanic white women.
Higher PCB and DDE levels have been previously reported among African-American
women compared with non-Hispanic white women by Millikan et al. (2013) and Zheng et
al. (1999), respectively. While race was found to be a protective factor against the odds
of breast cancer for all non-Hispanic white women, the small number of nonwhite breast
cancer cases limits the interpretation of the findings in this study. Differences between
races could be attributed to differences in diet and geographic locations. While these
results do not provide any evidence of causal associations, it is noteworthy that women
diagnosed with breast cancer have higher levels of dioxin-like, non-dioxin-like, and
individual PCB congeners compared to women who reported never being diagnosed with
cancer.

A landmark UN report assessing effects of human exposure to hormonedisrupting chemicals acknowledges that approximately 800 chemicals are suspected to
act as endocrine disruptors or mimic natural hormones or disrupt hormone regulation
(UNEP/WHO 2013). This report highlights that there is some associations between
exposures to many of the endocrine disruptors, particularly, estrogen-mimicking
chemicals and an increased risk of breast cancer in women. Exposure to EDCs, such as
PCBs, during early development of the breast can alter its development, and possibly
contribute to the susceptibility to diseases through effects on stem cells.
For women with detectable levels of blood PCBs, age adjusted GMs for PCB
congeners (99, 138, 153, and 180) were significantly higher among breast cancer cases
compared to noncases. These findings are consistent with previously reported studies by
Charlier et al. (2004) who found higher blood levels of PCB congeners 138 and 153,
Demers et al. (2002) who found significantly greater concentrations of PCB congeners
99, 118, and 156, and Recio-Vega et al. (2001) who found significantly higher
concentrations of 11 PCB congeners (8,105, 118, 126, 128, 138, 170, 180, 195, 206, and
209) in breast cancer cases compared to controls. The sum of dioxin-like and nondioxin-like PCBs were also found to be significantly higher in breast cancer cases
compared to noncases which is consistent with findings from Demers et al. (2002) (sum
of 105, 118, and 156) and Recio-Vega et al. (2001) (sum of 20 PCB congeners), however
significance only remained for non-dioxin-like PCBs after we adjusted for age. Our
results for age adjusted total PCBs are fairly consistent with epidemiological studies by
Cohn et al. (2012), Gammon et al. (2002), Gatto et al. (2007) and Wolff et al. (2000),
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however, these comparisons are limited due to the difference in PCB congeners used in
the sum of total PCBs and adjustment for confounding variables in each study.
Breast cancer risk appeared to be highest in women with the highest PCB
concentrations in unadjusted logistic regression models. Only PCB 138 was found to be
significantly associated with increased breast cancer risk after adjusting for age,
race/ethnicity, BMI, lactation, and age at menarche. There were no associations between
the sum of dioxin-like and non-dioxin-like PCBs and breast cancer when models were
adjusted for age, race/ethnicity, BMI, lactation, and age at menarche. While these results
are consistent with previous studies reporting age and multivariate adjusted ORs for
breast cancer risk and PCBs (Gammon et al. 2002, Gatto et al. 2007, Wolff et al. 2000), a
few studies have reported significant associations for specific PCB congeners or
subpopulations (Cohn et al. 2012, Millikan et al. 2103, Recio-Vega et al. 2001). Cohn et
al. (2012) found a significant association with breast cancer in women diagnosed before
50 years of age for PCB 203 after adjusting for lipids, race, year, lactation, and body
mass; Millikan et al. (2013) found a slightly elevated risk of breast cancer (OR=1.74,
95% CI:1.00-3.01) in African American women after adjusting for age, age-squared,
race, menopausal status, BMI, parity/lactation, HRT use, and income; and Recio-Vego et
al. (2001) found the risk of breast cancer to be positively associated with eight PCB
congeners: 118, 128, 138, 170, 180, 195, 206, and 209 and total PCBs (OR=1.09, 95%
CI: 1.02-1.16) after adjusting for age, age at menarche, lactation, menopausal status,
BMI, and family history.
There are a number of limitations to our study, the most important of which is its
cross-sectional design with self-reported data. Self-reported data increases the risk of
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misclassification bias of cases and controls, particularly in analyses of associations
between PCBs and reproductive outcomes. We also had a relatively small sample size
for breast cancer cases resulting in decreased statistical power within subgroup analyses.
Furthermore, observed associations could be potentially confounded by lack of
information on geographical location of primary residence and family history of some of
the variables. Strengths of this cross-sectional study design include the large sample
survey size, availability of biological measurements of environmental contaminants, and
oversampling of minority populations that make it highly representative and
generalizable to the U.S. population.
CONCLUSION
Based on our analysis of serum blood lipid PCB levels in the 1999-2004
NHANES data cycles, biological levels of PCBs may contribute to breast cancer risk
among U.S. women. Despite the ban on PCB production, environmental exposures
appear to pose significant threats on the reproductive health of the general population. A
single exposure to an internal or external environmental factor alone cannot explain the
development of a complex chronic disease, such as breast cancer, rather it appears that
exposure to multiple environmental and molecular factors across the lifespan and their
interactions influence the development of these chronic diseases in an individual. Given
the proven contribution of unopposed estrogens to the risk for breast cancer, it is
biologically plausible that altered endogenous estrogen levels presumably from exposure
to estrogen mimicking EDCs may contribute to the risk of disease. Findings of this study
are based on the use of cross-sectional self-reported data. Thus, further research is
needed to assess specific biological mechanisms of reproductive health outcomes and
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cancer development in relation to PCB biomarker levels among women in the general
population.
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CHAPTER V
MANUSCRIPT 2
ASSOCIATION OF POLYCHLORINATED BIPHENYLS, ENDOMETRIOSIS
AND UTERINE LEIOMYOMAS AMONG U.S. WOMEN: NHANES 1999-2004
ABSTRACT
Background: It is estimated that endometriosis occurs in 10% of women and is the most
common cause of infertility in the United States. Uterine leiomyomas are the most
common benign tumors in women and leading cause of hysterectomies. There is
considerable evidence that endometriosis and uterine leiomyomas are estrogen dependent
diseases. The estrogenic activity of polychlorinated biphenyls (PCBs) may play a role in
the development of these diseases.
Objectives: The purpose of this study was to examine the cross-sectional relationship
between exposure to PCBs and endometriosis and uterine leiomyomas among U.S.
women.
Methods: We analyzed data from female participants (20-54 years of age) who provided
blood samples for the Centers for Disease Control and Prevention’s National Health and
Nutrition Examination Survey (NHANES) between 1999 and 2004. Exposure was based
on lipid adjusted serum levels of 6 individual PCB congeners (74, 99, 118, 138, 153, and
180), the sum of dioxin-like PCBs (074 + 118), and the sum of non-dioxin-like PCBs
(099 + 138 + 153+187) in conjunction with data obtained from the reproductive health
questionnaire. We calculated geometric means to compare PCB concentrations in
women who self-reported an endometriosis or uterine leiomyoma diagnosis vs. women
who self-reported never being diagnosed with endometriosis or uterine leiomyomas. We
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used logistic regression models to estimate odds ratios (ORs) and 95% confidence
intervals (CIs) of endometriosis and uterine leiomyomas by concentration of lipidadjusted serum PCBs. We evaluated age, race/ethnicity, body mass index (BMI; kg/m2),
age at menarche, oral contraceptive use, parity, smoking status, and alcohol consumption
as potential confounders.
Results: Separate analyses showed weighted geometric mean levels of PCB congeners
138, 153, and 180 to be significantly higher among women diagnosed with endometriosis
and geometric mean levels of PCB congeners 74, 99, 118, 138, 153, and 180 to be
significantly higher among women diagnosed with uterine leiomyomas compared to the
rest of the study population. Dioxin-like PCBs were found to be significantly higher in
women diagnosed with uterine leiomyomas and non-dioxin-like PCBs were found to be
significantly higher in women diagnosed with endometriosis and uterine leiomyomas
compared to women who were not diagnosed. After adjusting for age, race, BMI, parity,
age at menarche, oral contraceptive use, alcohol, and smoking status we found that PCB
74 and 118 were significantly associated with uterine leiomyomas [ORs of 1.91; 95% CI:
1.10-3.29 and 1.91, 95% CI:1.13-3.22] in women with higher body burdens of individual
PCB congeners (< LOD vs. ≥ LOD), respectively. PCB 180 was also found to be
significantly associated with uterine leiomyomas for women in the second tertile (33rd to
66th %ile) [OR of 1.87, 95% CI: 1.15-3.02]. We did not find endometriosis to be
significantly associated with any PCBs in the adjusted logistic regression models.
Conclusions: Our results suggest a link between environmental exposures to PCBs and
increased risk of uterine leiomyomas among women in the general U.S. population.
Keywords: PCBs, NHANES, endometriosis, uterine leiomyomas.
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MANUSCRIPT 2
ASSOCIATION OF POLYCHLORINATED BIPHENYLS, ENDOMETRIOSIS,
AND UTERINE LEIOMYOMAS AMONG U.S. WOMEN:
NHANES DATA 1999-2004
INTRODUCTION
Endometriosis and uterine leiomyomas are estrogen dependent disorders
associated with pelvic pain, significant morbidity, and infertility (Borah et al. 2013,
Parker et al. 2007, Buttram and Reiter 1981). They are both common disorders among
reproductive women with prevalence estimates in premenopausal women of 10% and
30% for endometriosis and uterine leiomyomas, respectively (Baird et al. 2003, Ezkenazi
and Warner 2008, Diamanti-Kandarakis et al. 2009). Endometriosis is characterized by
growth of tissue outside the uterus and uterine leiomyomas, also known as uterine
fibroids, are benign tumors of the smooth muscle cells found in the human uterus. Both
are the leading indication of hysterectomy in the United States (Farquhar and Steiner
2002). Through research on hormone contraception, postmenopausal hormonal therapies
and estrogen-receptor (ER)-based endocrine therapies, we know estrogens are a major
risk factor for endometriosis and uterine leiomyomas (Evans et al. 2008, Lin et al. 2009,
Bertelsen et al. 2007, Hodges et al. 2006).
There is a renewed concern that exposure to environmental chemicals that act as
endocrine disruptors (EDs) and mimic natural hormones or disrupt hormone regulation
are associated with an increased risk of endometriosis and reproductive dysfunction in
women (UNEP/WHO 2013, EU 2013). Of particular concern are the estrogenmimicking EDs, such as polychlorinated biphenyls, that are persistent in the environment,
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highly lipophilic, and readily bio-accumulate and magnify within the food chain (Roy et
al. 1997, Roy et al. 1998). Polychlorinated biphenyls (PCBs) are a group of synthetic
organic chemicals with half-lives ranging from a few months to a few decades depending
on PCB chlorination, age, body fat, and breast feeding (Calafat et al. 2008, Woodruff et
al. 2011, Silva et al. 2004). PCBs have been shown to interfere with reproductive
function and development in animals and humans by either increasing or blocking
estrogen activity (Fielden et al. 2001, Ma and Sassoon 2006, McLachlan et al. 2006).
Adverse reproductive health effects have been established in a number of animal studies
and have linked PCB exposure to decreased sperm fertilizing ability in mice (Fielden et
al. 2001), changes in the uterine myometrium and gland formation in mice (Ma and
Sassoon 2006), and a significant dose-dependent relationship in the prevalence and
severity of endometriosis in rhesus monkeys (Rier et al.2001).
Epidemiologic studies demonstrating the association between exposure to EDCs
and endometriosis are limited and conflicting. Three case-control studies found
significant associations between exposure to total PCBs and risk of endometriosis (Buck
Louis et al. 2005, Porpora et al. 2009, Heiler et al.2005). Buck Louis et al. (2005) found
a significant increased risk of endometriosis for the sum of anti-estrogenic PCBs for
women in the third tertile (OR=3.77, 95% CI 1.12-12.68), however, the risk remained
elevated but not significant when adjusted for all listed covariates. Porpora et al. (2009)
found the GM of total PCBs to be significantly higher in cases than controls (301.3 vs.
203.0, p < 0.01) and the OR of endometriosis risk in the highest tertile of total PCBs
compared with the lowest tertile, was 5.63 (95% CI 2.25-14.10). Significant increased
risk of endometriosis was also found for PCB congeners 118, 138, 153, and 170. In a
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case-control study conducted by Heiler et al. (2005) dioxin-like PCB concentrations were
higher in women with deep endometriotic (DE) nodules compared to controls (12.4 vs.
8.5, p = .026) but did not significantly differ for women with peritoneal endometriosis
(PE) compared to controls (11.0 vs. 8.5) and for women with DE compared to women
with PE (12.4 vs. 11.0).
In contrast, a number of case-control studies have failed to find significant
associations between endometriosis and exposure to individual PCB congeners, total
PCBs, or specific sub-groups (Niskar et al. 2009, Pauwels et al. 2001, Trabert et al. 2010,
Tsukino et al. 2005). Niskar et al. (2009) conducted a case-control study with 60
confirmed endometriosis cases staged as I (minimal), II (mild), III (moderate), and IV
(severe) and 30 controls. Mean lipid-adjusted PCB concentrations were not significantly
different (179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases, stage III
cases, stage IV cases, and controls, respectively. In the largest case-control study,
conducted by Trabert et al. (2010), total PCBs (n=20), estrogenic PCBs (n=6), and
individual PCB congeners were measured in the serum from 251 cases and 538 controls,
matched for age and reference year. Adjusted total and estrogenic PCBs in the highest
quartiles were not associated with an increased risk of endometriosis (Total: OR=1.2,
95% CI 0.6-2.3, Estrogenic: OR=0.9, 95% CI 0.5-1.4). In two case-control studies
measuring median TEQ values (pg TEQ/g lipid) Pauwels et al. (2001) found no
association between endometriosis and the median TEQ values (pg TEQ/g lipid) in cases
and controls (29 vs. 27) and Tsukino et al. (2005) found no difference in median TEQ
values for endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs.
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3.59, PCBs: 4.61 vs. 5.14), respectively. The OR of endometriosis risk in the highest
quartile of total PCBs compared with the lowest quartile was 0.41 (95% CI 0.14-1.27).
Epidemiological studies pertaining to PCBs and uterine leiomyomas are limited.
Trabert et al. (2014) found PCB 99 (OR of 1.64, 95% CI: 1.08-2.49), PCB 138 (OR of
1.64, 95% CI: 1.03-2.59), PCB 146 (OR of 1.54, 95% CI: 1.01-2.37), PCB 153 (OR of
1.88, 95% CI: 1.12-3.13), PCB 196 (OR of 1.60, 95% CI: 1.02-2.51), and PCB 206 (OR
of 1.52, 95% CI: 1.01-2.29) to be associated with fibroids but only in the absence of
endometriosis.
In this study, we examined the relationship between 6 individual PCB congeners,
the sum of dioxin-like PCBs, and the sum of non-dioxin-like PCBs with self-reported
endometriosis and uterine leiomyomas in female subjects participating in the National
Health and Nutrition Examination Survey (NHANES) between the years 1999-2004. The
objectives of this study were to: 1) describe the mean PCB levels in women (20-54 years
of age) diagnosed with endometriosis or uterine leiomyomas compared to women not
diagnosed with endometriosis or uterine leiomyomas; and 2) assess the association
between higher body burdens of PCBs and increased risk of endometriosis or uterine
leiomyomas.
METHODS
Study design and population. NHANES is an ongoing cross-sectional survey designed to
be nationally representative of the non-institutionalized U.S. civilian population.
Conducted annually since 1999 by the National Center for Health Statistics of the Centers
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage
sampling design where approximately 5,000 survey participants a year complete in-home
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interviews and physical examinations in mobile examination units (CDC, 2012).
Sociodemographic information and medical histories were collected during the in-home
interview and biological samples and reproductive health information was collected in
the mobile examination component (MEC). All participants provided written informed
consent and all procedures were approved by the National Center for Health Statistics
(NCHS) Institutional Review Board (CDC, 2012). We merged data from the 1999-2000,
2001-2002 and 2003-2004 survey cycles. We limited our analysis to women 20 to 54
years of age who completed the reproductive questionnaire in a face-to-face interview at
a mobile examination center.
PCB measurements. Blood serum concentrations of individual PCB congeners were
measured in a representative, random one-third subsample of people 12 years of age and
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were
measured in serum by high-resolution gas chromatography/isotope-dilution highresolution mass spectrometry (HRGS/ID-HRMS). NHANES provides both wet-weight
and lipid adjusted values for each sample, corrected for sample weight and analyte
recovery; we used lipid adjusted values in our analyses. Detailed laboratory methods
were consistent among survey cycles and are available online (CDC 2013b). A detection
limit variable is provided for all PCB congeners in the data set. The variable LBD_LC
has two values: the value “0” indicates that the result was below the limit of detection
and the value “1” indicates that the result was at or above the limit of detection. Any
participant with a serum PCB concentration below the limit of detection was assigned a
serum level of the LOD divided by the square root of two. Limits of detection vary by
individual PCB congener and survey cycle and can be found in the CDC’s Fourth
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National Report on Human Exposure to Environmental Chemicals (CDC 2103). Lipidadjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (99 + 138 +153
+ 180) were used in this study. PCB congeners 74, 99, 118, 138, 153, and 180 were
selected because they were available in all three survey cycles and concentrations were
above the limit of detection (LOD) in > 60% of the survey participants.
Diagnosis of endometriosis and uterine leiomyomas. We included female 1999-2004
NHANES participants 20 to 54 years of age who completed the self-reported medical
health questionnaire and provided a response for “Have you ever been told by a doctor or
other health professional that you had endometriosis?” and “Have you ever been told by a
doctor or other health professional that you had uterine fibroids?”. Women who
answered “yes” were subsequently asked “How old were you when you were first told
you had endometriosis?” Questions pertaining to endometriosis and uterine leiomyoma
diagnosis were restricted to women 20 to 54 years of age in the NHANES datasets. PCB
measurements were available in 80 women who reported an endometriosis diagnosis for
PCB congeners 74, 99, 118, 138 and 153, and in 79 women for PCB 180. PCB
measurements were available in 1073 women who reported never being diagnosed with
endometriosis for PCBs 74, 153 and 180, and in 1,074 women for PCBs 99, 118, and
138. PCB measurements were available in 148 women who reported a diagnosis of
uterine leiomyomas for PCB congeners 74, 118, and 180, and in 149 women for PCBs
99, 138, and 153. PCB measurements were available in 1004 women who reported never
being diagnosed with uterine leiomyomas for PCBs 153 and 180, in 1005 women for
PCBs 74, 99 and 138, and in 1,006 women for PCB 118. The sum of dioxin-like PCBs
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was available in 80 endometriosis cases and 1,071 endometriosis non-cases and in 147
uterine leiomyoma cases and 1004 uterine leiomyoma noncases. The sum of non-dioxinlike PCBs was available in 79 endometriosis cases and 1,067 endometriosis noncases and
in 148 uterine leiomyoma cases and in 998 uterine leiomyoma noncases.
Statistical analysis. All statistical analyses were performed using SAS system software
(release 9.2; SAS Institute Inc. Cary, N.C.). A six year subsample weight was calculated
according to the National Center for Health Statistics guidelines to adjust for
oversampling of minority groups in the merged 1999-2004 NHANES data cycles (CDC
2013b). Nonmissing values for serum concentrations below the LOD were assigned a
serum level of the LOD divided by the square root of two. In our analysis, all lipidadjusted serum PCB concentrations were log transformed to satisfy normality
assumptions. Participants were categorized the following ways depending on data
analysis: < LOD vs. ≥ LOD and tertiles: < LOD to < 33rd percentile, ≥ 33rd percentile to
66th percentile, and ≥ 66th percentile. Significance was set at p < 0.05 for all analyses.
We used PROC SURVEYMEANS to account for the complex sampling design of
NHANES and to obtain weighted means, 95% CIs, and standard errors of individual PCB
congeners, the sum of dioxin-like PCBs, and the sum of non-dioxin-like PCBs. We used
the Taylor Series (linearization) method to estimate standard errors. A two-sided student
t-test was calculated using PROC SURVEYREG to test whether the mean PCB levels
between women who reported an endometriosis or uterine leiomyoma diagnosis and
women who reported no endometriosis or uterine leiomyoma diagnosis were significantly
different. Geometric mean (GM) PCB levels and geometric standard errors (GSE) were
reported for endometriosis and uterine leiomyoma status, age at time of interview (years),
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and race/ethnicity for all participants. Serum levels of dioxin-like and non-dioxin-like
PCBs and their 95% CIs were reported for endometriosis and uterine leiomyoma status
and select confounding variables (age, race, BMI, parity, age at menarche, alcohol
consumption and smoking status). Age was divided into four groups (20-29 years, 30-39
years, 40-49 years, and 50-54 years), race/ethnicity was divided into three groups (nonHispanic White, non-Hispanic Black and ‘Other’). The category of ‘Other’ includes
Mexican American, Other Hispanic and Other Race – Including Multi-Racial. To account
for the different age structures among ethnicities in our study population, we presented
age standardized GM PCB levels for race/ethnicity in individual PCB congeners and age
standardized arithmetic mean dioxin-like and non-dioxin-like PCB levels for
race/ethnicity. We used the direct method for age standardization provided by the CDC
(CDC 2014).
Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs
and their 95% CIs to evaluate the association between exposure to PCBs and
endometriosis and uterine leiomyomas. We conducted separate analyses for the sum of
dioxin-like and non-dioxin-like PCBs and individual PCB congeners and endometriosis
and uterine leiomyomas. ORs were calculated using the following groups: < LOD vs. >
LOD and tertiles (< LOD to 33rd percentile vs. 33rd percentile to 66th percentile vs. ≥ 66th
percentile).

The reference group for each PCB congener is defined as those participants

whose serum concentrations were < LOD or < LOD to 33rd percentile depending on the
analysis.
Covariates. We considered a number of potential confounders based on previous
literature and well-established risk factors for endometriosis. The following potential
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confounders were either self-reported in the questionnaire interviews or taken as a
laboratory measurement. The demographic variables of age at interview (20-29, 30-39,
40-49, and 50-54 years) and race (non-Hispanic White, non-Hispanic Black, Other) were
obtained during the NHANES home interview (CDC 2012). Reproductive variables
including age at menarche (<12 years, 12-14 years, ≥15 years), parity (0, 1, ≥ 2), number
of live births (0, 1, ≥ 2), oral contraceptive use (yes/no), having undergone a
hysterectomy (yes/no), having undergone a oophorectomy (yes/no) as well as lifestyle
variables including smoking (yes/no) and alcohol use (yes/no) were obtained from health
questionnaires completed in the mobile examination center. Body mass index (< 25
kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2) was obtained through the body measurement
component in the mobile examination center (CDC 2012). For individual PCB congeners,
the sum of dioxin-like PCBs and the sum of non-dioxin-like PCBs, ORs and 95% CIs are
reported for three models: unadjusted; age and race/ethnicity adjusted; and age,
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, and
alcohol adjusted.
RESULTS
Descriptive statistics. The study population included 1,154 female participants 2054years of age and older who completed the medical questionnaire and provided a
response for “Have you ever been told by a doctor or other health professional that you
had endometriosis?” and “Have you ever been told by a doctor or other health
professional that you had uterine fibroids?” Women who answered “yes” were
subsequently asked, “What was your age at diagnosis?” Among the 1,154 female
participants who responded to those two questions and had available PCB data, 1,074
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reported never being diagnosed with endometriosis, 80 reported being diagnosed with
endometriosis, 1,005 reported never being diagnosed with uterine leiomyomas, and 149
reported being diagnosed with uterine leiomyomas (Table 2.1). The majority of
participants were of non-Hispanic white ethnicity (44.9%). A diagnosis of endometriosis
occurred in 4.59% of non-Hispanic white women, 1.13% of non-Hispanic black women,
and 1.21% of women from ‘Other’ races. A diagnosis of uterine leiomyomas occurred in
5.11% of non-Hispanic white women, 4.59% of non-Hispanic black women, and 3.21%
of women from ‘Other’ races (Table 2.1). The mean age at time of interview was 37.2
years for the overall population, 41.0 and 44.3 years for women who an endometriosis or
uterine leiomyoma diagnosis and 36.8 and 35.9 years for women who reported never
being diagnosed with endometriosis or uterine leiomyoma, respectively. The mean age at
endometriosis diagnosis was 29.0 years and the mean age at uterine leiomyoma diagnosis
was 38.8 years (Table 2.1). The majority of endometriosis and uterine leiomyoma cases
were reported from women in the 30-39 and 40-49 year old age groups. BMI was
normal (< 25 kg/m2) for 37.5%, overweight (25to < 30 kg/m2) for 26.3%, and obese (≥ 30
kg/m2) for 36.2% of study participants. Age of menarche was < 12 years of age for
22.9%, 12-14 years for 65.5%, and ≥ 15 years for 11.6% of study participants. The
majority of study participants reported ≥ 2 live births (67.9%), responded yes to oral
contraceptive use (72.7%) , responded no to having a hysterectomy (81.2%), responded
no to having a oophorectomy (93.1%), responded no to a history of smoking (61.1%) and
yes to alcohol consumption (61.7%) (Table 2.1).
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Table 2.1. Descriptive statistics for endometriosis and uterine leiomyomas in the study population, women
20-54years of age, NHANES 1999-2004.
No
Overall
Endometriosis Endometriosis
n(%)
n(%)
n (%)
1154 (100%)
80 (6.93%)
1074 (93.1%)
37.2 ± 0.40
41.0 ± .89
36.8 ± .43
29.0 ± .62

Variable
Total Population (n,%)
Age at interview ( mean ± sd)
Age at diagnosis (mean ±sd)
Race/Ethnicity
Non-Hispanic white
518 (44.9%)
Non-Hispanic black
221 (19.2%)
Other
415 (36.0%)
Age at interview (years)
20-29
386 (33.5%)
30-39
354 (30.7%)
40-49
283 (24.5%)
50-54
131 (11.4%)
BMI (kg/m2)
Normal weight ( <25)
428 (37.5%)
Overweight (25 to <30)
300 (26.3%)
Obese (≥30)
412 (36.2%)
Parity (no. of live births)
0
64 (5.94%)
1
282 (26.2%)
≥2
731 (67.9%)
Age at menarche (years)
< 12
258 (22.9%)
12-14
740 (65.5%)
≥ 15
131 (11.6%)
Oral contraceptive use
Yes
837 (72.7%)
No
315 (27.3%)
Hysterectomy
Yes
102 (18.9%)
No
439 (81.2%)
Oophorectomy – at least one ovary removed.
Yes
79 (6.86%)
No
1072 (93.1%)
Alcohol Use
Yes
712 (61.7%)
No
442 (38.3%)
Ever Smoked
Yes
449 (38.9%)
No
704 (61.1%)

Uterine
No Uterine
Leiomyomas Leiomyomas
n(%)
n(%)
149(12.9%)
1005 (87.1%)
44.3 ± .65
35.9 ± .42
38.8 ± .79

53 (4.59%)
13 (1.13%)
14 (1.21%)

465 (40.3%)
208 (18.0%)
401 (34.8%)

59 (5.11%)
53(4.59%)
37 (3.21%)

460 (39.8%)
168 (14.6%)
378 (32.8%)

12 (1.04%)
25 (2.17%)
30 (2.60%)
13 (1.13%)

374 (32.4%)
329 (28.5%)
253 (21.9%)
118 (10.2%)

10(0.87%)
32 (2.77%)
67 (5.81%)
40 (3.47%)

376 (32.6%)
323 (27.9%)
216 (18.7%)
91 (7.89%)

24 (2.11%)
23 (2.02%)
32 (2.81%)

404 (35.4%)
277 (24.3%)
380 (33.3%)

43 (3.77%)
38 (3.33%)
68 (5.96%)

385 (33.8%)
263 (23.0%)
344 (30.2%)

9 (0.84%)
28(2.60%)
41 (3.81%)

55 (5.11%)
254 (23.6%)
690(64.1%)

10 (0.93%)
25 (2.32%)
112 (10.4%)

54 (5.01%)
257 (23.9%)
619 (57.5%)

22 (1.95%)
52 (4.61%)
5 (0.44%)

236(20.9%)
688 (60.9%)
126 (11.2%)

45 (3.99%)
87 (7.71%)
14 (1.24%)

213 (18.9%)
653 (57.8%)
117 (10.4%)

72 (6.24%)
8 (0.69%)

765 (66.4%)
307 (26.7%)

125 (10.9%)
24 (2.08%)

712 (61.8%)
291 (25.3%)

29(5.36%)
27 (4.99%)

73 (13.5%)
412 (76.2%)

49 (9.06%)
37 (6.84%)

53 (9.80%)
402 (74.3%)

25 (2.17%)
55 (4.78%)

54 (4.69%)
1017 (88.4%)

34 (2.95%)
113 (9.82%)

34 (2.95%)
113 (9.82%)

24 (2.08%)
56 (4.85%)

418 (36.2%)
656 (56.9%)

52 (4.51%)
97 (8.41%)

390 (33.8%)
615 (53.3%)

44 (3.82 %)
36 (3.12%)

660 (57.2%)
413 (35.8%)

88 (7.63%)
61 (5.29%)

616 (53.4%)
388 (33.7%)

Estimated percent distribution after applying NHANES sampling weights.

Table 2.2 presents GMs and GSEs of lipid adjusted PCBs by endometriosis and uterine
leiomyoma diagnosis for all study participants. GM PCB levels were significantly higher
for PCB congeners 138, 153, and 180 in women who reported a diagnosis of
endometriosis compared to women who reported no diagnosis (Table 2.2). Overall GM

levels of individual blood PCBs ranged from 4.90 ng/g lipid to 21.3 ng/g lipid in women
who reported never being diagnosed with endometriosis and from 5.31ng/g lipid to 27.1
ng/g lipid in women who reported being diagnosed with endometriosis, with the lowest
levels observed for PCB 99 and the highest levels observed for PCB 153 (Table 2.2;
Figure 2.1). GM PCB levels were significantly higher for all 6 PCB congeners in women
who reported a diagnosis of uterine leiomyomas compared to women who reported no
diagnosis (Table 2.2). Overall GM levels of individual blood PCBs ranged from 4.81
ng/g lipid to 20.3 ng/g lipid in women who reported never being diagnosed with uterine
leiomyomas and from 5.99 ng/g lipid to 33.1 ng/g lipid in women who reported no
diagnosis, with the lowest levels observed for PCB 99 and the highest levels observed for

Lipdi adjusted GM PCB levels
(ng/g)

PCB 153 (Table 2.2; Figure 2.2).

30
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Figure 2.1. Lipid adjusted geometric mean PCB levels (ng/g) by endometriosis status
among women 20-54 years of age, NHANES 1999-2004.
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Figure 2.2. Lipid adjusted geometric mean PCB levels (ng/g) by uterine leiomyoma
status among women 20-54 years of age, NHANES 1999-2004.

Table 2.3 presents age standardized GMs and GSEs of lipid adjusted PCBs by
race/ethnicity in participants with endometriosis data. Non-Hispanic black women who
reported being diagnosed with endometriosis had significantly higher GM PCB levels for
PCB 138 and 180 compared to non-Hispanic White women (Table 2.3). In women who
reported never being diagnosed with endometriosis, non-Hispanic black women had
significantly higher levels of PCB congeners 99, 118, 138, 153, and 180 compared to
non-Hispanic white women and significantly higher levels of all 6 PCB congeners
compared to women classified as ‘Other’ (Table 2.3). Non-Hispanic white women not
diagnosed with endometriosis had significantly higher levels of PCB 74, 118, 138, 153,
and 180 compared to women classified as ‘Other’ (Table 2.3).
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Table 2.3. Age standardized geometric mean PCB levels (ng/g) for race by endometriosis diagnosis among women
20-54 years of age, NHANES 1999-2004.

Analyte1
PCB 074
PCB 099
PCB 118
PCB 138
PCB 153
PCB 180

Non-Hispanic Black
No
Endometriosis Endometriosis
6.89 (1.05, 207)e
6.42(1.14, 13)
6.82 (1.05, 207)c,e 5.53(1.07, 13)
8.67 (1.06, 208)d,f 6.96 (1.15, 13)
22.0 (1.05, 208)c,e 19.9 (1.09, 13)d
29.1 (1.05, 208)d,e 27.7 (1.08, 13)
16.8 (1.04, 208)d,e 16.6 (1.11, 13)d,

Geometric mean2 (ng/g) (GSE, n)
Non-Hispanic White
Other Races
No
No
Endometriosis
Endometriosis
Endometriosis Endometriosis
6.17 (1.04, 464)f 5.87 (1.08, 53)
5.16 (1.04, 402)
6.42 (1.14, 14)
f
4.90 (1.04, 466)
4.66 (1.08, 53)
4.44 (1.04, 401)
5.16 (1.13, 14)
6.75 (1.04, 465)
6.75 (1.11, 53)
6.69 (1.06, 401)
8.17 (1.15, 14)
15.6 (1.04, 465)f 14.9 (1.09, 53)
14.0 (1.04, 401)
20.3 (1.16, 14)
21.9 (1.04, 465)f 21.3(1.09, 53)
18.5 (1.04, 400)
27.7 (1.15, 14)
14.3 (1.04, 463) f 14.9 (1.11, 52)
11.8 (1.04, 402) 18.0 (1.14, 14)

1

Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with endometriosis vs. women without endometriosis;
a
p < 0.0001, bp < 0.05.
GM PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;
c
p < 0.0001, dp < 0.05.
GM PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’ women;
e
p < 0.0001, fp < 0.05.
2

Table 2.4 presents age standardized GMs and GSEs of lipid adjusted PCBs by
race/ethnicity in participants with uterine leiomyoma data. Non-Hispanic black women
who reported being diagnosed with uterine leiomyomas had significantly higher GM
PCB levels for PCB 99, 118, 138, 153, and 180 compared to non-Hispanic White women
and higher levels of PCB 99 compared to women classified as ‘Other’ (Table 2.4). In
women who reported never being diagnosed with uterine leiomyomas, non-Hispanic
black women had significantly higher levels of PCB congeners 99, 118, 138, 153, and
180 compared to non-Hispanic white women and significantly higher levels of all 6 PCB
congeners compared to women classified as ‘Other’ (Table 2.4). Non-Hispanic white
women not diagnosed with uterine leiomyomas had significantly higher levels of PCB
74, 99, 118, 138, 153, and 180 compared to women classified as ‘Other’ (Table 2.4).
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Table 2.4. Age standardized geometric mean PCB levels (ng/g) for race by uterine leiomyoma diagnosis
among women 20-54 years of age, NHANES 1999-2004.

1

Analyte
PCB 074
PCB 099
PCB 118
PCB 138
PCB 153
PCB 180

Non-Hispanic Black
No Uterine
Uterine
Leiomyomas
Leiomyomas
6.69 (1.05, 168)e
6.96 (1.09, 52)
6.69 (1.05, 167)c,e 6.89 (1.09, 53) c,d
8.58 (1.06, 168)d,f 8.76 (1.08, 53)c
22.2 (1.05, 168)c,e 22.2 (1.09, 53)c
29.1 (1.05, 168)c,e 30.3 (1.11, 53)c
17.1 (1.05, 168 )d,e 17.1 (1.09, 53)c

Geometric mean2 (ng/g) (GSE, n)
Non-Hispanic White
No Uterine
Uterine
Leiomyomas
Leiomyomas
6.17 (1.04, 458)e
5.81 (1.09, 26)
4.90 (1.04, 460)f
4.10 (1.08, 25)
6.75 (1.04, 460)
5.99 (1.08, 26)
15.6 (1.04, 459)f
14.7 (1.09, 26)
21.5 (1.04, 459)f
20.9 (1.11, 26)
14.4 (1.04, 457)f
12.8 (1.11, 26)

Other Races
No Uterine
Uterine
Leiomyomas
Leiomyomas
5.00 (1.04, 379)
5.87 (1.05, 37)
4.39 (1.04, 378)
4.66 (1.08, 37)
6.49 (1.05, 378)
7.77 (1.07, 37)
13.9 (1.04, 378)
18.4 (1.13, 37)
18.4 (1.04, 377)
23.6 (1.12, 37)
11.6 (1.04, 379) 15.0 (1.12, 37)

1

Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women with uterine leiomyomas vs. women without uterine
leiomyomas; ap < 0.0001, bp < 0.05.
GM PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white
women; cp < 0.0001, dp < 0.05.
GM PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to
‘Other’ women; ep < 0.0001, fp < 0.05.
2

Table 2.5 shows the arithmetic means and 95% CIs of serum levels of dioxin-like
PCBs for endometriosis and uterine leiomyoma status and selected variables in the study
population. Arithmetic means of dioxin-like PCBs were not significantly higher in
women who reported being diagnosed with endometriosis (4.02 ng/g) compared to
women who reported never being diagnosed with endometriosis (3.70 ng/g) but were
significantly higher in women who reported being diagnosed with uterine leiomyomas
(4.36 ng/g) compared to women who reported never being diagnosed with uterine
leiomyomas (3.62 ng/g) (Table 2.5). Mean dioxin-like PCBs increased with age,
however there were no significant differences in the four age groups for endometriosis or
uterine leiomyoma diagnosis with the exception of the 20-29 year old age group that had
significantly higher dioxin-like PCB levels in the women not diagnosed with uterine
leiomyomas compared to women diagnosed with uterine leiomyomas (Table 2.5). Age
standardized dioxin-like PCBs were not found to be significantly different among races
for women diagnosed with endometriosis but were found to significantly different among
races for women not diagnosed with endometriosis. Non-Hispanic black women had
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significantly higher dioxin-like PCBs compared to non-Hispanic white women and
women classified as ‘Other’ (Table 2.5). Dioxin-like PCBs were also found to be
significantly higher in non-Hispanic black women with uterine leiomyomas compared to
non-Hispanic white women with uterine leiomyomas and in non-Hispanic black women
without uterine leiomyomas compared to non-Hispanic white women and women
classified as ‘Other’ (Table 2.5). Dioxin-like PCBs were not found to be different among
covariates for women with an endometriosis diagnosis but were found to be significantly
higher in women with a uterine leiomyoma diagnosis compared to women without a
uterine leiomyoma diagnosis for age at menarche, alcohol consumption and smoking
status (Table 2.5).
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Table 2.5. Arithmetic mean dioxin-like PCB levels in the study population, women 20 -54 years of age,
NHANES 1999-2004.
No
No
Endometriosis
Endometriosis
Leiomyomas
Leiomyomas
Variable
Mean (SE,n)
Mean (SE,n)
Mean (SE,n)
Mean (SE,n)
Dioxin-like PCBs
Race/Ethnicity3
Non-Hispanic white
Non-Hispanic black
Other
Age at interview (years)
20-29
30-39
40-49
50-54
BMI (kg/m2)
Normal weight ( <25)
Overweight (25 to <30)
Obese (≥30)
Parity (no. of live births)
0
1
≥2
Age at menarche (years)
< 12
12-14
≥ 15
Alcohol Use
No
Yes
Ever Smoked
No
Yes

4.02 (0.19, 80)

3.70 (0.06, 1071)

4.36 (0.14, 147)a

3.62 (0.07, 1004)

3.68 (0.17, 53)
3.67 (0.20, 13)
3.96 (0.26, 14)

3.74 (0.07, 463)e
4.08 (0.11, 207)c,e
3.54 (0.08, 401)

3.54 (0.16, 58)b
4.11 (0.16, 52)b ,c
3.82 (0.10, 37)a

3.73 (0.07, 458)e
4.04 (0.11, 168)c,e
3.47 (0.09, 378)

2.85 (0.13, 12)
3.37 (0.24, 25)
4.27 (0.25, 30)
5.11 (0.62, 13)

2.87 (0.07, 375)
2.54 (0.09, 327)
4.20 (0.08, 252)
4.77 (0.14, 117)

2.19 (0.10, 10)
3.80 (0.23, 32)
4.42 (0.22, 66)
5.02 (0.22, 39)

2.89 (0.07, 377)a
3.49 (0.08, 320)
4.15 (0.09, 216)
4.70 (0.16, 91)

4.18 (0.32, 24)
3.99 (0.37, 23)
3.88 (0.21, 32)

3.70 (0.08, 403)
3.55 (0.12, 277)
3.82 (0.09, 378)

4.38 (0.26, 42)
4.13 (0.27, 38)
4.51 (0.14, 67)

3.65 (0.08, 385)
3.48 (0.12, 262)
3.67 (0.10, 343)

4.47 (0.50, 9)
4.26 (0.37, 27)
3.81 (0.25, 34)

3.65 (0.20, 54)
3.66 (0.13, 224)
3.82 (0.08, 573)

4.60 (0.56, 9)b
4.50 (0.43, 25)
4.34, (0.14, 111)

3.62 (0.21, 54)
3.64 (0.13, 258)
3.71 (0.07, 618)

3.92 (0.18, 52)
4.05 (0.47, 22)
4.70 (0.41, 5)b

3.68 (0.08, 688)
3.91 (0.14, 235)
3.42 (0.09, 125)

4.57 (0.31, 45) b
4.30 (0.16, 86) b
4.11 (0.34, 14)b

3.75 (0.13, 212)
3.61 (0.09, 654)
3.38 (0.10, 116)

3.90 (0.23, 24)
4.07 (0.22, 56)

3.56 (0.09, 415)
3.77 (0.07, 656)

4.11 (0.25, 51)b
4.47 (0.16, 96)a

3.51 (0.08, 388)
3.67 (0.08, 616)

3.88 (0.25, 44)
4.17 (0.28, 36)

3.67 (0.08, 657)
3.74 (0.08, 413)

4.35, (0.18, 87)b
4.37 (0.20, 60)b

3.58 (0.08, 614)
3.68 (0.08, 389)

1

Means calculated after applying NHANES sampling weights.
Sum of Dioxin-like PCBs = (074 +118); Lipid adjusted and log transformed PCBs (ng/g).
3
Age standardized.
PCB levels significantly higher in women with endometriosis or uterine leiomyomas vs. women without
endometriosis or uterine leiomyomas; ap < 0.0001, bp < 0.05.
PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;
c
p < 0.0001, dp < 0.05.
PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’
women; ep < 0.0001, fp < 0.05.
2

Table 2.6 shows the arithmetic means and 95% CIs of serum levels of nondioxin-like PCBs for endometriosis and uterine leiomyoma status and selected variables
in the study population. Arithmetic means of non-dioxin-like PCBs were significantly
higher in women who reported being diagnosed with endometriosis (10.9 ng/g) compared
to women who reported no endometriosis diagnosis (10.0 ng/g) and in women who
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reported a uterine leiomyoma diagnosis (11.5 ng/g) compared women who reported no
uterine leiomyoma diagnosis (9.84 ng/g) (Table 2.6). Mean non-dioxin-like PCBs
increased with age, however there were only significant differences among women in the
20-29 year old age group for both endometriosis diagnosis and uterine leiomyoma
diagnosis (Table 2.6). In women diagnosed with endometriosis, age standardized nondioxin-like PCBs were found to be significantly higher in non-Hispanic black women
compared to non-Hispanic white women and in women not diagnosed with
endometriosis, age-standardized non-dioxin-like PCBs were significantly higher in nonHispanic black women compared to non-Hispanic white women and women classified as
‘Other’. In women diagnosed with uterine leiomyomas, age standardized non-dioxin-like
PCBs were found to be significantly higher in non-Hispanic black women compared to
non-Hispanic white women and women classified as ‘Other’ and in women not
diagnosed with uterine leiomyomas, age-standardized non-dioxin-like PCBs were
significantly higher in non-Hispanic black women compared to non-Hispanic white
women and women classified as ‘Other’ (Table 2.5). Non-dioxin-like PCBs were found
to be significantly higher in women with a uterine leiomyoma diagnosis compared to
women without a uterine leiomyoma diagnosis for BMI, parity, age at menarche, alcohol
consumption and smoking status (Table 2.6).
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Table 2.6. Arithmetic mean non-dioxin-like PCB levels in the study population, women 20 -54years of age,
NHANES 1999-2004.
Variable
Non-Dioxin-like PCBs
Race/Ethnicity3
Non-Hispanic white
Non-Hispanic black
Other
Age at interview (years)
20-29
30-39
40-49
50-54
BMI (kg/m2)
Normal weight ( <25)
Overweight (25 to <30)
Obese (≥30)
Parity (no. of live births)
0
1
≥2
Age at menarche (years)
< 12
12-14
≥ 15
Alcohol Use
No
Yes
Ever Smoked
No
Yes

Endometriosis
Mean (SE,n)
10.9 (0.34, 79)b

No
Endometriosis
Mean (SE,n)
10.0 (0.12, 1067)

Leiomyomas
Mean (SE,n)
11.5 (0.19, 148)a

No
Leiomyomas
Mean (SE,n)
9.84 (0.13, 998)

10.0 (0.34, 52)
10.8 (0.29, 13)c
10.9 (0.51, 14)

10.1 (0.15, 461)e
11.2 (0.17, 207)d ,e
9.52 (0.14, 399)

9.70 (0.34, 53)a
11.3 (0.33, 58)b,d
10.3 (0.38, 37)a

10.1 (0.15, 455)e
11.2 (0.19, 167)c,e
9.48 (0.15, 376)

8.07 (0.44, 12)b
9.74 (0.46, 25)
11.4 (0.39, 30)
13.6 (1.18, 12)

7.78 (0.014 372)
9.77 (0.19, 327)
11.4 (0.14, 252)
12.3 (0.25, 116)

7.22 (0.55, 10)
10.5 (0.37, 32)
11.4 (0.33, 67)
13.1 (0.41, 39)

7.81 (0.14 , 374)a
9.69 (0.18, 320)
11.4 (0.16, 215)
12.1 (0.33, 89)

11.8 (0.53, 24)
11.0 (0.67, 22)
9.94 (0.39, 32)

10.2 (0.16, 402)
9.72(0.21, 276)
9.93 (0.20, 377)

12.5 (0.37, 43)a
10.9 (0.48, 37)b
11.4 (0.23, 68)a

10.1 (0.17, 383)
9.63 (0.20, 261)
9.60 (0.21, 341)

11.2 (1.04, 9)
11.1 (0.66, 28)
10.8 (0.44, 40)

9.97 (0.54, 55)
9.81 (0.28, 252)
10.4 (0.13, 685)

11.2 (0.56, 10)a
12.2 (0.79, 25)b
11.5 (0.66, 111)

9.91 (0.56, 54)
9.72 (0.26, 255)
10.2 (0.14, 614)

10.7 (0.38, 52)
10.8 (0.86, 21)
12.7 (1.20, 5)b

9.96 (0.15, 682)
10.2 (0.29, 236)
10.1 (0.20, 125)

11.5 (0.57, 44)b
11.5 (0.26, 87)b
11.8 (0.69, 14)b

9.92 (0.29, 213)
9.81 (0.17, 647)
9.93 (0.20, 116)

10.6 (0.23, 24)
11.0 (0.38, 55)b

9.77 (0.17, 417)
10.1 (0.15, 650)

11.0 (0.40, 52)b
11.7 (0.23, 96)a

9.65 (0.17, 389)
9.94 (0.16, 609)

9.74 (0.16, 656)
10.4 (0.15, 410)

11.2 (0.26, 87)a
11.9 (0.32, 61)a

9.54 (0.16, 612)
10.3 (0.16, 385)

10.2 (0.47, 43)
11.6 (0.55, 36)

b

1

Means calculated after applying NHANES sampling weights.
Sum of Dioxin-like PCBs = (099 +138 + 153 + 180); Lipid adjusted and log transformed PCBs (ng/g).
3
Age Standardizd Mean.
PCB levels significantly higher in women with endometriosis or uterine leiomyomas vs. women without
endometriosis or uterine leiomyomas; ap < 0.0001, bp < 0.05.
PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;
c
p < 0.0001, dp < 0.05.
PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’
women;
e
p < 0.0001, fp < 0.05.
2

GM and 95% CI’s of lipid-adjusted PCB levels are reported in table 2.7 for
women with PCB levels < LOD and ≥ LOD. Women with PCB concentrations ≥ LOD
who reported being diagnosed with endometriosis had significantly higher GM levels of
PCB 138 (22.0 ng/g vs 17.3 ng/g), PCB 153 (29.7 ng/g vs. 23.8 ng/g), and PCB 180 (24.0
ng/g vs. 16.3 ng/g), compared to women who reported never being diagnosed with
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endometriosis (Table 2.7). Women with PCB concentrations ≥ LOD who reported being
diagnosed with uterine leiomyomas had significantly higher GM levels of all 6 PCB
congeners 74 (9.39 ng/g vs.6.75 ng/g), PCB 99 (1.70 ng/g vs. 5.70 ng/g), PCB 118 (10.9
ng/g vs. 8.08 ng/g), PCB 138 (25.3 ng/g vs. 16.4 ng/g), PCB 153 (35.9 ng/g vs. 21.5
ng/g), and PCB 180 (25.5 ng/g vs. 15.5 ng/g), compared to women who reported never
being diagnosed with uterine leiomyomas (Table 2.7).
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Table 2.7. Geometric mean PCB levels (ng/g) by diagnosis of endometriosis or uterine leiomyomas
among women 20 to 54 years of age, NHANES 1999-2004.
Geometric mean2(ng/g) (95% CI)
No.
No.
No
Analyte1
Noncases Cases
Endometriosis
Endometriosis
PCB 074
< LOD
396
23
4.01 (3.90-4.18)
3.74 (3.39-4.10)
≥ LOD
677
57
7.10 (6.49-7.69)
8.24 (6.69-10.2)
PCB 099
< LOD
475
35
3.97 (3.86-4.10)
3.49 (3.25-3.78)b
≥ LOD
599
45
5.70 (5.16-6.30)
7.03 (5.26-9.39)
PCB 118
< LOD
350
24
4.01 (3.90-4.18)
3.82 (3.42-4.26)
≥ LOD
724
56
8.41 (7.77-9.12)
9.87 (7.92-12.4)
PCB 138
< LOD
293
21
11.8 (10.9-12.7)
11.5 (9.21-14.4)
≥ LOD
781
59
17.3 (16.0-18.7)
22.0 (18.2-26.3)b
PCB 153
< LOD
247
16
16.3 (15.2-17.6)
17.5 (16.4-18.5)
≥ LOD
826
64
23.8 (21.1-25.0)
29.7 (23.8-36.6)b
PCB 180
< LOD
298
18
7.61 (7.17-8.17)
7.39 (5.93-9.21)
≥ LOD
775
61
16.3 (15.0-17.6)
24.0 (19.5-56.8)b
No.
No.
No
Analyte1
Noncases
Cases
Uterine Leiomyomas
Uterine Leiomyomas
PCB 074
< LOD
396
23
4.01 (3.90-4.18)
3.67 (3.22-7.39)
≥ LOD
609
125
6.75 (6.17-7.39)
9.39 (8.08-10.8)b
PCB 099
< LOD
472
38
3.97 (3.86-4.10)
3.60 (3.28-3.90)b
≥ LOD
533
111
5.70 (4.90-6.17)
7.10 (6.11-8.33)b
PCB 118
< LOD
355
19
4.06 (3.89-4.22)
3.49 (3.03-3.97
≥ LOD
651
129
8.08 (7.39-8.85)
10.9 (9.39-12.7)b
PCB 138
< LOD
295
19
11.7 (10.7-12.8)
12.4 (11.0-13.9)
≥ LOD
710
130
16.4 (15.2-17.8)
25.3 (22.4-28.8)a
PCB 153
< LOD
247
16
16.4 (15.2-17.8)
16.0 (13.7-18.5)
≥ LOD
757
133
21.5 (19.7-23.6)
35.9 (31.8-40.4)a
PCB 180
< LOD
299
17
7.69 (7.17-8.17)
6.89 (5.10-9.21)
≥ LOD
705
131
15.5 (14.3-16.8)
25.5 (22.9-28.5)a
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
GM PCB levels significantly higher in women diagnosed with endometriosis or uterine leiomyomas vs.
women not diagnosed with endometriosis or uterine leiomyomas;ap < 0.0001, b < 0.05.

We further explored endometriosis and uterine leiomyoma diagnosis with
exposure to PCBs in tertiles (Table 2.8 and 2.9) For women with data on endometriosis,
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only non-dioxin-like PCBs were found to be significantly higher in women diagnosed
with endometriosis compared to women not diagnosed with endometriosis (8.19 ng/g vs.
7.60 ng/g) for subjects in the first tertile (Table 2.8). For women with uterine
leiomyomas, PCB 138 was significantly higher for women in the first tertile (10.1 ng/g
vs. 8.25 ng/g), PCB 153 was significantly higher for women in the first tertile (13.1 ng/g
vs. 10.8 ng/g) and second tertile (30.3 ng/g vs. 26.8 ng/g), and non-dioxin-like PCBs
were significantly higher for women in the first tertile (8.36 ng/g vs 7.58 ng/g) and
second tertile (11.2 ng/g vs. 10.8 ng/g) (Table 2.9).
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Table 2.8. Geometric Mean PCB levels (ng/g) by endometriosis status among women 20 to 54 years of age,
NHANES 1999-2004.
Geometric mean2(ng/g) (95% CI)
No.
No.
PCB Percentiles1
Noncases Cases
No Endometriosis
Endometrios is
PCB 074
< 33rd
576
28
3.39 (3.25-3.49)
3.35 (3.03-3.71)
33rd to 66th
345
38
7.39 (7.03-7.69)
7.17 (6.62-7.77)
≥ 66th
151
14
17.5 (16.4-18.5)
20.3 (15.2-27.1)
PCB 099
< 33rd
33rd to 66th
≥ 66th

494
372
208

36
23
21

2.83(2.69-2.94)
5.21 (5.10-5.31)
12.2 (11.4-13.1)

2.92 (1.10-3.16)
5.21 (4.85-5.58)
14.4 (10.9-18.9)

PCB 118
< 33rd
33rd to 66th
≥66th

544
348
180

33
29
18

3.71 (3.60-3.82)
8.05 (7.85-8.33)
22.4 (20.7-24.5)

3.74 (3.42-4.18)
7.92 (7.03-8.94)
22.4 (16.4-30.6)

PCB 138
< 33rd
33rd to 66th
≥ 66th

562
333
179

32
27
21

8.33 (7.85-8.76)
19.7 (18.9-19.9)
47.9 (44.7-51.4)

9.30 (7.92-11.0)
18.2 (16.6-19.7)
48.9 (37.7-63.4)

PCB 153
< 33rd
33rd to 66th
≥ 66th

576
326
171

30
29
21

10.8 (10.3-11.4)
27.7 (26.8-28.5)
66.7 (62.2-68.7)

12.7 (10.8-14.9)
26.8 (24.3-29.7)
68.0 (51.9-88.2)

PCB 180
< 33rd
33rd to 66th
≥ 66th

615
308
149

27
33
19

6.69 (6.30-7.03)
19.9 (19.5-20.5)
48.9 (45.2-53.0)

7.39 (6.23-8.67)
18.5 (16.6-20.9)
49.4 (40.4-59.7)

Dioxin-like PCBs3
< 33rd
33rd to 66th
≥ 66th

556
260
254

29
27
24

2.56 (2.48-2.63)
3.83 (3.76-3.89)
5.41 (5.31-5.52)

2.59 (2.38-2.80)
3.79 (3.59-3.99)
5.42 (4.89-5.96)

Non-Dioxin-like PCBs4
< 33rd
575
30
7.60 (7.44-7.76)
8.19 (7.73-8.66)b
rd
th
33 to 66
317
28
10.9 (10.8-11.0)
10.7 (10.4-11.1)
175
27
14.2 (14.0-14.5)
14.4 (13.4-15.4)
≥ 66th
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
3
Arithmetic Mean Dioxin-like PCBs: Sum of PCB 074 +118.
4
Arithmetic Mean Non-Dioxin-like-PCBs: Sum of PCB 099 + 138 +153 +180.
GM PCB levels significantly higher in women diagnosed with endometriosis vs. women not diagnosed with
endometriosis; ap < 0.0001, b < 0.05.
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Table 2.9. Geometric Mean PCB levels (ng/g) by uterine leiomyoma status among women 20 to 54 years of
age, NHANES 1999-2004.
Geometric mean2(ng/g) (95% CI)
No.
No.
No
Noncases Cases
Uterine Leiomyomas
Uterine Leiomyomas
PCB Percentiles1
PCB 074
565
39
3.35 (3.25-3.49)
3.49 (3.19-3.82)
< 33rd
319
64
7.24 (7.03-7.54)
7.61 (7.03-8.25)
33rd to 66th
120
45
17.5 (16.4-18.5)
18.2 (16.6-20.1)
≥ 66th
PCB 099
< 33rd
33rd to 66th
≥ 66th

489
340
176

41
55
53

2.80(2.69-2.94)
5.16 (5.10-5.26)
12.2 (11.4-12.9)

2.94 (2.69-3.22)
5.26 (5.05-5.53)
13.2 (11.5-15.0)

PCB 118
< 33rd
33rd to 66th
≥66th

543
313
148

34
64
50

3.74 (3.60-3.86)
8.00 (7.77-8.25)
22.2 (20.3-24.3)

3.53 (3.16-3.90)
8.33 (7.85-8.94)
23.1 (20.1-26.6)

PCB 138
< 33rd
33rd to 66th
≥ 66th

559
298
148

35
62
52

8.25 (7.77-8.67)
19.1 (18.5-19.9)
48.4 (44.7-53.0)

10.1 (9.03-11.4)b
20.1 (18.9-21.1)
46.5 (41.3-52.5)

PCB 153
< 33rd
33rd to 66th
≥ 66th

572
291
141

34
64
51

10.8 (10.3-11.2)
26.8 (26.0-27.9)
67.4 (62.1-73.0)

13.1 (11.1-15.3)b
30.3 (27.9-32.8)b
64.7 (57.4-73.0)

PCB 180
< 33rd
33rd to 66th
≥ 66th

607
270
126

35
71
42

6.69 (6.30-7.03)
19.3 (18.7-19.9)
49.4 (45.2-55.1)

6.96 (5.64-8.50)
21.5 (19.9-23.3)b
47.5 (43.4-51.9)

Dioxin-like PCBs3
< 33rd
33rd to 66th
≥ 66th

550
243
210

35
44
68

2.56 (2.49-2.64)
3.81 (3.75-3.86)
5.38 (5.25-5.52)

2.55 (2.37-2.74)
3.91 (3.77-4.04)
5.51 (5.27-5.74)

Non-Dioxin-like PCBs4
569
36
7.58 (7.41-7.74)
8.36 (7.81-8.90)b
< 33rd
rd
th
33 to 66
282
63
10.8 (10.6-10.9)
11.2 (11.1-11.4)b
th
≥ 66
147
49
14.2 (13.9-14.5)
14.3 (13.9-14.8)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Geometric means calculated after applying NHANES sampling weights.
3
Arithmetic Mean Dioxin-like PCBs: Sum of PCB 074 +118.
4
Arithmetic Mean Non-Dioxin-like-PCBs: Sum of PCB 099 + 138 +153 +180.
GM PCB levels significantly higher in women diagnosed with uterine leiomyomas vs. women not
diagnosed with uterine leiomyomas; ap < 0.0001, b < 0.05.
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Estimated ORs and 95% confidence intervals for the risk of having breast cancer
and the six individual PCB congeners are shown in table 2.10. We estimated
endometriosis and uterine leiomyoma risk for subjects with PCB levels < LOD (reference
group) and ≥ LOD. Results are presented for three logistic regression models: unadjusted;
age and race/ethnicity adjusted; and age, race/ethnicity, BMI, parity, age at menarche,
oral contraceptive use, smoking, and alcohol consumption adjusted. In unadjusted
models, PCBs were significantly associated with endometriosis for PCB 74 (OR of 1.71,
95% CI: 1.07-2.21). PCBs were not significantly associated with endometriosis in any of
the adjusted models (Table 2.10). In unadjusted models, all six PCB congeners were
significantly associated with uterine leiomyomas. After adjusting final models for age,
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, and
alcohol, PCB 74 and 118 remained significantly associated with uterine leiomyomas ORs
of 1.91 (95% CI: 1.10-3.29) and 1.91 (95% CI: 1.13-3.22), respectively (Table 2.10).
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Table 2.10. Estimated ORs (95% CIs) of endometriosis or uterine leiomyomas by concentrations of PCBs
among women 20-54 years of age, NHANES 1999-2004.
No.
No.
Unadjusted OR
Adjusted OR2
Adjusted OR3,a
1
Analyte
Cases Noncases
(95% CI)
(95% CI)
(95% CI)
ENDOMETRIOSIS
PCB 074
< LOD
23
396
1.00
1.00
1.00
≥ LOD
57
677
1.71 (1.07-2.71)b
1.15 (0.66-2.01)
1.18 (0.59-2.38)
PCB 099
< LOD
35
475
1.00
1.00
1.00
≥ LOD
45
599
1.02 (0.58-1.80)
0.84 (0.44-1.60)
0.83 (0.40-1.73)
PCB 118
< LOD
24
350
1.00
1.00
1.00
≥ LOD
56
724
1.26 (0.72-2.20)
0.93 (0.49-1.77)
0.86 (0.40-1.85)
PCB 138
< LOD
21
293
1.00
1.00
1.00
≥ LOD
59
781
1.24 (0.76-2.03)
0.97 (0.56-1.68)
1.02 (0.63-1.63)
PCB 153
< LOD
16
247
1.00
1.00
1.00
≥ LOD
64
826
1.35 (0.76-2.39)
0.97 (0.97-1.72)
1.13 (0.68-1.87)
PCB 180
< LOD
18
298
1.00
1.00
1.00
≥ LOD
61
775
1.49 (0.94-2.37)
0.97 (0.62-1.50)
1.07 (0.74-1.55)
No.
No.
Unadjusted OR
Adjusted OR2
Adjusted OR3,b
1
Analyte
Cases Noncases
(95% CI)
(95% CI)
(95% CI)
UTERINE LEIOMYOMAS
PCB 074
< LOD
23
396
1.00
1.00
1.00
≥ LOD
125
609
3.63 (2.10-6.29)a
1.96 (1.15-3.35)b
1.91 (1.10-3.29)b
PCB 099
< LOD
38
472
1.00
1.00
1.00
1.47 (0.87-2.48)
1.60 (0.95-2.72)
≥ LOD
111
533
2.25 (1.38-3.68)b
PCB 118
< LOD
19
355
1.00
1.00
1.00
≥ LOD
129
651
3.35 (1.87-6.03)a
2.00 (1.17-3.42)b
1.91 (1.13-3.22)b
PCB 138
< LOD
19
295
1.00
1.00
1.00
1.31 (0.63-2.74)
1.63 (0.86-3.10)
≥ LOD
130
710
2.24 (1.22-4.12)b
PCB 153
< LOD
16
247
1.00
1.00
1.00
≥ LOD
133
757
2.42 (1.55-3.78)a
1.32 (0.78-2.23)
1.45 (0.83-2.54)
PCB 180
< LOD
17
299
1.00
1.00
1.00
≥ LOD
131
705
2.78 (1.64-4.74)b
1.28 (0.72-2.28)
1.38 (0.70-2.74)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age, race/ethnicity .
3
Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol
use.
a
Cases/noncases: 77/962 in PCB 074, 153, 180; 77/963 in PCB 138; 77/964 in PCB 099;
77/965 in PCB 118.
b
Cases/noncases: 143/896 in PCB 074; 144/897 in PCB 099;144/898 in PCB 118; 144/896 in PCB 138;
144/895 in PCB 153, 180.
Significance: ap < 0.0001, bp < 0.05.
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ORs and 95% confidence intervals for risk of endometriosis and uterine
leiomyomas were further analyzed for subjects with PCB concentrations divided into
tertiles (Tables 2.11and 2.12). Subjects with PCB concentrations in the first tertile (<
33rd percentile) were used as the reference group. In the unadjusted models, risk of
endometriosis was significantly associated with PCB 74 for subjects in the second tertile
(OR of 2.32, 95% CI: 1.27-4.24) and PCB 180 for subjects in the second and third tertiles
[ORs of 2.38 (95% CI: 1.38-4.09) and 3.44 (95% CI: 1.46-8.11)], respectively (Table
2.11). Endometriosis did not remain significantly associated with any PCBs in the
adjusted models. In the unadjusted models, risk of uterine leiomyomas were significantly
associated with PCB 99 in the third tertile and PCBs 74, 118, 138, and 180 for subjects
in the second and third tertiles (Table 2.12). After adjusting for age and race/ethnicity,
PCB 180 remained significantly associated with uterine leiomyoma for subjects in the
second tertile (OR of 1.64, 95% CI: 1.07-2.51). After adjusting for all variables in the
final model, PCB 180 continued to remain significantly associated with uterine
leiomyomas for subjects in the second tertile (OR of 1.87, 95% CI: 1.15-3.02) (Table
2.12).

149

Table 2.11. Estimated ORs (95% CIs) of endometriosis by concentrations of PCBs among women 20-54
years of age, NHANES 1999-2004.
No.
No.
Unadjusted OR
Adjusted OR2
Adjusted OR3,a
1
Percentiles
Cases Noncases
(95% CI)
(95% CI)
(95% CI)
PCB 074
28
576
1.00
1.00
1.0 0
< 33rd
38
345
2.32 (1.27-4.24)b
1.64 (0.85-3.18)
1.80 (0.90-3.57)
33rd to 66th
≥ 66th
14
151
1.75 (0.73-4.23)
1.04 (0.45-2.38)
1.00 (0.46-2.16)
PCB 099
< 33rd
33rd to 66th
≥ 66th

36
23
21

494
372
208

1.00
0.72 (0.36-1.44)
1.12 (0.66-1.89)

1.00
0.64 (0.31-1.32)
0.79 (0.44-1.40)

1.00
0.74 (0.36-1.50)
0.83 (0.42-1.63)

PCB 118
< 33rd
33rd to 66th
≥66th

33
29
18

544
348
180

1.00
1.22 (0.63-2.37)
1.75 (0.82-3.74)

1.00
0.94 (0.46-1.95)
1.19 (0.55-2.59)

1.00
0.96 (0.44-2.09)
1.09 (0.47-2.51)

PCB 138
< 33rd
33rd to 66th
≥ 66th

32
27
21

562
333
179

1.00
1.39 (0.65-2.98)
1.97 (0.95-4.11)

1.00
0.98 (0.43-2.25)
1.25 (0.58-2.70)

1.00
1.13 (0.49-2.58)
1.33 (0.56-3.16)

PCB 153
< 33rd
33rd to 66th
≥ 66th

30
29
21

576
326
172

1.00
1.52 (0.90-2.57)
2.02 (0.91-4.47)

1.00
1.04 (0.55-1.98)
1.18 (0.50-2.78)

1.00
1.25 (0.63-2.45)
1.43 (0.54-3.83)

PCB 180
< 33rd
27
615
1.00
1.00
1.00
33rd to 66th
33
308
2.38 (1.38-4.09)b
1.59 (0.83-3.04)
1.69 (0.78-3.65)
≥ 66th
19
149
3.44 (1.46-8.11)b
2.20 (0.82-5.96)
2.70 (0.93-7.81)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age, race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol.
a
Cases/Noncases: 79/1034 in PCB 074; 79/1037 in PCB 099, 79/1035 in PCB 118 and 153;
79/1036 in PCB 138; 78/1034 in PCB 180.
Significance: ap < 0.0001, bp < 0.05.
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Table 2.12. Estimated ORs (95% CIs) of uterine leiomyomas by concentrations of PCBs among women 2054 years of age, NHANES 1999-2004.
No.
No.
Unadjusted OR
Adjusted OR2
Adjusted OR3,a
1
Percentiles
Cases
Noncases
(95% CI)
(95% CI)
(95% CI)
PCB 074
39
565
1.00
1.00
1.0 0
< 33rd
64
319
2.24 (1.36-3.70)b
1.29 (0.72-2.34)
1.30 (0.72-2.35)
33rd to 66th
≥ 66th
45
120
4.39 (2.42-7.97)a
1.68 (0.84-3.34)
1.56 (0.81-3.02)
PCB 099
< 33rd
33rd to 66th
≥ 66th

41
55
53

489
340
176

1.00
1.32 (0.75-2.30)
2.25 (1.32-3.86)b

1.00
1.04 (0.56-1.91)
1.00 (0.57-1.76)

1.00
1.06 (0.58-1.95)
1.04 (0.61-1.78)

PCB 118
< 33rd
33rd to 66th
≥66th

34
64
50

543
313
148

1.00
1.54 (1.43-4.53)b
4.11 (2.34-7.08)a

1.00
1.61 (0.88-2.95)
1.66 (0.91-3.05)

1.00
1.62 (0.90-2.91)
1.57 (0.88-2.79)

PCB 138
< 33rd
33rd to 66th
≥ 66th

35
62
52

559
298
148

1.00
2.16 (1.23-3.77)b
4.12 (2.42-7.03)a

1.00
1.14 (0.60-2.16)
1.39 (0.75-2.59)

1.00
1.28 (0.67-2.46)
1.61 (0.89-2.88)

PCB 153
< 33rd
33rd to 66th
≥ 66th

34
64
51

572
291
141

1.00
2.69 (1.64-4.42)
4.65 (2.61-8.29)

1.00
1.41 (0.79-2.52)
1.54 (0.77-3.09)

1.00
1.61 (0.89-2.89)
1.71 (0.86-3.39)

PCB 180
< 33rd
35
607
1.00
1.00
1.00
33rd to 66th
71
270
3.80 (2.56-5.64)a
1.64 (1.07-2.51)b
1.87 (1.15-3.02)b
th
a
≥ 66
42
126
5.47 (3.38-8.86)
1.60 (0.87-2.97)
1.70 (0.84-3.45)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age, race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol.
a
Cases/Noncases: 145/968 in PCB 074; 146/968 in PCB 118 and 153; 146/969 in PCB 118,
146/970 in PCB 099; 145/967 in PCB 180.
Significance: ap < 0.0001, bp < 0.05.

Estimated ORs and 95% CIs of endometriosis and uterine leiomyomas by dioxinlike and non-dioxin-like PCBs are shown in table 2.13. In the unadjusted models, nondioxin-like PCBs were significantly associated with endometriosis (OR of 1.11, 95% CI:
1.02-1.21). Dioxin and non-dioxin-like PCBs did not remain significantly associated
with endometriosis in the adjusted models (Table 2.13). In all of the unadjusted models,
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dioxin-like and non-dioxin-like PCBs were significantly associated with uterine
leiomyomas, however, none of the models remained significant after adjusting for age,
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking status, and
alcohol consumption (Table 2.13).
Table 2.13. Estimated ORs (95% CIs) of endometriosis and uterine leiomyomas by concentration of lipid
adjusted dioxin-like and non-dioxin-like PCBs in women 20 to 54 years of age, NHANES 1999-2004.
Unadjusted OR
(95% CI)

Adjusted OR1
(95% CI)

Adjusted OR2
(95% CI)

80/1071

1.18 (0.96-1.41)

1.03 (0.84-1.27)

0.97 (0.76-1.23)+

Dioxin-like PCBs4,7
< 33rd
33rd to 66th
≥ 66th

29/566
27/260
24/254

1.00
1.75 (0.82-3.73)
1.89 (0.88-4.07)

1.00
1.35 (0.62-3.04)
1.20 (0.54-2.68)

1.00
1.48 (0.62-3.51)
1.04 (0.46-2.38)

Non- Dioxin-like PCBs5

79/1067

1.11 (1.02-1.21)b

1.04 (0.93-1.16)

1.04 (0.91-1.18)*

Non-Dioxin-like PCBs4,7
< 33rd
33rd to 66th
≥ 66th

30/575
28/317
27/175

1.00
1.37 (0.77-2.44)
2.01 (0.98-4.14)

1.00
0.92 (0.47-1.77)
1.22 (0.53-2.79)

1.00
1.08 (0.50-2.34)
1.23 (0.46-3.30)

Dioxin-like PCBs4

80/1071

1.47 (1.27-1.71)a

1.12 (0.94-1.33)

1.11 (0.94-1.30)++

Dioxin-like PCBs4,7
< 33rd
33rd to 66th
≥ 66th

35/550
71/270
42/126

1.00
1.99 (1.14-3.49)b
3.81 (2.22-6.54)a

1.00
1.22 (0.65-2.28)
1.59 (0.84-3.02)

1.00
1.24 (0.65-2.39)
1.56 (0.87-2.80)

Non- Dioxin-like PCBs5

79/1067

1.23 (1.15-1.31)a

1.05 (0.96-1.14)

1.06 (0.97-1.15)**

Cases/
Noncases

Endometriosis

Dioxin-like PCBs4

Uterine Leiomyomas

Non-Dioxin-like PCBs4,7
< 33rd
36/569
1.00
1.00
1.00
33rd to 66th
63/282
2.45 (1.55-3.85)b
1.20 (0.70-2.05)
1.39 (0.78-2.45)
≥ 66th
49/147
3.62 (2.05-6.39)a
1.08 (0.70-2.05)
1.23 (0.63-2.38)
1
Adjusted for age and race/ethnicity.
2
Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol.
4
Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118).
+
Cases/noncases: 77/962; ++Cases/noncases: 143/896.
5
Non-Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (099+138+153+180).
*
Cases/noncases: 76/957; **Cases/noncases: 143/890.
Significance: ap < 0.0001, bp < 0.05.
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DISCUSSION
Evidence supporting the role of PCBs in endometriosis and uterine leiomyoma is
conflicting and inconclusive. Experimental animal studies have linked PCB exposure to
prolonged estrus and decreased sexual receptivity in rats, decreased sperm fertilizing
ability in mice (Fielden et al. 2001), decreased conception in mice, changes in the uterine
myometrium and gland formation in mice (Ma and Sassoon 2006), prolonged
menstruation, decreased birth weights, and decreased conception rates in rhesus monkeys
(ASTDR 2000), and a significant dose-dependent relationship in the prevalence and
severity of endometriosis in rhesus monkeys (Rier et al. 2001). Although these animal
studies have shown the have potential endocrine disrupting activities of PCBs, the data on
their endocrine disrupting effects in humans is inconsistent (Buck Louis et al. 2005,
Porpora et al. 2009, Heiler et al. 2005, Trabert et al. 2010, Pauwels et al. 2001). In this
cross-sectional study of U.S. women, we evaluated the concentrations of 6 PCB
congeners, dioxin-like PCBs, and non-dioxin-like PCBs and explored the association
between PCB exposure and diagnosis of endometriosis and uterine leiomyomas.
Analysis of dioxin-like PCBs and non-dioxin-like PCBs by endometriosis and
uterine leiomyoma status and age and race/ethnicity was done to assess PCB
concentrations in subpopulations. Dioxin-like and non-dioxin-like PCBs showed an
increasing trend with age. These results are supported by previously reported associations
of PCB body burdens and age in women (Axelrad et al. 2009, Thompson et al. 2013).
While this may be a result of lower levels of PCBs in the environment today, it may also
be due to the persistent nature of PCBs and increased accumulations in the human body
over time. Although not significant, women diagnosed with uterine leiomyomas had the
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highest dioxin-like PCB levels in the 30-39, 40-49 and 50-54 year old age groups. NonHispanic black women had significantly higher mean PCB levels compared to nonHispanic white women and women classified as ‘Other’. This finding is consistent with
higher PCB and DDE levels that have been previously reported among African-American
women compared with non-Hispanic white women by Millikan et al. (2013) and Zheng et
al. (1999), respectively. While these results do not provide any evidence of causal
associations, it is noteworthy that women diagnosed with uterine leiomyomas have higher
levels of dioxin-like and non-dioxin-like PCBs and all six PCB congeners compared to
women who reported never being diagnosed with uterine leiomyomas.
Our results show that women diagnosed with endometriosis have slightly higher
body burdens of PCB congeners 138, 153, and 180 compared to women never diagnosed
with endometriosis. Our findings of the association between endometriosis and higher
body burdens of PCB congeners 138, 153, 180, and the sum of non-dioxin-like PCBs are
consistent with a two previously reported case-control studies by Porpora et al. (2006
and 2009). Porpora et al. (2006) reported higher levels of total PCBs in endometriosis
cases vs. controls (410 ng/g vs.250 ng/g), as well as an increased risk in involving both
dioxin-like (105, 118, 156, 167) and non-dioxin-like (101, 138, 153, 170, 180) congeners,
after adjusting for age and smoking. Porpora et al. (2009) found the GM of total PCBs to
be significantly higher in cases than controls (301.3 vs. 203.0, p < 0.01). In contrast,
Niskar et al. (2009) did not find mean lipid-adjusted PCB concentrations to be
significantly different (179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases,
stage III cases, stage IV cases, and controls, respectively. Pauwels et al. (2001) found no
association between endometriosis and the median TEQ values (pg TEQ/g lipid) in cases
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and controls (29 vs. 27) and Tsukino et al.(2005) found no difference in median TEQ
values for endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs.
3.59, PCBs: 4.61 vs. 5.14), respectively.
Risk of endometriosis was only present for PCB 74 and non-dioxin-like PCBs in
unadjusted logistic regression models and did not remain in any of the adjusted models.
These findings are consistent with Trabert et al. (2005), who reported no association
between adjusted total and estrogenic PCBs in the highest quartiles and an increased risk
of endometriosis (Total PCBs: OR=1.2, 95% CI: 0.6-2.3, Estrogenic PCBs: OR=0.9,
95% CI: 0.5-1.4) after adjusting for age, lipids, income, alcohol consumption, and DDE
exposure. Our findings do not agree with Buck Louis et al. (2005) who reported a
significant increased risk of endometriosis for the sum of anti-estrogenic PCBs for
women in the third tertile (OR=3.77, 95% CI: 1.12-12.68), however, the risk remained
elevated but not significant when adjusted for all listed covariates and Porpora et al.
(2009) who reported the OR of endometriosis risk in the highest tertile of total PCBs
compared with the lowest tertile to be 5.63 (95% CI: 2.25-14.10).
We observed significantly higher body burdens of PCBs in women diagnosed
with uterine leiomyomas and an increased risk of uterine leiomyomas in association with
PCB 180 after adjusting for age, race/ethnicity, BMI, parity, age at menarche, oral
contraceptive use, smoking status, and alcohol consumption. Epidemiological studies
demonstrating the association between PCBs and uterine leiomyomas are lacking. Our
findings are difficult to compare due to differences in the study population and methods.
Findings from Lambertino et al. (2011) reported that uterine leiomyomas were
significantly associated with exposure to dioxin-like- PCBs in women who never
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breastfed (OR=8.6, 95% CI: 2.0-36.6) but not in women who breastfed (OR=0.80, 95%
CI: .023-2.8). Qin et al. (2009) et al. found significantly higher concentrations of PCB
123 (17.8 ng/g vs.11.7 ng/g, p<0.01), 126 (21.0 ng/g vs. 10.4 ng/g, p<0.01), and 180
(13.9 ng/g vs. 6.99 ng/g, p<0.05) in the subcutaneous fat of patients compared to
controls. While these results are consistent with our findings for PCB 180, they are
difficult to compare because they assessed PCB concentrations in adipose tissue as
opposed to serum blood.
There are a number of limitations to our study, the most important of which is its
cross-sectional design with self-reported data. Self-reported data increases the risk of
misclassification bias of cases and controls. It is possible that false reports or
undiagnosed endometriosis or uterine leiomyoma cases may have occurred.
Furthermore, observed associations could be potentially confounded by lack of
information on geographical location of primary residence and family history of some of
the variables. Strengths of this cross-sectional study design include the large sample
survey size, availability of biological measurements of environmental contaminants, and
oversampling of minority populations that make it highly representative and
generalizable to the U.S. population.
CONCLUSION
Based on our analysis of serum blood lipid PCB levels in the 1999-2004
NHANES data cycles, biological levels of PCBs may contribute to reproductive
dysfunction among U.S. women. Given the proven contribution of unopposed estrogens
to the risk for endometriosis or endometrial neoplasia, it is biologically plausible that an
altered endogenous estrogen levels presumably from exposure to estrogen mimicking

156

EDCs may contribute to the risk of these diseases. In conclusion, we have identified
preliminary evidence suggesting that exposure to PCBs may be associated with uterine
leiomyomas. Thus, further research with an epidemiologic approach is warranted to
investigate reproductive health outcomes in relation to PCB exposure among women in
the general population.
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CHAPTER VI
MANUSCRIPT 3
ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE CANCERS
AMONG U.S. WOMEN: NHANES 1999-2010
ABSTRACT
Background. A number of chemicals are suspected to act as endocrine disruptors (EDs)
by mimicking natural or synthetic estrogen resulting in an increased risk of hormonal
cancer in women. Polychlorinated biphenyls (PCBs), phthalates and bisphenol A (BPA)
have been recognized as endocrine disrupters due to their ability to interfere with
reproductive function and development in animals and humans by either increasing
estrogen activity or blocking estrogens from acting.
Objectives: The purpose of this study was to explore the cross-sectional relationship
between exposure to PCBs, phthalates, and BPA and reproductive cancers (breast,
cervical, ovarian, and uterine) among U.S. women.
Methods: We analyzed data from female participants (20 years of age and older) who
provided blood and urine samples for the Centers for Disease Control and Prevention’s
National Health and Nutrition Examination Survey (NHANES) between 1999 and 2010.
Exposure was based on lipid adjusted serum levels of 6 individual PCB congeners (74,
99, 118, 138, 153, and 180), the sum of dioxin-like PCBs (074 + 118), the sum of nondioxin-like PCBs (099 + 138 + 153+187), 8 urinary phthalate metabolites (MNP, MEP,
MEHP, MBzP, MCPP, MEHHP, MEOHP, and MIB), the sum of DEHP metabolites
(MHP + MHH + MOH), the sum of total phthalates, and urinary BPA in conjunction
with data obtained from the medical and reproductive health questionnaires. We
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calculated geometric means to compare EDCs concentrations in women who selfreported a breast, cervical, ovarian, or uterine cancer diagnosis vs. women who selfreported never being diagnosed with cancer. We used logistic regression models to
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association
between exposure to EDCs and reproductive cancers. We evaluated age, race/ethnicity,
body mass index (BMI; kg/m2), and age at menarche as potential confounding variables
in our final models.
Results: Separate analyses showed weighted geometric mean levels of individual PCB
congeners to be significantly higher among women with breast cancer, ovarian cancer,
and uterine cancer when compared to the rest of the study population. Mono-(2-ethyl-5hydroxyhexyl) phthalate (MEHHP) was found to be significantly higher among women
with ovarian cancer compared to women never diagnosed with cancer and BPA was
significantly higher in women never diagnosed with cancer compared to women
diagnosed with breast cancer. After adjusting for age, race, BMI, and age at menarche we
found PCB 138 to be significantly associated with breast cancer, cervical cancer, and
uterine cancer [odds ratios of 2.52.; 95% confidence interval (CI): 1.06-5.99; 3.05, 95%
CI: 1.21-7.69; and 5.83, 95% CI: 1.63-20.9], respectively, and PCB 74 and 118 to be
significantly associated with ovarian cancer [odds ratios of 6.47, 95% CI: 1.23-3.41 and
6.68, 95% CI: 1.39-32.3), respectively. We also found the sum of non-dioxin-like PCBs
to be significantly associated with ovarian cancer (OR of 1.12, 95% CI: 1.03-1.23) and
the sum of dioxin-like PCBs to be significantly associated with ovarian cancer (OR of
2.02, 95% CI: 1.06-3.85). We found null associations between urinary phthalates and
BPA and reproductive cancers.
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Conclusions: Our results suggest a link between environmental exposures to PCBs and
an increased risk of reproductive cancers (breast, cervix, ovarian and uterine) among U.S.
women.
Keywords: NHANES, PCBs, phthalates, BPA, EDC, reproductive cancers.
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MANUSCRIPT 3
ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE CANCERS
AMONG U.S. WOMEN: NHANES 1999-2010
INTRODUCTION
Human populations are continually exposed to a wide variety of environmental
estrogen-like chemicals. A recent report by the United Nations Environment Programme
(UNEP) and WHO highlighted the increasing rates of endocrine-related cancers over
the past 40-50 years in conjunction with approximately 800 chemicals that are suspected
to act as endocrine disruptors (EDs) (UNEP/WHO 2013, EU 2013). Many of these
chemicals are used in a variety of consumer products; therefore exposure to EDCs among
the general population is widespread. Human exposure to EDCs may result from
inhalation through the air, absorption through the skin, and most commonly through the
ingestion of contaminated food and water (Balabanic et al. 2001). In the last decade,
exposure to multiple EDCs such as polychlorinated biphenyls (PCBs), phthalates, and
bisphenol A (BPA) have been detected in  90% of blood and urine samples collected
(Calafat et a. 2008, Woodruff et al. 2011, Silva et al. 2004)
Although a number of experimental animal studies have shown many chemicals
have potential endocrine disrupting activities, the data on their endocrine disrupting
effects in humans is limited. The role of EDC’s in the etiology of some of the human
cancers and reproductive health hazards has been implicated, although the linkage
between these two processes is highly controversial (Burantrevedh and Roy 2001). PCBs
have been shown to interfere with reproductive function and development in animals and
humans by either increasing or blocking estrogen activity (Fielden et al. 2001, Ma and
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Sassoon 2006, McLachlan et al. 2006, Roy et al. 1997, Roy et al. 1998). Animal studies
have linked PCB exposure to decreased sperm fertilizing ability in mice (Fielden et al.
2001), changes in the uterine myometrium and gland formation in mice (Ma and Sassoon
2006), and a significant dose-dependent relationship in the prevalence and severity of
endometriosis in rhesus monkeys (Rier et al. 2001). Among various phthalates, di (2ethylhexyl) phthalate (DEHP), di-butyl phthalate (DBP) and butylbenzyl phthalate (BBP)
have been studied for their endocrine disrupting effects. Phthalates have been shown to
produce anti-androgenic effects by suppressing testosterone and estrogen production.
Reproductive abnormalities reported in rodent females include increased uterine and
ovarian weights and malformations at very high phthalate levels, delayed onset of
puberty and modified morphology of the mammary gland (Moral et al. 2008). We have
shown that bisphenol A (BPA) is oxidized to bisphenol-o-quinone by cytochrome P450
activation system. Administration of a single dose or multiple doses of 200 mg/kg of
BPA to CD1 male rats produces in vivo DNA adducts matching the profile of dGMP-bisphenol-o-quinone. Covalent modifications in DNA by in vivo exposure of BPA are
suspected to be a factor in the induction of endocrine toxicity (Atkinson and Roy 1995).
In rodent females, BPA exposure has shown to cause alterations in the mammary gland
development, changes in gene expression of the mammary gland, cystic ovaries,
endometrial hyperplasia, adenomyosis, leiomyomas, atypical hyperplasia, stromal
polyps, ductal hyperplasias and carcinoma, a decline in fertility and fecundity, decreased
wet weight of the vagina, decreased volume of the endometrial lamina propria, and an
increased expression of estrogen receptor- (ER) and progesterone receptors (Moral et
al. 2008, Atkinson et al. 1995, Colerangle and Roy 1997, Munoz-de-Toro et al. 2005,
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Newbold et al. 2007, Murray et al. 2007, Signorile et al. 2010, Cabaton et al. 2011). In
summary, exposure to EDCs - PCBs, BPA, or phthalates during early development of the
breast, endometrium, and prostate can alter their development, possibly contributing to
the susceptibility to complex chronic diseases through effects on stem cells. Through
research on hormone contraception, postmenopausal hormonal therapies and estrogenreceptor (ER)-based endocrine therapies, we know estrogens are a major risk factor of
both breast cancer and endometriosis (Evans 2008, Lin et al. 2009, Bertelsen et al. 2007).
Given the proven contribution of unopposed estrogens to the risk for hormonal cancer,
renewed health concerns have aroused about estrogen mimicking EDCs found in food,
personal care products or as environmental contaminants. PCBs, BPA, and phthalates are
the most extensively studied EDCs, and therefore, our objective of this study was to use
the National Health and Nutrition Examination Survey (NHANES) data to assess the
association of reproductive cancers (breast, cervix, ovarian, and uterine) with exposure to
these three selected classes of EDCs: PCBs, BPA, and phthalates, commonly found in the
environment today.
METHODS
Study design and population. NHANES is an ongoing cross-sectional survey designed to
be nationally representative of the non-institutionalized U.S. civilian population.
Conducted annually since 1999 by the National Center for Health Statistics of the Centers
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage
sampling design where approximately 5,000 survey participants a year complete in-home
interviews and physical examinations in mobile examination units (CDC, 2012).
Sociodemographic information and medical histories were collected during the in-home
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interview and biological samples and reproductive health information was collected in
the mobile examination component (MEC). All participants provided written informed
consent and all procedures were approved by the National Center for Health Statistics
(NCHS) Institutional Review Board (CDC, 2012). We merged data from the 2003-2004,
2005-2006, 2007-2008, and 2009-2010 survey years to analyze phthalate metabolites and
from the 2005-2006, 2007-2008, and 2009-2010 survey years to analyze bisphenol A.
During the 2003-2004 survey years, NHANES sampled urinary phenols and phthalates
from two separate one-third subsets, therefore we did not include the 2003-2004 survey
years in our analysis of bisphenol A. We conducted a separate analysis of PCBs with
data merged from the 1999-2000, 2001-2002, and 2003-2004 survey years. We were not
able to analyze PCBs from the 2005-2006 and 2007-2008 survey years because the
datasets were withdrawn due to a quality control issue (CDC 2014). In each survey year,
subsets are a representative one-third sample of NHANES participants. We limited our
analysis to women 20 to 85 years of age who completed the reproductive and medical
condition questionnaires in a face-to-face interview at a mobile examination center.
Measurement of PCBs. Blood serum concentrations of individual PCB congeners were
measured in a representative, random one-third subsample of people 12 years of age and
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were
measured in serum by high-resolution gas chromatography/isotope-dilution highresolution mass spectrometry (HRGS/ID-HRMS). NHANES provides both wet-weight
and lipid adjusted values for each sample, corrected for sample weight and analyte
recovery; we used lipid adjusted values in our analyses. Detailed laboratory methods
were consistent among survey cycles and are available online (CDC, 2013b). Lipid-
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adjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (118 + 138
+153 + 170) were used in this study. PCB congeners 74, 99, 118, 138, 153, and 180 were
selected because they were available in all three survey cycles and concentrations were
above the LOD in > 60% of the survey participants.
Measurement of urinary phthalates and phenols. Bisphenol A and phthalate metabolites
were quantified in urine by the use of solid phase extraction (SPE) coupled to reverse
phase high performance liquid chromatography-tandem mass spectrometry (HPLCMS/MS). Laboratory methods and quality control were consistent across survey years
and documentation in available online (CDC, 2012). We examined 8 phthalate
metabolites measured in the 4 consecutive NHANES cycles: mono-n-butyl phthalate
(MBP), mono-ethyl phthalate (MEP), mono-(2-ethyl)-hexyl phthalate (MEHP), monobenzyl phthalate (MBzP), mono-(3-carboxypropyl) phthalate (MCPP), mono-(2-ethyl-5hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), and
mono-isobutyl phthalate (MIB). We summed MEHP, MEHHP, and MEOHP to represent
the sum of di (2-ethylhexyl) phthalate (DEHP) and we summed all 8 phthalate
metabolites (MBP + MEP + MEHP + MBzP + MCPP + MEHHP + MEOHP + MIB) to
represent total phthalate exposure. Bisphenol A (BPA) was the only phenol included in
this study. To correct for urine dilution, we divided all phthalate metabolites and BPA
concentrations by urinary creatinine concentration and used the resulting creatinine
corrected concentrations (mg/g) for all of our analyses. Urine samples with creatinine
levels > 300 mg/dL or < 30 mg/dL were excluded because they were too dilute or too
concentrated for accurate analysis (Sata et al. 1995).
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Limit of detection. A detection limit variable is provided for each PCB congener,
phthalate metabolite and BPA in the data sets. The variable LBD_LC has two values:
the value “0” indicates that the result was below the limit of detection and the value “1”
indicates that the result was at or above the limit of detection. Any participant with a
serum PCB concentration below the limit of detection was assigned a serum level of the
LOD divided by the square root of two. Limits of detection vary by metabolite and
survey cycle and can be found in the CDC’s Fourth National Report on Human Exposure
to Environmental Chemicals (CDC, 2013b).
Data analysis. We included female NHANES participants 20 to 85 years of age who
completed the physical exam, reproductive questionnaire, and medical health
questionnaire and provided a response for “Have you ever been told by a doctor or other
health professional that you had cancer or a malignancy of any kind?” Women who
answered “yes” were subsequently asked “What kind of cancer was it?” and “What was
your age at diagnosis?”
PCB data analysis. 8,315 women 20 to 85 years of age provided a response in the 19992004 survey cycles to for “Have you ever been told by a doctor or other health
professional that you had cancer or a malignancy of any kind?” After deleting
observations that were missing PCB data our PCB study population consisted of 2,072
participants: 43 reported a breast cancer diagnosis, 27 reported a cervical cancer
diagnosis, 11 reported an ovarian cancer diagnosis, 26 reported a uterine cancer diagnosis
and women who reported never being diagnosed with cancer ranged from 1955 to 1962
participants depending on the PCB congener being evaluated.
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Phthalate data analysis. Our phthalate study population consisted of women 20 to 85
years of age who provided a response in the 2003-2010 survey years to “Have you ever
been told by a doctor or other health professional that you had cancer or a malignancy of
any kind?” After deleting creatinine observations that were < 30 mg/dL and > 300
mg/dL our study populations consisted of 3,003 participants of whom 97 reported a
breast cancer diagnosis, 28 reported a cervical cancer diagnosis, 20 reported an ovarian
cancer diagnosis, 27 reported a uterine cancer diagnosis, and 2,731reported never being
diagnosed with cancer.
BPA data analysis. Our BPA study population consisted of women 20 to 85 years of
age provided a response in the 2005-2010 survey cycles to for “Have you ever been told
by a doctor or other health professional that you had cancer or a malignancy of any
kind?” After deleting creatinine observations that were < 30 mg/dL and > 300 mg/dL our
study populations consisted of 2,202 participants of whom 78 reported a breast cancer
diagnosis, 16 reported a cervical cancer diagnosis, 16 reported an ovarian cancer
diagnosis, 22 reported a uterine cancer diagnosis, and 2,070 reported never being
diagnosed with cancer.
Statistical analysis. All statistical analyses were performed using SAS system software
(release 9.2; SAS Institute Inc. Cary, N.C.). Appropriate subsample weights were
calculated according to the National Center for Health Statistics guidelines to adjust for
oversampling of minority groups (CDC, 2013b). Nonmissing values for serum
concentrations below the LOD were assigned a serum level of the LOD divided by the
square root of two. In our PCB analysis, all lipid-adjusted serum PCB concentrations
were log transformed to satisfy normality assumptions. In our phthalate and BPA
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analyses, all urinary compounds and metabolites were log transformed and creatinine
corrected. Due to a small number of cervical, ovarian and uterine cancer cases, we
conducted logistic regression analyses using the following two groups: < LOD to 50th
percentile (reference) vs. ≥ 50th percentile. We also conducted separate analyses on
females with serum PCB, phthalate, and BPA levels > LOD where cancer cases were
compared with non-cancer cases. Significance was set at p < 0.05.
We used PROC SURVEYMEANS to account for the complex sampling design of
NHANES and to obtain weighted means, 95% confidence intervals, and standard errors
of individual PCB congeners, the sum of dioxin-like PCBs, the sum of non-dioxin-like
PCBs, individual phthalate metabolites, the sum of DEHP (MHH+MOH+MHP), and
BPA. We used the Taylor Series (linearization) method to estimate standard errors. A
two-sided student t-test was calculated using PROC SURVEYREG to test whether the
mean EDC (PCB, phthalate, or BPA) levels between women who reported a breast,
cervical, ovarian, or uterine cancer diagnosis and women who reported no cancer
diagnosis were significantly different.

Age was divided into three groups (20-59 years,

60-74 years, and ≥ 75 years) that were selected based on the age distribution of
reproductive cancer cases and noncases in our data set. Race/ethnicity was divided into
two groups (non-Hispanic White and ‘Other’) due to a very small number of reproductive
cancer cases from races/ethnicities other than non-Hispanic White. The category of
‘Other’ includes Mexican American, Non-Hispanic Black, Other Hispanic and Other
Race – Including Multi-Racial. We also calculated GMs for reproductive cancer cases
and noncases in women with PCB, phthalate, and BPA levels above the LOD.
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Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs and
their 95% CIs to evaluate the association between exposure to EDCs and breast cancer,
cervical cancer, ovarian cancer, or uterine cancer. We conducted separate analyses for
the sum of dioxin-like and non-dioxin-like PCBs and individual PCB congeners and
reproductive cancers. Due to a small number of cervical, ovarian, and uterine cancer
cases, ORs and 95% CIs were calculated using the following group: < LOD to 50th
percentile vs. ≥ 50th percentile.

The reference group for each PCB congener is defined

as those participants whose serum concentrations were < LOD to 50th percentile.
Covariates. We considered a number of potential confounders based on previous
literature and well-established risk factors for reproductive cancers. The following
potential confounders were either self-reported in the questionnaire interviews or taken as
a laboratory measurement. The demographic variables of age at interview (20-59 years,
60-74 years, and ≥ 75 years), race (white vs. other) were obtained during the NHANES
home interview (CDC 2012). Reproductive variables including age at menarche (<12
years, 12-14 years, ≥15 years), parity (0, 1, ≥ 2), oral contraceptive use (yes/no) and
lactation (yes/no) as well as lifestyle variables including smoking (yes/no) and alcohol
use (yes/no) were obtained from health questionnaires completed in the mobile
examination center. Body mass index (< 25 kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2)
was obtained through the body measurement component in the mobile examination
center (CDC 2013b). For all EDCs, ORs and 95% CIs are reported for three models:
unadjusted; age and race/ethnicity adjusted; and age, race/ethnicity, BMI, and age at
menarche adjusted. Parity, oral contraceptive use and lactation were not included in the
models because of the extent of missing data. Smoking history and alcohol consumption
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were not significant predictors of breast cancer risk and therefore were also not presented
in the final models.
RESULTS
PCB descriptive statistics. The study population included 2,008 female participants 20
years of age and older with available PCB data and who completed the medical
conditions questionnaire and provided a response for “Have you ever been told by a
doctor or other health professional that you had cancer or a malignancy of any kind?”
Women who answered “yes” were subsequently asked, “What kind of cancer was it?”
and “What was your age at diagnosis?” Among the women who responded to the
questions stated above and had available PCB data, 1,965 (91.5%) reported never being
diagnosed with cancer, 43 (2.14%) reported being diagnosed with breast cancer, 27
(1.36%) reported being diagnosed with cervical cancer, 11 (0.56%) reported being
diagnosed with ovarian cancer, and 26 (1.31%) reported being diagnosed with uterine
cancer (Table 3.1). Participants were fairly evenly distributed over the two races: 48.6%
were of non-Hispanic white ethnicity and 51.4% were classified as ‘Other’, however the
majority of breast cancer cases were in non-Hispanic white women (81.5%). The
majority of participants were 20-59 years of age at the time of interview (65.9%) (Table
3.1). The mean age at time of interview was 45.6 years for women who reported never
being diagnosed with cancer, 65.7 years, 47.5 years, 52.0 years, and 52.4 years for
women who reported being diagnosed with breast cancer, cervical cancer, ovarian cancer,
and uterine cancer, respectively. The mean age at diagnosis was 54.9 years, 30.6 years,
41.9 years, and 53.2 years for women diagnosed with breast cancer, cervical cancer,
ovarian cancer, and uterine cancer, respectively (Table 3.1). BMI was normal (< 25
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kg/m2) for 35.5%, overweight (25to < 30 kg/m2) for 28.6%, and obese (≥ 30 kg/m2) for
39.0% of study participants. The majority of study participants reported and an age of
menarche of 12-14 years (64%), ≥ 2 live births (71.4%), responded yes to breastfeeding
(57.6%), responded yes to oral contraceptive use (58.8%), responded no to a history of
smoking (57.8%), and yes to alcohol consumption (54.5%) (Table 3.1).
Table 3.1. Descriptive statistics for cancer diagnosis and selected covariates among women ≥ 20 years of
age with serum PCB measurements, NHANES 1999-2004.
Variable
Total Population (n,%)
Age at interview (years; mean ± se)
Age at diagnosis (years; mean ± se)
Race/Ethnicity 1
Non-Hispanic white
Other
Age (years)
20-59
60-74
≥ 75
Age at menarche (years)
< 12 years
12-14 years
≥ 15 years
Parity (no. of live births)
0
1
>2
BMI (kg/m2)
Normal weight (18.5 to <25)
Overweight (25 to <30)
Obese (≥30)
Breastfed
Yes
No
Oral Contraceptive Use
Yes
No
Ever Smoked
Yes
No
Alcohol Use
Yes
No

No Cancer
n(%)
1965 (91.5%)
45.6 ± .42

Breast
Cancer
n(%)
43 (2.14%)
65.7 ± 2.12
54.9 ± 3.91

Cervical
Cancer
n(%)
27 (1.36%)
47.5 ± 2.61
30.6± 1.14

Ovarian
Cancer
n(%)
11 (0.56%)
52.0 ± 3.75
41.9 ± .1.97

Uterine
Cancer
n(%)
26 (1.31%)
52.4 ± 5.17
53.2 ± 1.52

942 (44.0%)
1023 (47.6%)

35 (1.74%)
8 (0.40%)

19 (0.95%)
8 (0.40%)

6 (0.30%)
5 (0.25%)

17 (0.85%)
9 (0.45%)

1369(63.7%)
384 (17.8%)
212 (9.87%)

7 (0.35 %)
26 (1.29%)
10 (0.50%)

18(0.90%)
6 (0.30%)
3 (0.15%)

7 (0.35%)
3 (0.15%)
1 (0.05%)

11 (0.55%)
11 (0.55%)
4 (0.20%)

344 (17.9%)
1161 (60.4%)
254 (13.2%)

6 (0.33%)
30 (1.67%)
4 (0.22%)

10 (0.56%)
14 (0.79%)
0 (0.00%)

2 (0.11%)
6 (0.34%)
2 (0.11%)

7 (0.39)
14 (0.78%)
4 (0.22%)

82 (4.89%)
319 (19.0%)
1121 (66.9%)

0 (0.00%)
5 (0.32%)
29 (1.86)%

3 (0.19%)
4 (0.26%)
16(1.04%)

1 (0.07%)
2 (0.13%)
6 (0.39%)

1 (0.06%)
5 (0.32%)
18 (1.16%)

715 (33.3%)
580(27.0%)
670 (31.2%)

13 (0.65%)
18 (0.90%)
12 (0.60%)

16 (0.80%)
2 (0.10%)
9 (0.45%)

4 (0.20%)
4 (0.20%)
3 (0.15%)

12 (0.60%)
8 (0.40%)
6 (0.30%)

835 (54.1%)
559 (36.2%)

19 (1.33%)
15 (1.05%)

12 (0.85%)
8 (0.57%)

5 (0.36%)
3 (0.21%)

13 (0.92%)
10 (0.71%)

1101(55.9%)
701 (35.5%)

22 (0.91%)
30 (1.25%)

18 (0.98%)
6 (0.33%)

6 (0.33%)
4 (0.22%)

12 (0.66%)
14 (0.76%)

775(36.1 %)
1189 (55.4%)

21 (1.14%)
19 (1.03%)

13 (0.65%)
14 (0.70%)

7 (0.35%)
4 (0.20%)

16 (0.80%)
10 (0.50%)

1019 (51.5%)
790 (39.9%)

23 (1.15%)
20 (1.00%)

10 (0.55%)
15 (0.85%)

7 (0.38%)
3 (0.16%)

17 (0.93%)
9 (0.49%)

Estimated percent distribution after applying NHANES sampling weights.
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Phthalate and BPA descriptive statistics. The study population included 3,003 female
participants 20 years of age and older with available phthalate and/or BPA data and who
completed the medical conditions questionnaire and provided a response for “Have you
ever been told by a doctor or other health professional that you had cancer or a
malignancy of any kind?” Women who answered “yes” were subsequently asked, “What
kind of cancer was it?” and “What was your age at diagnosis?” Among the 3,003
participants, 2,731 (90.4%) reported never being diagnosed with cancer, 97 (2.22%)
reported being diagnosed with breast cancer, 28 (0.65%) reported being diagnosed with
cervical cancer, 20 (0.47%) reported being diagnosed with ovarian cancer, and 27
(0.63%) reported being diagnosed with uterine cancer (Table 3.2). Of the women who
reported a reproductive cancer or no cancer, 43.5% of the participants were of nonHispanic white ethnicity and 52.6% were classified as ‘Other’. The majority of
participants were 20-59 years of age at the time of interview (67.7%) (Table 3.2). The
mean age at time of interview was 45.3 years for women who reported never being
diagnosed with cancer, 65.1 years, 48.1 years, 56.1 years, and 58.3 years for women who
reported being diagnosed with breast cancer, cervical cancer, ovarian cancer, and uterine
cancer, respectively. The mean age at diagnosis was 56.0 years, 30.5 years, 46.3 years,
and 52.3 years for women diagnosed with breast cancer, cervical cancer, ovarian cancer,
and uterine cancer, respectively (Table 3.2). BMI was normal (< 25 kg/m2) for 28.3%,
overweight (25to < 30 kg/m2) for 28.6%, and obese (≥ 30 kg/m2) for 39.3% of study
participants. The majority of study participants reported and an age of menarche of 1214 years (62.1%), ≥ 2 live births (74.0%), responded yes to breastfeeding (54.9%), and
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responded yes to oral contraceptive use (63.4%) , responded no to a history of smoking
(58.4%), and yes to alcohol consumption (57.1%) (Table 3.2).
Table 3.2. Descriptive statistics for cancer diagnosis and selected covariates among women ≥ 20 years of
age with urinary phthalate and bisphenol A measurements, NHANES 2003-2010.
Variable
Total Population (n,%)
Age at interview (years; mean ± se)
Age at diagnosis (years; mean ± se)
Race/Ethnicity
Non-Hispanic white
Other
Age (years)
20-59
60-74
≥ 75
Age at menarche (years)
< 12 years
12-14 years
≥ 15 years
Parity (no. of live births)
0
1
>2
BMI (kg/m2)
Normal weight (18.5 to <25)
Overweight (25 to <30)
Obese (≥30)
Breastfed
Yes
No
Oral Contraceptive Use
Yes
No
Ever Smoked
Yes
No
Alcohol Use
Yes
No

No Cancer
n(%)
2731 (90.4%)
45.3 ± .40

Breast
Cancer
n(%)
97 (2.22%)
65.1 ± 2.40
56.0 ± 2.27

Cervical
Cancer
n(%)
28 (0.65%)
48.1 ± 2.71
30.5 ± 0.76

Ovarian
Cancer
n(%)
20 (0.47%)
56.1 ± 5.09
46.3 ± 1.42

Uterine
Cancer
n(%)
27 (0.63%)
58.3 ± 3.10
52.3 ± 2.04

1202 (39.6%)
1529 (50.4%)

63 (2.23%)
34 (1.20%)

18 (0.65%)
10 (0.36%)

9 (0.33%)
11 (0.40%)

20 (0.73%)
7 (0.25%)

1971(65.0%)
504(16.6%)
256 (8.44%)

22 (0.78%)
38 (1.34%)
37 (1.31%)

24 (0.87%)
3 (0.11%)
1 (0.04%)

9 (0.33%)
6 (0.22%)
5 (0.18%)

8 (0.29%)
11 (0.40%)
8 (0.29%)

517 (19.0%)
1574 (58.0%)
343 (12.6%)

18 (0.71%)
57 (2.26%)
16 (0.63%)

5 (0.20%)
18 (0.73%)
3 (0.12%)

4 (0.16%)
10 (0.41%)
3 (0.12%)

5(0.20%)
17 (0.69%)
5 (0.20%)

54 (2.42%)
400 (17.9%)
1531(68.5%)

2 (0.10%)
13 (0.63%)
63 (3.05%)

1 (0.05%)
4 (0.20%)
21 (1.04%)

0 (0.00%)
4 (0.20%)
11 (0.55%)

0 (0.00%)
1 (0.21%)
4 (0.82%)

800 (26.6%)
803 (26.7%)
1102 (36.7%)

32 (1.14%)
26 (0.93%)
38 (1.36%)

7 (0.26%)
7 (0.26%)
14 (0.51%)

3 (0.11%)
12 (0.44%)
5 (0.18%)

6(0.22%)
6 (0.22%)
15 (0.55%)

1117 (51.1%)
816 (37.4%)

42 (2.09%)
35 (1.74%)

15 (0.77%)
10 (0.51%)

7 (0.36%)
8 (0.41%)

11 (0.56%)
15 (0.77%)

1650 (60.0%)
827 (30.%)

42 (1.64%)
49 (1.91%)

21(0.84%)
5 (0.20%)

7 (0.28%)
10 (0.40%)

15 (0.60%)
12 (0.48%)

1060 (35.0%)
1669 (55.1%)

39 (1.38%)
58 (2.05%)

21 (0.76%)
7 (0.25%)

6 (0.22%)
14 (0.51%)

13 (0.47%)
14 (0.51%)

1480 (53.6%)
998 (36.1%)

50 (1.95%)
41 (1.60%)

19 (0.76%)
7 (0.28%)

6 (0.24%)
11 (0.44%)

14 (0.56%)
13 (0.52%)

Estimated percent distribution after applying NHANES sampling weights.

Table 3.3 presents GMs and GSEs of EDCs by reproductive cancer status. GM
PCB levels were significantly higher for all 6 PCB congeners in women diagnosed with
breast cancer, PCB 74, 99, 118, 138, and 153 were significantly higher in women
diagnosed with uterine cancer and PCB 138, 153, and 180 were significantly higher in
women diagnosed with uterine cancer compared to women never diagnosed with cancer.
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None of the PCB congeners were significantly higher in women diagnosed with cervical
cancer (Table 3.3, Figure 3.1). MEHHP was significantly higher in women diagnosed
with ovarian cancer and MEP was significantly higher in women diagnosed with uterine
cancer compared to women never diagnosed with cancer (Table 3.3, Figure 3.2). MBzP
was found to be significantly higher in women without cancer compared to women with
breast cancer. Women diagnosed with a reproductive cancer did not have significantly
higher levels of BPA compared to women never diagnosed with cancer. In contrast,
women never diagnosed with cancer had significantly higher levels of BPA than women
diagnosed with breast cancer (Table 3.3).
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Table 3.3. Geometric Mean serum PCB, urinary phthalate and urinary BPA levelsby cancer diagnosis for
women ≥ 20 years of age.
No
Cancer
PCB Metabolites2
PCB 074
8.08 (1.03, 1960)
PCB 099
5.99 (1.03, 1958)
PCB 118
9.49 (1.03, 1960)
PCB 138
20.9 (1.03, 1961)
PCB 153
28.8 (1.02, 1962)
PCB 180
19.5 (1.02, 1955)
Phthalate Metabolites3
MBP
1.93 (1.01, 2723)
MEP
2.83 (1.01, 2723)
MEHP
1.19 (1.01, 2723)
MBzP
1.54 (1.01, 2723)d
MCCP
1.21 (1.01, 2723)
MEHHP
1.90 (1.01, 2723)
MEOHP
1.72 (1.01, 2723)
MIB
1.46 (1.01, 2723)
DEHP4
3.86 (1.03, 2723)
Total Phthalates5
58.0 (1.04, 2723)
Bisphenol A6
BPA
1.16 (1.01, 2070)c

Geometric mean1(ng/g) (GSE,n)
Breast
Cervical
Cancer
Cancer

Ovarian
Cancer

Uterine
Cancer

15.6 (1.14, 43)a
9.39 (1.12, 43)b
17.5 (1.16, 43)b
39.6 (1.11, 43)a
56.2 (1.11, 43)a
44.3 (1.10, 43)a

9.58 (1.21, 27)
6.82 (1.16, 26)
12.2 (1.25, 27)
25.3 (1.20, 27)
33.8 (1.20, 27)
23.8 (1.17, 27)

30.0 (1.32, 11)b
51.9 (1.32, 11)b
38.9 (1.38, 11)b
22.3 (1.36, 11)b
12.2 (1.42, 11)b
16.6 (1.28, 11)

10.8 (1.21, 26)
7.24 (1.21, 25)
11.1 (1.32, 26)
30.9 (1.14, 26)b
40.9 (1.15, 26)b
30.3 (1.20, 26)b

1.90 (1.04, 97)
2.66 (1.05, 97)
1.14 (1.05, 97)
1.45 (1.04, 97)
1.19 (1.03, 97)
1.92 (1.03, 97)
1.73 (1.04, 97)
1.39 (1.05, 97)
3.78 (1.13, 97)
46.5 (1.15, 97)

1.92 (1.04, 28)
2.86 (1.04, 28)
1.20 (1.05, 28)
1.51 (1.05, 28)
1.18 (1.05, 28)
1.88 (1.05, 28)
1.77 (1.05, 28)
1.39 (1.04, 28)
3.34 (1.17, 28)
54.6 (1.31, 28)

1.93 (1.04, 20)
2.64 (1.05, 20)
1.36 (1.05, 20)
1.68 (1.07, 20)
1.26 (1.09, 20)
2.32 (1.25, 20)b
2.03 (1.28, 20)
1.46 (1.06, 20)
6.55 (2.08, 20)
102 (1.54, 20)

2.03 (1.07, 27)
3.10 (1.16, 27)b
1.07 (1.07, 27)
1.46 (1.08, 27)
1.20 (1.04, 27)
1.93 (1.08, 27)
1.72 (1.08, 27)
1.46 (1.09, 27)
3.53 (1.23, 27)
56.8 (1.22, 27)

1.06 (1.03, 78)

1.17 (1.08, 16)

1.23 (1.08, 16)

1.09 (1.06, 22)

1

Geometric means calculated after applying NHANES sampling weights.
2
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g); NHANES 1999-2004.
3
Log transformed and creatinine corrected urinary phthalate metabolites (ng/mg); NHANES 2003-2010.
4
DEHP = Sum of MEHP, MEHHP and MEOHP.
5
Total Phthalates = Sum of MBP, MEP, MEHP, MBzP, MCCP, MEHHP, MEOHP and MIB.
6
Log transformed and creatinine corrected urinary BPA measurements (ng/g); NHANES 2005-1010.
PCB or phthalate levels significantly higher in women with cancer vs. women without cancer;
a
p < 0.0001, bp < 0.05.
BPA significantly higher in women without cancer vs. women with breast cancer, cp < 0.05.
MBzP is significantly higher in women without cancer vs. women diagnosed with breast cancer, dp<0.05.
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Figure 3.1. Geometric Mean PCB levels (ng/g) by cancer diagnosis among women ≥ 20
years of age, NHANES 1999-2004.

Figure 3.2. Geometric mean urinary phthalate levels (ng/mg) by cancer diagnosis among
women ≥ 20 years of age, NHANES 2003-2010.

GM EDC levels were also examined by cancer status in women with individual
PCB concentrations above the LOD (Table 3.4). All 6 PCB congeners remained
significantly higher in women diagnosed with breast cancer, PCB 74, 99, 118, 138, and

180

153 were significantly higher in women diagnosed with ovarian cancer, and PCB 138
was significantly higher in women diagnosed with uterine cancer compared to women
never diagnosed with cancer. For women with phthalate concentrations above the LOD,
GM levels did not differ between women diagnosed with a reproductive cancer and
women never diagnosed with cancer (Table 3.4). When observations below the LOD
were removed BPA became significantly higher in women diagnosed with cervical
cancer compared to women never diagnosed with cancer (Table 3.4).
Table 3.4. Geometric Mean PCB, urinary phthalate and urinary BPA levels by cancer diagnosis among
women ≥ 20 years of age with concentrations above the LOD.
No
Cancer
PCB Metabolites2
PCB 074
9.87 (1.03, 1484)
PCB 099
7.24 (1.02, 1334)
PCB 118
11.7 (1.03, 1534)
PCB 138
23.6 (1.03, 1594)
PCB 153
31.8 (1.03, 1651)
PCB 180
23.3 (1.03, 1600)
Phthalate Metabolites3
MBP
1.93 (1.01, 2718)
MEP
2.83 (1.01, 2722)
MEHP
1.34 (1.01, 1913)
MBzP
1.55 (1.01, 2704)
MCCP
1.22 (1.01, 2677)
MEHHP
1.90 (1.01, 2719)
MEOHP
1.72 (1.01, 2714)
MIB
1.48 (1.01, 2695)
Bisphenol A4
BPA
1.18 (1.01, 1959)

Geometric mean1 (GSE,n)
Breast
Cervical
Ovarian
Cancer
Cancer
Cancer

Uterine
Cancer

16.0 (1.07, 43)b
9.87 (1.08, 43)b
17.5 (1.16, 43)b
39.6 (1.11, 43)a
56.2 (1.11, 43)a
44.3 (1.10, 43)a

10.7 (1.25, 24)
7.61 (1.21, 21)
14.4 (1.29, 24)
28.2 (1.22, 24)
37.7 (1.21, 25)
25.0 (1.17, 25)

21.8 (1.19, 9)a
20.1 (1.21, 8)b
30.9 (1.25, 9)a
47.5 (1.38, 9)b
63.4 (1.35,9)b
37.7 (1.36, 9)

10.9 (1.21, 23)
8.50 (1.22, 19)
12.9 (1.25, 23)
31.5 (1.14, 25)b
41.3 (1.15, 25)
30.9 (1.21, 24)

1.93 (1.03, 97)
2.66 (1.04, 97)
1.28 (1.04, 64)
1.46 (1.03, 96)
1.22 (1.03, 95)
1.92 (1.03, 97)
1.73 (1.03, 97)
1.42 (1.03, 95)

1.92 (1.04, 27)
2.86 (1.06, 28)
1.45 (1.06, 18)
1.51 (1.05, 28)
1.19 (1.05, 28)
1.88 (1.06, 28)
1.77 (1.05, 28)
1.43 (1.04, 27)

1.93 (1.04, 20)
2.64 (1.05, 20)
1.55 (1.27, 16)
1.68 (1.07, 20)
1.26 (1.09, 20)
2.32 (1.25, 20)
2.03 (1.28, 20)
1.46 (1.06, 20)

2.03 (1.08, 27)
3.10 (1.06, 27)
1.16 (1.04, 19)
1.46 (1.05, 27)
1.20 (1.05, 27)
1.93 (1.04, 27)
1.72 (1.03, 27)
1.46 (1.06, 27)

1.11 (1.03, 71)

1.27 (1.05, 14)a

1.30 (1.08, 15)

1.16 (1.05, 20)

1

Geometric means calculated after applying NHANES sampling weights.
2
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g); NHANES 1999-2004.
3
Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 2003-2010.
4
Log transformed and creatinine corrected urinary BPA measurements (ng/g); NHANES 2005-1010.
PCB, BPA, or phthalate levels significantly higher in women with cancer vs. women without cancer;
a
p < 0.0001, bp < 0.05

Estimated ORs and 95% confidence intervals for the risk of having breast,
cervical, ovarian, or uterine cancers cancer and the six individual PCB congeners are
shown in tables 3.5-3.8. Due to the lack of breast cancer cases in women with low blood
PCB levels and in women with blood PCB levels below the LOD, the following two
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groups were used to estimate breast cancer risk: < LOD to 50th percentile (reference
group) and ≥ 50th percentile. Results are presented for three logistic regression models:
unadjusted; age and race/ethnicity adjusted; and age, race/ethnicity, BMI, and age at
menarche adjusted. In unadjusted models, PCBs were significantly associated with breast
cancer risk for subjects in the second group (≥ 50th percentile) when compared to the
reference group (< LOD to 50th percentile) for PCB congeners 74, 99, 118, 138, 153, and
180 (Table 3.5). After adjusting for age and race/ethnicity, PCB138 was the only
congener found to be significantly associated with breast cancer [OR of 3.16; 95% CI:
1.14-8.76] (Table 3.5)After adjusting for age, race/ethnicity, BMI, lactation, and age at
menarche, PCB138 remained significantly associated with breast cancer (OR of 2.88,
95% CI) (Table 3.5).

182

Table 3.5. Estimated ORs (95% CIs) of breast cancer by concentration of PCBs, among women ≥ 20 years
of age, NHANES 1999-2004.
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
4
1047
1.00
1.00
1.00
1.62 (0.48-5.38)
1.95 (0.31-12.4)
≥ 50%
39
912
5.82 (2.56-13.1)a
PCB 099
< LOD to 50%
12
1172
1.00
1.00
1.00
1.40 (0.66-2.94)
1.52 (0.62-3.74)
≥ 50%
31
787
3.09 (1.60-5.98)b
PCB 118
< LOD to 50%
6
999
1.00
1.00
1.00
1.38 (0.40-4.78)
1.54 (0.29-8.35)
≥ 50%
37
960
4.34 (1.95-9.70)b
PCB 138
< LOD to 50%
4
1068
1.00
1.00
1.00
3.14 (1.14-8.62)b
2.52 (1.06-5.99)b
≥ 50%
39
891
7.35 (3.10-17.5)a
PCB 153
< LOD to 50%
4
1078
1.00
1.00
1.00
3.94 (0.58-26.6)
3.15 (0.53-18.6)
≥ 50%
39
882
9.20 (2.30-36.8)b
PCB 180
< LOD to 50%
4
1148
1.00
1.00
1.00
4.33 (0.79-23.6)
3.45 (0.76-15.6)
≥ 50%
39
806
10.6 (3.03-37.1)b
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 40/1754 in 074; 40/1753 in099;
40/1755 in 118; 40/1756 in 138 and 153; 40/1749 in 180.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having cervical and the six
individual PCB congeners are shown in table 3.6. In unadjusted models, PCBs were
significantly associated with cervical cancer risk for subjects in the second group (≥ 50th
percentile) when compared to the reference group (< LOD to 50th percentile) for PCB
congeners 138 and 153 (Table 3.6). After adjusting for age and race/ethnicity, PCB138
was the only congener found to be significantly associated with cervical cancer (OR of
3.12; 95% CI: 1.32-8.74) (Table 3.6). After adjusting for age, race/ethnicity, BMI,
lactation, and age at menarche, PCB138 remained significantly associated with cervical
cancer (OR of 3.05, 95% CI: 1.21-7.69) (Table 3.6).
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Table 3.6. Estimated ORs (95% CIs) of cervical cancer by concentration of PCBs, among women ≥ 20
years of age, NHANES 1999-2004.
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
12
1048
1.00
1.00
1.00
0.87 (0.28-2.70)
≥ 50%
15
912
1.26 (0.55-2.87)
1.01 (0.37-2.77)
PCB 099
< LOD to 50%
13
1172
1.00
1.00
1.00
1.40 (0.72-2.74)
≥ 50%
13
787
1.52 (0.81-2.83)
1.53 (0.81-2.88)
PCB 118
< LOD to 50%
11
1000
1.00
1.00
1.00
1.39 (0.48-3.96)
1.28 (0.40-4.04)
≥ 50%
16
960
1.47 (0.57-3.77)
PCB 138
< LOD to 50%
9
1070
1.00
1.00
1.00
3.12 (1.32-87.40)b 3.05 (1.21-7.69)b
≥ 50%
18
891
2.96 (1.45-6.06)b
PCB 153
< LOD to 50%
11
1080
1.00
1.00
1.00
≥ 50%
16
882
2.17 (1.04-4.53)b
2.18 (0.86-5.53)
2.46 (0.90-6.67)
PCB 180
< LOD to 50%
14
1149
1.00
1.00
1.00
1.61 (074-3.50)
1.58 (0.70-3.56)
≥ 50%
13
806
1.75 (0.95-3.23)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 24/1754 in 074; 23/1753 in 099;
24/1755 in 118; 24/1756 in 138 and 153; 24/1749 in 180.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having ovarian cancer and
the six individual PCB congeners are shown in table 3.7. In unadjusted models, PCBs
were significantly associated with ovarian cancer risk for subjects in the second group (≥
50th percentile) when compared to the reference group (< LOD to 50th percentile) for
PCB congeners 74 and 118 (Table 3.7). After adjusting for age, race/ethnicity, BMI,
lactation, and age at menarche, PCB 74 and 118 remained significantly associated with
ovarian cancer [ORs of 6.47 (95% CI: 1.23-34.1) and 6.68 (95% CI: 1.39-32.3)] (Table
3.7).
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Table 3.7. Estimated ORs (95% CIs) of ovarian cancer by concentration of PCBs among women ≥ 20
years of age, NHANES 1999-2004,
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
2
1048
1.00
1.00
1.00
7.31 (1.62-32.9)b
6.47 (1.23-34.1)b
≥ 50%
9
912
5.88 (1.67-207)b
PCB 099
< LOD to 50%
3
1171
1.00
1.00
1.00
3.69 (0.43-31.7)
≥ 50%
8
787
3.67 (0.65-20.9)
4.15 (0.55-31.3)
PCB 118
< LOD to 50%
2 1000
1.00
1.00
1.00
7.17 (1.64-31.3)b
6.68 (1.39-32.3)b
≥ 50%
9
960
5.81 (1.66-20.4)b
PCB 138
< LOD to 50%
4
1070
1.00
1.00
1.00
0.97 (0.12-7.63)
≥ 50%
7
891
1.22 (0.24-6.28)
1.23 (0.15-9.81)
PCB 153
< LOD to 50%
3
1080
1.00
1.00
1.00
2.05 (0.50-8.41)
≥ 50%
8
882
2.12 (0.49-9.13)
2.36 (0.46-12.0)
PCB 180
< LOD to 50%
3
1149
1.00
1.00
1.00
2.88 (0.53-15.6)
2.55 (0.66-9.85)
≥ 50%
8
806
2.49 (0.58-10.7)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 10/1754in 074; 10/1753 in 099;
10/1755 in 118; 10/1756 in 138 and 153; 10/1749 in 180.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having uterine cancer
and the six individual PCB congeners are shown in table 3.8. In unadjusted models, PCBs
were significantly associated with uterine cancer risk for subjects in the second group (≥
50th percentile) when compared to the reference group (< LOD to 50th percentile) for
PCB congeners 138 and 153 (Table 3.8). After adjusting for age, race/ethnicity, BMI,
lactation, and age at menarche, PCB 138 remained significantly associated with ovarian
cancer [OR of 5.83 (95% CI: 1.63-20.9)] (Table 3.8).
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Table 3.8. Estimated ORs (95% CIs) of uterine cancer by concentration of PCBs among women ≥ 20 years
of age, NHANES 1999-2004.
1

No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Analyte
PCB 074
< LOD to 50%
8
1048
1.00
1.00
1.00
1.55 (0.34-7.06)
≥ 50%
18
912
2.13 (0.63-7.15)
1.41 (0.36-5.55)
PCB 099
< LOD to 50%
13
1171
1.00
1.00
1.00
1.43 (0.34-6.06)
≥ 50%
12
787
1.55 (0.46-5.27)
1.19 (0.28-4.97)
PCB 118
< LOD to 50%
10
1000
1.00
1.00
1.00
1.07 (0.24-4.76)
1.52 (0.39-5.92)
≥ 50%
16
960
1.60 (0.55-4.63)
PCB 138
< LOD to 50%
7
1070
1.00
1.00
1.00
4.29 (1.21-15.2)b
5.83 (1.63-20.9)b
≥ 50%
19
891
4.84 (1.68-13.9)b
PCB 153
< LOD to 50%
8
1080
1.00
1.00
1.00
≥ 50%
18
882
3.71 (1.39-9.89)b
3.14 (0.89-11.0)
4.07 (1.19-14.0)
PCB 180
< LOD to 50%
8
1149
1.00
1.00
1.00
2.00 (0.60-6.61)
1.70 (0.53-5.45)
≥ 50%
18
806
2.64 (0.79-8.87)
1
Lipid adjusted and log transformed polychlorinated biphenyls (ng/g).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 24/1754 in 074; 24/1753in 099;
25/1755 in 118; 25/1756 in 138 and 153; 25/1749 in 180.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having a reproductive
cancer and dioxin-like and non-dioxin-like PCBs are shown in table 3.9. In the
unadjusted models, dioxin-like and non-dioxin-like PCBs were significantly associated
with breast cancer, ovarian cancer and uterine cancer. In the age and race/ethnicity
adjusted models, dioxin-like PCBs were significantly associated with breast cancer (OR
of 1.50, 95% CI: 1.27-1.77) and ovarian cancer (OR of 1.95, 95% CI: 1.25-3.05) and
non-dioxin-like PCBs were significantly associated with breast cancer (OR of 1.14, 95%
CI: 1.00-1.29), cervical cancer (OR of 1.29, 95% CI: 1.18-1.40), ovarian cancer (OR of
1.32, 95% CI: 1.02-1.69), and uterine cancer (OR of 1.11, 95% CI: 1.01-1.22). After
adjusting for age, race/ethnicity, BMI, and age at menarche dioxin-like PCBs remained
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significantly associated with ovarian cancer risk (OR of 2.02, 95% CI: 1.06-3.85) and
non-dioxin-like PCBs remained significantly associated with uterine cancer risk (OR of
1.12, 95% CI: 1.03-1.23) (Table 3.9). We further analyzed reproductive cancer risk of
dioxin-like and non-dioxin-like PCBs using the following two groups: < LOD to 50th
percentile (reference group) and ≥ 50th percentile. In subjects with PCB levels ≥ 50th
percentile, breast cancer, ovarian cancer, and uterine cancer were associated with dioxinlike and non-dioxin-like PCBs in the unadjusted models. Non-dioxin-like PCBs were
significantly associated with cervical cancer risk and ovarian cancer risk in the age and
race/ethnicity adjusted models [ORs of 2.59, (95% CI: 1.04-6.42) and 6.62, )95% CI:
1.50-29.2)], respectively. Dioxin-like PCBs were associated with the risk of ovarian
cancer in the age and race/ethnicity adjusted models [OR of 6.32 (95% CI: 1.44-27.7)].
In the final adjusted models (age, race/ethnicity, BMI, age at menarche) the risk of
ovarian cancer remained significant for dioxin-like PCBs [OR of 5.71 (95% CI: 1.1229.2)] and non-dioxin-like PCBs [OR of 5.99 (95% CI: 1.20-29.9)] and the risk of uterine
cancer remained significant for non-dioxin-like PCBs [OR of 4.85 (95% CI: 1.32-17.8)]
(Table 3.9).
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Table 3.9. Estimated ORs (95% CIs) of a reproductive cancer by concentrations of dioxin-like and nondioxin-like PCBs among women ≥ 20 years of age, NHANES 1999-2004.
Unadjusted OR
Cases/Noncases
(95% CI)
Breast Cancer
Dioxin-like PCBs3
3,5
Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
4
Non- Dioxin-like PCBs
4,5
Non-Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
Cervical Cancer
Dioxin-like PCBs3
3,5
Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
4
Non- Dioxin-like PCBs
4,5
Non-Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
Ovarian Cancer
Dioxin-like PCBs3
3,5
Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
3
Non- Dioxin-like PCBs
4,5
Non-Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
Uterine Cancer
Dioxin-like PCBs3
3,5
Dioxin-like PCBs_50
< LOD to 50%
≥ 50%
4
Non- Dioxin-like PCBs
4,=
Non-Dioxin-like PCBs_50
< LOD to 50%
≥ 50%

Adjusted OR1
(95% CI)

Adjusted OR2a,b
(95% CI)

43/1953

1.50 (1.27-1.78)a

1.50 (1.27-1.77)a

1.08 (0.80-1.45)

4/985
39/968
43/1941

1.00
5.23 (2.25-12.2)a
a
1.28 (1.18-1.38)

1.00
1.55 (0.49-4.90)
b
1.14 (1.00-1.29)

1.00
1.90 (0.33-10.8)
1.12 (0.98-1.28)

2/997
41/944

1.00
b
12.7 (2.58-62.2)

1.00
5.40 (0.87-33.5)

1.00
4.27 (0.68-26.8)

27/1954

1.15(0.91-1.45)

1.13 (0.82-1.56)

1.10 (0.78-1.55)

1 2/985
15/968
26/1941

1.00
1.13 (0.50-2.58)
1.05 (0.94-1.16)

1.00
1.04 (0.90-1.20)
a
1.29 (1.18-1.40)

1.00
0.80 (0.27-2.38)
1.02 (0.87-1.19)

9/997
17/944

1.00
b
2.38 (1.14-4.94)

1.00
b
2.59 (1.04-6.42)

1.00
2.51 (0.94-6.68)

11/1954

1.61 (1.19-2.17)a

1.95 (1.25-3.05)b

2.02 (1.06-3.85)b

2/985
9/968
11/1941

1.00
5.26 (1.51-18.4)b
b
1.24 (1.01-1.53)

1.00
6.32 (1.44-27.7)b
b
1.32 (1.02-1.69)

1.00
5.71 (1.12-29.2)b
1.30 (0.98-1.72)

2/997
9/994

1.00
b
5.51 (1.56-19.5)

1.00
b
6.62 (1.50-29.2)

1.00
b
5.99 (1.20-29.9)

26/1954

1.16 (0.88-1.52)

1.02 (0.76-1.37)

1.10 (0.83-1.46)

10/985
16/968
25/1941

1.00
1.14 (1.04-1.25)b
b
1.28 (1.18-1.38)

1.00
0.87 (0.18-4.21)
b
1.11 (1.01-1.22)

1.00
1.24 (0.29-5.28)
b
1.12 (1.03-1.23)

7/997
18/944

1.00
4.14 (1.44-11.3)b

1.00
3.53 (0.96-13.1)

1.00
4.85 (1.32-17.8)b
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1

Adjusted for age and race/ethnicity.
Adjusted for age, race/ethnicity, BMI, age at menarche.
a
Cases/Noncases in dioxin-like PCBs : 40/1749 for breast cancer, 24/1749 for cervical cancer, 10/1749 for
ovarian cancer, 25/1749 for uterine cancer.
b
Cases/Noncases in non-dioxin-like PCBs: 40/1737 for breast cancer, 23/1737 for cervical cancer, 10/1737
for ovarian cancer, 24/1737 for uterine cancer.
3
Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118).
4
Non-Dioxin-like PCBs: Sum of lipid adjusted & log transformed PCB Congeners (099 + 138 + 153 + 180).
5
Serum PCB Levels < 50th percentile vs ≥ 50th percentile.
Significance ap < 0.0001, bp < 0.05.
2

Estimated ORs and 95% CIs for the risk of having breast, cervical, ovarian, or
uterine cancer and the eight phthalate metabolites, the sum of DEHP, and total phthalates
are shown in tables 3.10-3.13. We analyzed the phthalate levels the in the following
group: < LOD to 50th percentile (reference group) and ≥ 50th percentile. Results are
presented for two logistic regression models: age and race adjusted; and age,
race/ethnicity, BMI, and age at menarche adjusted. Results were not presented for
unadjusted models because the derived ORs and 95% CIs did not differ from the models
presented. A significant association between breast cancer or cervical cancer and
phthalates was not found in any of the models (Table 3.10 and 3.11).
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Table 3.10. Estimated ORs (95% CIs) of breast cancer by concentration of creatinine corrected urinary
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.
1

No.
Cases

No.
Noncases

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Metabolite
MBP
< LOD to 50%
41
1045
1.00
1.00
≥ 50%
56
1678
0.89 (0.49-1.64)
0.85 (0.47-1.55)
MEP
< LOD to 50%
47
1106
1.00
1.00
≥ 50%
50
21616
0.66 (0.38-1.15)
0.63 (0.36-1.10)
MEHP
< LOD to 50%
57
1339
1.00
1.00
≥ 50%
40
1376
0.94 (0.50-1.76)
0.92 (0.48-1.74)
MBzP
< LOD to 50%
52
1205
1.00
1.00
≥ 50%
45
1517
0.75 (0.44-1.29)
0.72 (0.42-1.23)
MCCP
< LOD to 50%
51
1396
1.00
1.00
≥ 50%
46
1326
0.86 (0.51-1.43)
0.83 (0.49-1.40)
MEHHP
< LOD to 50%
40
1280
1.00
1.00
≥ 50%
57
1443
1.23 (0.74-2.03)
1.15 (0.71-1.86)
MEOHP
< LOD to 50%
39
1267
1.00
1.00
≥ 50%
58
1456
1.27 (0.75-2.17)
1.19 (0.71-1.99)
MIB
< LOD to 50%
57
1260
1.00
1.00
≥ 50%
40
1457
0.69 (0.42-1.14)
0.71 (0.42-1.18)
DEHP
< LOD to 50%
50
1301
1.00
1.00
≥ 50%
47
1422
0.91 (0.50-1.64)
0.85 (0.46-1.55)
Total
< LOD to 50%
55
1423
1.00
1.00
≥ 50%
42
1300
0.84 (0.48-1.48)
0.81 (0.40-1.63)
1
Log transformed and creatinine adjusted urinary phthalates (ng/mg).
2
Adusted for age and race/ethnicity .
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 91/2410 in MBP, MEHHP,
MEOHP, MIB, DEHP; 91/2409 in MEP, MCCP, MBzP; 91/2403 in MEHP.
Significance ap < 0.001, bp < 0.05.
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Table 3.11. Estimated ORs (95% CIs) of cervical cancer by concentration of creatinine corrected urinary
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.
1

No.
Cases

No.
Noncases

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Metabolite
MBP
< LOD to 50%
10
1045
1.00
1.00
≥ 50%
18
1678
0.70 (0.25-1.97)
0.64 (0.22-1.85)
MEP
< LOD to 50%
14
1106
1.00
1.00
≥ 50%
14
1616
0.91 (0.39-2.14)
0.80 (0.33-1.97)
MEHP
< LOD to 50%
12
1339
1.00
1.00
≥ 50%
16
1376
0.95 (0.46-1.96)
0.91 (0.44-1.88)
MBzP
< LOD to 50%
10
1205
1.00
1.00
≥ 50%
18
1517
1.07(0.51-2.22)
1.04 (0.49-2.21)
MCCP
< LOD to 50%
16
1396
1.00
1.00
≥ 50%
12
1326
0.73 (0.38-1.38)
0.77 (0.41-1.47)
MEHHP
< LOD to 50%
10
1280
1.00
1.00
1.00 (0.36-2.77)
≥ 50%
18
1443
1.10 (0.39-3.11)
MEOHP
< LOD to 50%
11
1267
1.00
1.00
≥ 50%
17
1456
0.77 (0.31-1.87)
0.68 (0.28-1.65)
MIB
< LOD to 50%
14
1260
1.00
1.00
≥ 50%
14
1457
0.81 (0.35-1.87)
0.85 (0.35-2.03)
DEHP
< LOD to 50%
12
1301
1.00
1.00
≥ 50%
16
1422
0.79 (0.33-1.92)
0.73 (0.30-1.76)
Total
< LOD to 50%
12
1423
1.00
1.00
≥ 50%
16
1300
0.98 (0.44-2.17)
0.81 (0.38-1.74)
1
Log transformed and creatinine adjusted urinary phthalates (ng/mg).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 26/2410 in MBP, MEHHP,
MEOHP, MIB, DEHP; 26/2409 in MEP, MBzP, MCCP; 26/2403 in MEHP.
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% CIs for the risk of ovarian cancer and uterine cancer by
concentration of the eight phthalate metabolites, the sum of DEHP, and total phthalates
are shown in table 3.12 and 3.13. In the age and race adjusted model, MEHHP showed a
weak association with ovarian cancer [OR of 3.63 (95%CI: 1.00-13.2), p=.0497],
however this association did remain significant after adjusting for age, race/ethnicity,
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BMI, and age at menarche (Table 3.12). None of the phthalates were significantly
associated with the risk of uterine cancer (Table 3.13).
Table 3.12. Estimated ORs (95% CIs) of ovarian cancer by concentration of creatinine corrected urinary
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.
1

No.
Cases

No.
Noncases

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Metabolite
MBP
< LOD to 50%
6
1045
1.00
1.00
≥ 50%
14
1678
1.96 (0.61-6.31)
1.48 (0.42-5.19)
MEP
< LOD to 50%
11
1106
1.00
1.00
≥ 50%
9
1616
0.43 (0.17-1.12)
0.38 (0.11-1.30)
MEHP
< LOD to 50%
7
1339
1.00
1.00
≥ 50%
13
1376
2.56 (0.92-7.10)
1.91 (0.61-5.94)
MBzP
< LOD to 50%
10
1205
1.00
1.00
≥ 50%
10
1517
1.65 (0.56-4.83)
1.59 (0.50-5.11)
MCCP
< LOD to 50%
12
1396
1.00
1.00
≥ 50%
8
1326
1.13 (0.35-3.60)
1.24 (0.36-4.25)
MEHHP
< LOD to 50%
4
1280
1.00
1.00
2.73 (0.67-11.1)
≥ 50%
16
1443
3.63 (1.00-13.2)b
MEOHP
< LOD to 50%
4
1267
1.00
1.00
≥ 50%
16
1456
3.58(0.98-13.1)
2.67 (0.678-10.6)
MIB
< LOD to 50%
11
1260
1.00
1.00
≥ 50%
9
1457
0.57 (0.16-1.99)
0.61 (0.13-2.83)
DEHP
< LOD to 50%
6
1301
1.00
1.00
≥ 50%
14
1422
2.88 (0.95-8.76)
2.29 (0.64-8.23)
Total
< LOD to 50%
9
1423
1.00
1.00
≥ 50%
11
1300
1.21 (0.46-3.17)
1.38 (0.46-4.17)
1
Log transformed and creatinine adjusted urinary phthalates (ng/mg).
2
Adjusted for age and race/ethnicity.
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 17/2410 in MBP, MEHHP,
MEOHP, MIB, DEHP; 17/2409 in MEP, MBzP, MCCP; 17/2403 in MEHP.
Significance ap < 0.0001, bp < 0.05.
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Table 3.13. Estimated ORs (95% CIs) of uterine cancer by concentration of creatinine corrected urinary
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.
1

No.
Cases

No.
Noncases

Adjusted OR2
(95% CI)

Adjusted OR3
(95% CI)

Metabolite
MBP
< LOD to 50%
10
1045
1.00
1.00
≥ 50%
17
1678
1.17 (0.36-3.78)
1.11 (0.33-3.68)
MEP
< LOD to 50%
12
1106
1.00
1.00
≥ 50%
15
1616
1.02 (0.47-2.20)
0.99 (0.46-2.12)
MEHP
< LOD to 50%
21
1339
1.00
1.00
≥ 50%
6
1376
0.34 (0.11-1.03)
0.34 (0.11-1.09)
MBzP
< LOD to 50%
16
1205
1.00
1.00
≥ 50%
11
1517
0.59 (0.23-1.48)
0.55 (0.21-1.43)
MCCP
< LOD to 50%
14
1396
1.00
1.00
≥ 50%
13
1326
0.88 (0.32-2.45)
0.85 (0.31-2.32)
MEHHP
< LOD to 50%
10
1280
1.00
1.00
1.43 (0.61-3.34)
≥ 50%
17
1443
1.55 (0.65-3.70)
MEOHP
< LOD to 50%
11
1267
1.00
1.00
≥ 50%
16
1450
1.02 (0.46-2.23)
0.95 (0.45-2.02)
MIB
< LOD to 50%
12
1260
1.00
1.00
≥ 50%
15
2337
1.20 (0.45-3.17)
1.21 (0.45-3.20)
DEHP
< LOD to 50%
15
1301
1.00
1.00
≥ 50%
12
1422
0.92 (0.40-2.12)
0.87 (0.39-1.93)
Total
< LOD to 50%
13
1423
1.00
1.00
0.92 (0.30-2.79)
≥ 50%
14
1300
0.98(0.34-2.84)
1
Log transformed and creatinine adjusted urinary phthalates (ng/mg).
2
Adjusted for age and race/ethnicity
3
Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases: 27/2410 in MBP, MEHHP,
MEOHP, MIB, DEHP; 27/2409 in MEP, MBzP, MCCP; 27/2403 in MEHP
Significance ap < 0.0001, bp < 0.05.

Estimated ORs and 95% confidence intervals for the risk of having breast,
cervical, ovarian, or uterine cancers cancer by concentration of BPA are shown in table
3.14. The following two groups were used to estimate reproductive cancer risk: < LOD
to 50th percentile (reference group) and ≥ 50th percentile. Results are presented for three
logistic regression models: unadjusted; age and race/ethnicity adjusted; and age,
race/ethnicity, BMI, and age at menarche adjusted. None of the models showed a
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significant association between BPA and breast cancer, cervical cancer, ovarian cancer,
or uterine cancer (Table 3.14).
Table 3.14. Estimated ORs (95% CIs) of a reproductive cancer by concentration of creatinine adjusted
urinary BPA among women ≥ 20 years of age, NHANES 2005-2010.
No.
Cases

No.
Noncases

Unadjusted OR
(95% CI)

Adjusted OR1
(95% CI)

Adjusted OR2
(95% CI)

Breast Cancer
< LOD to 50%
44
985
1.00
1.00
1.00
≥ 50%
34
1082
0.67 (0.40-1.14)
0.76 (0.45-1.30)
0.73 (0.42-1.23)
Cervical Cancer
< LOD to 50%
6
985
1.00
1.00
1.00
1.33 (0.42-4.18)
≥ 50%
9
1082
1.34 (0.37-4.81)
1.39 (0.39-4.91)
Ovarian Cancer
< LOD to 50%
6
985
1.00
1.00
1.00
≥ 50%
10
1082
1.57 (0.43-5.76)
1.64 (0.43-6.25)
1.41 (0.30-6.70)
Uterine Cancer
< LOD to 50%
13
985
1.00
1.00
1.00
0.57 (0.25-1.29)
≥ 50%
9
1082
0.58 (0.27-1.28)
0.65 (0.30-1.41)
Log –transformed and creatinine adjusted BPA measurements (ng/mg); NHANES 2005-2010.
1
Adjusted for age and race/ethnicity.
2
Adjusted for age, race/ethnicity, BMI, age at menarche; Noncases=1821.
Significance ap < 0.0001, bp < 0.05.

DISCUSSION
In this cross-sectional study of women 20-85 years of age, we separately
evaluated 6 individual PCB congeners, the sum of dioxin-like PCBs, the sum of nondioxin-like PCBs, eight phthalate metabolites, the sum of DEHP, the sum of total
phthalates, and BPA in association with reproductive cancers (breast, cervical, ovarian,
and uterine) in women. In women with detectable PCB levels, higher exposures were
found in women diagnosed with breast cancer, ovarian cancer, and cervical cancer
compared to women never diagnosed with cancer. Epidemiological studies on the
association of PCBs with cervical cancer, ovarian cancer, and uterine cancer are lacking
but our findings are consistent with breast cancer studies that have reported higher PCB
levels in breast cancer cases compared to controls (Charlier et al. 2004 and Recio-Vega et
al. 2001) Charlier et al. 2004found total PCBs and PCB 153 to be significantly higher in
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cases compared to controls [7.08 ppb vs. 5.10 ppb (p=0.012)] and [1.63 ppb vs. 0.63 ppb
(p <0.0001)] respectively, and Recio-Vega et al. (2001 ) found total PCBs to be
significantly higher in cases vs. controls (5.26 ppb vs. 3.33 ppb) as well as an increased
risk of breast cancer among 8 PCB congeners. While these results do not provide any
evidence of causal associations, it is noteworthy that women diagnosed with breast
cancer, ovarian cancer, and uterine cancer have higher body burdens of PCBs compared
to women never diagnosed with cancer.
Significant higher MEHHP levels were found in women diagnosed with ovarian
cancer and significantly higher MEP levels were found in women diagnosed with uterine
cancer compared between to women never diagnosed with cancer. However, when
comparing phthalate levels only among women with concentrations above the LOD, GM
levels of phthalate metabolites did not differ in the study population. In women with
detectable levels of BPA, higher exposure was found in women with cervical cancer
only. Epidemiological studies on the association with phthalates and BPA with breast,
cervical, ovarian, and uterine cancers are lacking or limited. Our findings are not
consistent with findings by Lopez-Carillo et al. 2010, who reported significantly higher
concentrations of MEP in breast cancer cases compared to controls when comparing the
highest vs. lowest tertile of exposure (169.58 vs 106.78 ug/g creatinine) and significant
negative associations for MBzP (OR=0.46, 95% CI 0.27-0.79) and MCPP (OR=0.44,
95% CI 0.24-0.80). Yang et al. (2008) measured median blood BPA levels in 70 cases
and 80 controls and reported higher median BPA levels in cases compared to controls
(0.61 vs. 0.03 ug/L), however, the differences were not found to be statistically
significant (p = 0.42).
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Risk of a reproductive cancer (breast, cervix, ovarian, or uterine) was not found to
be significantly associated with BPA in unadjusted or adjusted logistic regression models.
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) was weakly associated (p=0.0497)
with ovarian cancer risk in the model adjusted for age and race but did not remain
significantly associated when the additional variables of BMI and age at menarche were
added. PCBs showed the most significant associations with all reproductive cancers.
After adjusting for all confounding variables, women with ovarian cancer had significant
associations with PCB 74 and 118, and therefore the dioxin-like PCBs. PCB 138 had the
strongest associations and was found to significantly increase the risk of breast, cervical,
and uterine cancers. Epidemiological data is lacking on the associations between PCBs
and cervical, ovarian, and uterine cancers, however significant associations have been
found between individual PCB congeners and breast cancer risk (Charlier et al. 2004,
Cohn et al. 2012, Demers et al. 2002). Dioxin-like PCBs were significantly associated
with ovarian cancer and non-dioxin-like PCBs were significantly associated with ovarian
and uterine cancers, after adjusting for age, race, BMI, and age at menarche. In contrast
to our findings , Gammon et al. (2002) failed to find any association between PCB
exposure and breast cancer risk when comparing the highest quintile of serum Peak-4
(nos. 118, 153, 138, and 180) PCB levels to the lowest quintile (OR=0.83, 95% CI 0.541.29).
There are a number of limitations to our study, the most important of which is its
cross-sectional design with self-reported data that does not allow for causal inferences to
be made. Self-reported data increases the risk of misclassification bias of cases and
controls with the possibility of undiagnosed or incorrectly reported cancer cases. In the
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PCB data analysis, we had relatively small sample sizes for cervical cancer (n=27),
ovarian cancer (n=11), and uterine cancer (n=26), resulting in decreased statistical power.
Breast cancer cases were larger in the phthalate and BPA data analysis (n=97 and 78,
respectively), however cervical, ovarian, and uterine cancer cases were still limited.
Missing data on reproductive confounding variables such as parity and lactation also
limits the findings of our study. Furthermore, observed associations could be potentially
confounded by lack of information on family history of hormonal cancers. Strengths of
this cross-sectional study design include the large sample survey size, availability of
biological measurements of environmental contaminants, and oversampling of minority
populations that make it highly representative and generalizable to the U.S. population.
In addition, this study has the ability to analyze the combined effect of EDCs within a
class or across classes. Since chemicals may have an additive, synergistic, or
antagonistic effect when combined, it is important to investigate associations for
combined chemical exposures in addition to single chemical exposures.
CONCLUSION
Based on our analysis of urinary phthalates and BPA from the 2003-2010 and
2003-2008 NHANES data cycles, biological levels of phthalates and BPA did not
contribute to the risk of reproductive cancers in women. In contrast, our analysis of
serum blood lipid PCB levels in the 1999-2004 NHANES data cycles, showed a
significantly increased risk of breast, ovarian, and uterine cancers in women with higher
body burdens of PCBs. Due to their lipophilic nature, exposures to environmental PCBs
appear to continue to pose significant threats on the reproductive health of women.
Given the proven contribution of unopposed estrogens to the risk for hormonal cancers, it
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is biologically plausible that altered endogenous estrogen levels presumably from
exposure to estrogen mimicking EDCs may contribute to the risk of disease. Exposure to
EDCs, such as PCBs, during early development of the breast and endometrium can alter
its development, and possibly contribute to the susceptibility to diseases through effects
on stem cells. Although we did not find significant associations between phthalates, BPA,
and reproductive cancers, our research is based on the use of cross-sectional self-reported
data thus further research is needed. Our findings, coupled with the lack of available
epidemiological evidence concerning EDCs and cervical, ovarian, and uterine cancers
warrants the need for future prospective studies.
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CHAPTER VII
OVERALL CONCLUSIONS
The primary objective of the findings in this dissertation was to assess exposure to
EDCs (PCBs, BPA, and phthalates) and determine whether exposure to these agents is a
contributing factor in reproductive dysfunction in the U.S. general population. In
particular, the associations between PCBs and endometriosis and leiomyomas and the
associations between PCBs, phthalates, and BPA and reproductive cancers (breast,
cervical, ovarian, and uterine) were examined using the CDC’s NHANES database.
A number of chemicals are suspected to act as endocrine disruptors (EDs) by
mimicking natural or synthetic estrogen resulting in an increased risk of hormonal cancer
in women. Polychlorinated biphenyls (PCBs), phthalates and bisphenol A (BPA) have
been recognized as endocrine disrupters due to their ability to interfere with reproductive
function and development in animals and humans by either increasing estrogen activity or
blocking estrogens from acting. Epidemiologic studies on the role of EDCs and
reproductive toxicity are inconsistent and lacking, particularly in regards to the role of
EDCs in the development of cervical, breast, and uterine cancers. Thus, our specific aims
were identified to address gaps in the literature and provide recommendations for future
studies.
To support or refute the proposed role of EDCs, secondary statistical analysis
was conducted using data from the CDCs 1999-2010 NHANES. NHANES, conducted
annually since 1999 by the Centers for Disease Control and Prevention (CDC), is an
ongoing cross-sectional survey designed to be nationally representative of the noninstitutionalized, U.S. civilian population. Once eligibility is determined participants
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complete a confidential and voluntary home interview followed by a standardized
physical examination in a specially equipped mobile evaluation clinic (MEC). The MEC
examination consists of a physical examination, dental examination, detailed face-to-face
personal interview, and collection of biological specimens. Each survey includes a
nationally representative sample of approximately 5,000 participants.
The first specific aim addressed in manuscript 1 examined the cross-sectional
relationship between exposure to PCBs and breast cancer among U.S. women. We
analyzed data from female participants (20-85 years of age) with available PCB data
using the 1999 to 2004 data cycles. Exposure was based on lipid adjusted serum levels of
6 individual PCB congeners (PCB 074, 099, 118, 138, 153, and 180), the sum of dioxinlike PCBs (074 + 118), and the sum of non-dioxin-like PCBs (099 + 138 + 153+187) in
conjunction with self-reported data obtained from the medical and reproductive health
questionnaires. We calculated geometric means to compare PCB concentrations in
women with a breast cancer diagnosis vs. women without a cancer diagnosis. Geometric
means of the 6 PCB congeners were found to be significantly higher among women with
breast cancer when compared to the rest of the study population. We used logistic
regression models to estimate odds ratios (ORs) and 95% confidence intervals (CI) for
the association between PCB measurements and breast cancer. After adjusting for age,
race, BMI, lactation, and age at menarche we found that PCB 138 was significantly
associated with breast cancer [odds ratios of 2.88; 95% CI: 1.14-7.30; 2.93, 95% CI:
1.04-8.26; and 3.43, 95% CI: 1.12-10.4] in women with higher body burdens of
individual PCB congeners. After adjusting for age and race, we also found the sum of
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non-dioxin-like PCBs to be significantly associated with breast cancer [OR of 1.14; 95%
CI: 1.00-1.29].
The second specific aim, addressed in manuscript 2 examined the relationship
between exposure to PCBs endometriosis and uterine leiomyomas among U.S. women,
20-54 years of age. Endometriosis and uterine leiomyomas have been identified as
estrogen dependent diseases that occur during the reproductive years, however previous
research on the role of EDCs in the development of endometriosis and uterine
leiomyomas is conflicting. Due to the role of estrogen in the development of
endometriosis and uterine leiomyomas we hypothesized that women with higher body
burdens of PCBs would have an increased risk of disease. We calculated GMs to
compare PCB concentrations in women who self-reported an endometriosis or uterine
leiomyoma diagnosis vs. women who self-reported never being diagnosed with
endometriosis or uterine leiomyomas. We used logistic regression models to estimate
ORs and 95% CIs of endometriosis and uterine leiomyomas by concentration of lipidadjusted serum PCBs. GM levels of PCB congeners 138, 153, and 180 were found to be
significantly higher among women diagnosed with endometriosis, GM levels of PCB
congeners 74, 99, 118, 138, 153, and 180 were found to be significantly higher among
women diagnosed with uterine leiomyomas, dioxin-like PCBs were found to be
significantly higher in women diagnosed with uterine leiomyomas and non-dioxin-like
PCBs were found to be significantly higher in women diagnosed with endometriosis and
uterine leiomyomas compared to the rest of the study population. We found PCB 74 and
118 to be significantly associated with uterine leiomyomas [OR of 1.91: 95% CI: 1.103.29 and 1.91, 95% CI: 1.13-3.22] and non-dioxin-like PCBs to be significantly
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associated with endometriosis [OR of 95% CI: 1.00-1.29] in women with higher body
burdens of PCBs.
The third specific aim, addressed in manuscript 3, explored the cross-sectional
relationship between exposure to PCBs, phthalates, and BPA and reproductive cancers
(breast, cervical, ovarian, and uterine) among U.S. women. We evaluated the risk of
breast cancer, cervical cancer, ovarian cancer, and uterine cancer with exposure to 6
individual PCB congeners (74, 99, 118, 138, 153, and 180), the sum of dioxin-like PCBs
(074 and 118), the sum of non-dioxin-like PCBs (099 + 138 + 153+187), 8 urinary
phthalate metabolites (MNP, MEP, MEHP, MBzP, MCPP, MEHHP, MEOHP, and
MIB), the sum of DEHP metabolites (MHP + MHH + MOH), the sum of total
phthalates, and urinary BPA. We calculated geometric means to compare EDCs
concentrations in women who self-reported a breast, cervical, ovarian, or uterine cancer
diagnosis vs. women who self-reported never being diagnosed with cancer and used
logistic regression models to estimate ORs and 95% CIs for the association between
exposure to EDCs and reproductive cancers.
Separate analyses showed geometric mean levels of individual PCB congeners to
be significantly higher among women with breast cancer, ovarian cancer, and uterine
cancer when compared to the rest of the study population. Mono-(2-ethyl-5hydroxyhexyl) phthalate (MEHHP) was found to be significantly higher among women
with ovarian cancer and monoethyl phthalate (MEP) was found to be significantly higher
among women with uterine cancer compared to women never diagnosed with cancer,
however BPA was significantly higher in women never diagnosed with cancer compared
to women diagnosed with breast cancer. When evaluating GM levels in only women with
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phthalate and BPA concentrations above the LOD, phthalate levels did not differ among
the study population, however women diagnosed with cervical cancer had significantly
higher levels of BPA compared to women never diagnosed with cancer. We found PCB
138 to be significantly associated with breast cancer, cervical cancer, and uterine cancer
[ORs of 2.52.; 95% CI: 1.06-5.99; 3.05, 95% CI: 1.21-7.69; and 5.83, 95% CI: 1.6320.9], respectively, and PCB 74 and 118 to be significantly associated with ovarian
cancer [ORs of 6.47, 95% CI: 1.23-3.41 and 6.68, 95% CI: 1.39-32.3), respectively, in
the final adjusted models. We also found the sum of non-dioxin-like PCBs to be
significantly associated with uterine cancer (OR of 1.12, 95% CI: 1.03-1.23) and the sum
of dioxin-like PCBs to be significantly associated with ovarian cancer (OR of 2.02, 95%
CI: 1.06-3.85). We found a very weak association between MEHHP and ovarian cancer
(OR of 3.63, 95% CI: 1.00-13.2, p=.0497) but did not find significant associations
between any other phthalate metabolites or BPA and reproductive cancers.
In sum, the major findings from the research in this dissertation indicate that
exposure to PCBs may increase the risk of endometriosis, uterine leiomyomas, and
cancers of the breast, cervix, ovaries, and uterus. Our findings are consistent with the
proven contributions of unopposed estrogens to the risk for reproductive toxicity.
Exposure to estrogenic environmental chemicals, particularly PCBs, during early
development of the breast and endometrium can alter their development, and possibly
contribute to the susceptibility to diseases through effects on stem cells.
Limitations
There are a number of limitations to our study, the most important of which is its
cross-sectional design with self-reported data that does not allow for causal inferences to

207

be made. Self-reported data increases the risk of recall bias and misclassification bias of
cases ad controls with the possibility of undiagnosed or incorrectly reported cancer,
endometriosis, or uterine leiomyoma cases, thereby impacting the observed associations
in the study. We also had relatively small sample sizes for cervical cancer (n=27), ovarian
cancer (n=11), and uterine cancer (n=26), resulting in decreased statistical power within
analyses. Missing data on reproductive confounding variables such as parity and
lactation also limits the findings of our study. We were not able to assess the potential of
additional reproductive health variables in our analysis due the extent of non-response.
Furthermore, observed associations could be potentially confounded by lack of
information on family history of endometriosis, uterine leiomyomas, and reproductive
cancers.
Future Studies
Although our findings must be interpreted with caution, they indicate that EDCs
still deserve consideration for their impact on the female reproductive system.
Epidemiological studies on EDCs are often lacking or inconsistent, especially in regards
to their in the development of cervical, ovarian, and uterine cancers. Because a single
exposure to an internal or external environmental factor alone cannot explain the
development of a complex chronic disease, such as cancer, future studies exploring the
combined effect of EDCs and their influence in the development of chronic diseases in an
individual are warranted. Widespread human exposure to EDC’s and the increasing
concern for their potential to induce reproductive toxicity, especially in susceptible
populations with sensitive gene polymorphisms, warrants a clear need for more research.
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